 
 
 
 
 
 
Protocol 
[ADDRESS_368847] intramuscular 
dose of [COMPANY_004] Biologicals‚Äô investigational  RSV maternal vaccine ([COMPANY_004]388550A) when given  alone and 
given in co -administration with a single  intramuscular dose of Boostrix (US formulation  SB776423 or ex -
US formulation SB263855) and to  evaluate the safety, reactogenicity and immunogenicity  of a 2nd dose of 
the RSV maternal vaccine.  
EudraCT number : 2019-002258-22 
Date of Document : 14 APRIL 2021 
 
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  1  Clinical Study Protocol  
Sponsor:  
GlaxoSmithKline Biologicals SA  
Rue de l‚ÄôInstitut 89,  
1330 Rixensart, Belgium  
Primary Study vaccine(s)  
and number(s)  GlaxoSmithKline ([COMPANY_004]) Biological Respi[INVESTIGATOR_301864] (RSV) RSVPreF3 candidate vaccine 
([COMPANY_004]3888550A)  
Other Study 
vaccine(s)/product(s)  [COMPANY_004] Biologicals‚Äô combined reduced -antigen-content 
diphtheria, tetanus and acellular pertussis (dTpa) 
vaccine (Boostrix [US formulation SB776423])  
[COMPANY_004] Biologicals‚Äô combined reduced -antigen-content 
diphtheria, tetanus and acellular pertussis (dTpa) 
vaccine (Boostrix [ex-US formulation  SB263855])  
Placebo (150  mM Sodium chloride [NaCl])  
eTrack study number and 
abbreviated title  209141 (RSV MAT -011) 
Investigational New Drug 
(IND) number  [ADDRESS_368848] number  2019-002258-22 
Date of protocol  Final Version 3: [ADDRESS_368849] 2019  
Date of protocol 
amendment  Amendment 1 Final:  21 October 201 9 
Amendment 2 Final: 23 January 2020 
Amendment 3 Final: 3 April 2020  
Amendment 4 Final : [ADDRESS_368850] 2020  
Amendment 5 Final: 2 November 2020  
Amendment 6 Final: [ADDRESS_368851] 
intramuscular dose of [COMPANY_004] Biologicals‚Äô investigational 
RSV maternal vaccine ([COMPANY_004]388550A) when given 
alone and given in co -administration with a single 
intramuscular dose of Boostrix (US formulation 
SB776423 or e x-US formulation SB263855)  and to 
evaluate the safety, reactogenicity and immunogenicity 
of a 2nd dose of the RSV maternal vaccine . 
Short title  A Phase II study of a primary dose of investigational 
RSV maternal vaccine, given alone or with Boostrix, 
with a 2nd dose investigational RSV maternal vaccine.  
209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW)LQDO 
$SULO  H7UDFNVWXG\QXPEHUDQG
DEEUHYLDWHGWLWOH 5690$7
,QYHVWLJDWLRQDO1HZ'UXJ
,1'QXPEHU 
(XGUD&7QXPEHU 
7LWOH 3KDVH,,UDQGRPL]HGREVHUYHUEOLQGSODFHER
FRQWUROOHGPXOWL FRXQWU\VWXG\LQKHDOWK\QRQ SUHJQDQW
ZRPHQ \HDUVRIDJHWRHYDOXDWHWKHVDIHW\
UHDFWRJHQLFLW\DQGLPPXQRJHQLFLW\RID VW
LQWUDPXVFXODUGRVHRI*6.%LRORJLFDOV¬∂LQYHVWLJDWLRQDO
569PDWHUQDOYDFFLQH*6.$ZKHQJLYHQ
DORQHDQGJLYHQLQFR DGPLQLVWUDWLRQZLWKDVLQJOH
LQWUDPXVFXODUGRVHRI %RRVWUL[86IRUPXODWLRQ
6%RUH[ 86IRUPXODWLRQ6% DQGWR
HYDOXDWHWKHVDIHW\UHDFWRJHQLFLW\DQGLPPXQRJHQLFLW\RID
QGGRVHRIWKH569PDWHUQDOYDFFLQH 
&RRUGLQDWLQJDXWKRUV 6FLHQFH:ULWHU 
&RQWULEXWLQJDXWKRUV
&RQW
$PHQGHG $35x-RRQ+\XQJ.LP  

x  

x /HDG6WDWLVWLFLDQ 
x 6WXG\6WDWLVWLFLDQ 
x 2YHUVLJKW'DWD0DQDJHU 
x 6WXG\'HOLYHU\/HDG 
x 6DIHW\3K\VLFLDQ 
x 6DIHW\3K\VLFLDQ 
x 6DIHW\3URGXFW/HDGHU 
x 6DIHW\6FLHQWLVW 
x 5HJXODWRU\$IIDLUV
5HSUHVHQWDWLYH 
x &OLQLFDO5HDG 2XW7HDP
/HDGHU
x &OLQLFDO7ULDO6XSSO\PDQDJHU 
*6.3URWRFRO:6Y 
¬ã*6.JURXSRIFRPSDQLHVRULWVOLFHQVRU_3URWRFRO$PHQGPHQW$SU_70)_
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  3 Protocol  Amendment 6 Sponsor Signatory Approval  
eTrack study number and 
Abbreviated Title  209141(RSV MAT -011) 
IND number  [ADDRESS_368852] number  2019-002258-22 
Date of protocol amendment  Amendment 6 Final: [ADDRESS_368853] 
Lead 
  
Signature   
  
[CONTACT_1782]  
  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  4 Protocol  Amendment  6 Investigator Agreement  
I agree: 
‚Ä¢ To conduct the study in compliance with this protocol, any future protocol 
amendments or protocol administrative changes, with the terms of the clinical trial 
agreement and with any other study conduct procedure s and/or study conduct 
documents provided by [CONTACT_35316] ([COMPANY_004]) Biologicals  SA. 
‚Ä¢ To assume responsibility for the proper conduct of the study at this site.  
‚Ä¢ That I am aware of, and will comply with, ‚ÄòGood Clinical Practice‚Äô (GCP) and all 
applicable regula tory requirements.  
‚Ä¢ To ensure that all persons assisting me with the study are adequately informed  about 
the [COMPANY_004] study vaccine(s)  and other study -related duties and functions as described 
in the protocol.  
‚Ä¢ To supervise any individual or party to whom I have  delegated trial -related duties 
and functions conducted at the trial site.  
‚Ä¢ To ensure that any individual or party to whom I have delegated trial -related duties 
and functions conducted at the trial site are qualified to perform those trial -related 
duties and functions.  
‚Ä¢ To acquire the reference ranges for laboratory tests performed locally and, if required 
by [CONTACT_427], obtain the laboratory‚Äôs current certification or Quality 
Assurance procedure manual.  
‚Ä¢ To ensure that no clinical samples (including se rum samples) are retained onsite or 
elsewhere without the approval of [COMPANY_004] and the express written informed consent of 
the subject and/or the subject‚Äôs legally acceptable representative.  
‚Ä¢ To perform no other biological assays on the clinical samples except t hose described 
in the protocol or its amendment(s).  
‚Ä¢ To co-operate with a representative of [COMPANY_004] in the monitoring process of the study 
and in resolution of queries about the data.  
‚Ä¢ To have control of all essential documents and records generated under my 
responsibility before, during, and after the trial.  
‚Ä¢ That I have been informed that certain regulatory authorities require the sponsor to 
obtain and supply, as necessary, details about the investigator‚Äôs ownership interest in 
the sponsor or the investig ational vaccine(s) , and more generally about his/her 
financial ties with the sponsor. [COMPANY_004] will use and disclose the information solely for 
the purpose of complying with regulatory requirements.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  5 Hence, I: 
‚Ä¢ Agree to supply [COMPANY_004] with any necessary information regardi ng ownership interest 
and financial ties (including those of my spouse and dependent children).  
‚Ä¢ Agree to promptly update this information if any relevant changes occur during the 
course of the study and for 1 year following completion of the study.  
‚Ä¢ Agree that [COMPANY_004] may disclose any information about such ownership interests and 
financial ties to regulatory authorities.  
‚Ä¢ Agree to provide [COMPANY_004] with an updated Curriculum Vitae and other documents 
required by [CONTACT_227236].  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  6 eTrack study number  and 
Abbreviated Title  209141(RSV MAT -011) 
IND number   [ADDRESS_368854] number  2019-002258-22 
Date of protocol amendment  Amendment 6 Final: 9 April 2021 
Short Title A Phase II study of a primary dose of investigational 
RSV maternal vaccine, given alone or  with Boostrix, 
with a 2nd dose investigational RSV maternal vaccine.  
Investigator name   
  
[CONTACT_227280]  
  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  7 SPONSOR INFORMATION  
1. Sponsor 
GlaxoSmithKline Biologicals  SA 
Rue de l‚Äôinstitut 89,  
[ADDRESS_368855] for Reporting SAEs: refer to protocol Section 
[IP_ADDRESS]  
Study Contact [CONTACT_43075]: refer to the local study  contact [CONTACT_227237].  
5. [COMPANY_004] Central Safety Physician On -Call Contact [CONTACT_301886] -up Phone contact: [CONTACT_301887]  
[IP_ADDRESS]. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  8 PROTOCOL AMENDMENT/ADMINISTRATIVE CHANGE 
SUMMARY OF CHANGES TAB LE 
Table [ADDRESS_368856] -2019  
Original Protocol  23-AUG -2019  
Amendment 6: 9 April 2021  
Overall Rationale for Amendment 6:  
This study has been amended to include a clarification in the Exclusion criteria section to 
align with Protocol section 7.5.[ADDRESS_368857] the flexibility of reducing the interval 
between administration of a coronavirus disease 2019 (COVID -19) vaccine and the RSV 
maternal vaccine.  Also, several administrative changes in personnel and minor edits to 
the protocol are included.  
Table [ADDRESS_368858] of main changes in the protocol and their rationale  
Section # and Name  [CONTACT_301958]  
6.4.2 Prior/Concomitant therapy for extension  Note added describing flexibility of 
reducing vaccination window in 
case COVID -[ADDRESS_368859] of protocol  
[IP_ADDRESS] Contact [CONTACT_301888] (SAEs), pregnancies 
and study holding rules  New [COMPANY_004] Clinical Safety & 
Pharmacovigilance email address  The email address recently 
changed and is updated here  
8.5.4 Reporting of serious adverse events, 
pregnancies, and other event s Changed Pregnancy Report ing 
from 2 weeks to 24 hrs  To align the protocol with the 
SOP for pregnancy reporting 
all new amendments should 
make this edit per the new 
templates  [IP_ADDRESS] Completion and transmission of 
pregnancy reports to [COMPANY_004]  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  9 TABLE OF CONTENTS  
PAGE 
SPONSOR INFORMATION  ................................ ................................ ............................  7 
PROTOCOL AMENDMENT/A DMINISTRATIVE CHANGE  SUMMARY OF 
CHANGES TABLE  ................................ ................................ ................................ ... 8 
1. SYNOPSIS  ................................ ................................ ................................ .............  16 
2. SCHEDULE OF ACTIVITI ES (SOA)  ................................ ................................ ....... 20 
3. INTRODUCTION  ................................ ................................ ................................ .... 24 
3.1. Study rationale  ................................ ................................ ............................  24 
3.2. Backgro und ................................ ................................ ................................  25 
3.3. Benefit/Risk assessment  ................................ ................................ .............  25 
3.3.1.  Risk assessment  ................................ ................................ ..........  25 
3.3.2.  Benefit assessment  ................................ ................................ ..... 26 
3.3.3.  Overall Benefit: Risk conclusion  ................................ ...................  26 
4. OBJECTIVE(S) AND END POINT(S)  ................................ ................................ ...... [ADDRESS_368860] and study completion  ................................ ................................ ..... 35 
6. STUDY POPULATION  ................................ ................................ ...........................  35 
6.1. Inclusion criteria for enrolment (primary study)  ................................ ...........  35 
6.2. Exclusion criteria for enrolment (primary study)  ................................ ..........  36 
6.2.1.  Medical conditions  ................................ ................................ ....... 36 
6.2.2.  Prior/Concomitant therapy  ................................ ...........................  37 
6.2.3.  Prior/Concurrent clinical study experience  ................................ ... 37 
6.2.4.  Other exclusions  ................................ ................................ ..........  38 
6.3. Inclu sion criteria for study extension  ................................ ...........................  38 
6.4. Exclusion criteria for extension  ................................ ................................ ... 38 
6.4.1.  Medical conditions for extension  ................................ ..................  39 
6.4.2.  Prior/Concomitant therapy for extension (Amended 09 -
APR-2021)  ................................ ................................ ...................  39 
6.4.3.  Prior/Concurrent clinical study experience for extension  ..............  [ADDRESS_368861] identific ation  ................................ ................................ .... 44 
[IP_ADDRESS].  Randomisation of supplies  ................................ ..........  44 
[IP_ADDRESS].  Treatment allocation to the subject  .............................  44 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  10 [IP_ADDRESS].1.  Study group and treatment 
number allocation  ................................ ... 44 
7.3. Blinding and unblinding  ................................ ................................ ...............  45 
7.3.1.  Emergency unblinding  ................................ ................................ . 45 
7.4. Handling, storage and replacement of study vaccine(s)/product(s)  .............  47 
7.4.1.  Storage and handling of study vaccine(s)  ................................ .... 47 
7.4.2.  Replacement of unusable vaccine(s) doses  ................................ . 47 
7.5. Concomitant medication(s)/product(s) and concomitant vaccinations  .........  48 
7.5.1.  Recording of concomitant medications/products and 
concomitant vaccinations  ................................ .............................  48 
7.5.2.  Concomitant medications/products/vaccines that may lead 
to the elimination of a subject from per -protocol analyses  ............  [ADDRESS_368862] from per -protocol analyses  ................................ .............................  49 
7.7. Contraindications to subsequent vaccine(s) administration  .........................  49 
7.8. Warnings and precautions  ................................ ................................ ..........  49 
7.9. Treatment after completion of the study  ................................ ......................  50 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  50 
8.1. Study Procedures During Special Circumstances  ................................ ....... 50 
8.2. General study aspects  ................................ ................................ ................  52 
8.3. Pre-vaccination procedures  ................................ ................................ ........  52 
8.3.1.  Collection of demographic data  ................................ ....................  52 
8.3.2.  Medical and vaccination history (Amended 09 APR 2021)  ...........  [ADDRESS_368863]  ................................ ................................ .............  53 
8.3.5.  Pre-vaccination body temperature  ................................ ...............  53 
8.3.6.  Pre-vaccination Vital Signs  ................................ ..........................  53 
8.4. Immunogenicity assessments  ................................ ................................ ..... 53 
8.4.1.  Use of specified study materials  ................................ ..................  54 
8.4.2.  Biological samples  ................................ ................................ ....... 54 
8.4.3.  Laboratory assays  ................................ ................................ ....... 55 
8.4.4.  Biological samples evaluation  ................................ ......................  60 
[IP_ADDRESS].  Immunological read -outs ................................ ............  60 
8.4.5.  Immunological correlates of protection  ................................ .........  61 
[IP_ADDRESS].  RSV ................................ ................................ ............  61 
[IP_ADDRESS].  Boostrix  ................................ ................................ ...... 61 
8.5. Safety Asse ssments  ................................ ................................ ...................  61 
8.5.1.  Safety definitions  ................................ ................................ .........  61 
8.5.2.  Time period and frequency for collecting AE and serious 
adverse event (SAE) information  ................................ .................  62 
8.5.3.  Method of detecting AEs and SAEs  ................................ .............  64 
8.5.4.  Reporting of serious adverse events, pregnancies, and 
other -events (Amended [ADDRESS_368864]-study adverse events and serious adverse events  ...............  64 
[IP_ADDRESS].  Contact [CONTACT_301889] (SAEs), pregnancies and study 
holding rules (Amended 09 APR 2 021).......................  [ADDRESS_368865]  ................................ ................................ .................  66 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  11 8.6. Holding rules and safety monitoring  ................................ ............................  66 
8.7. Genetic Research (Pharmacogenetics)  ................................ ......................  67 
8.8. Biomarkers and pharmacogenomics  ................................ ...........................  67 
8.9. Economic assessment  ................................ ................................ ................  68 
8.9.1.  Regulatory reporting requirements for SAEs  ................................  68 
9. DISCONTINUATION CRIT ERIA  ................................ ................................ .............  68 
9.1. Discontinuation from the study  ................................ ................................ .... 68 
9.2. Discontinuation of study vaccine(s)  ................................ .............................  [ADDRESS_368866] to follow -up................................ ................................ ..........................  70 
10. STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  70 
10.1.  Sample size determination  ................................ ................................ ..........  70 
10.1.1.  Hypotheses related to primary and secondary objectives  ............  70 
10.1.2.  Sample size calculation  ................................ ...............................  70 
10.2.  Populations for analyses  ................................ ................................ .............  72 
10.3.  Statistical analyses  ................................ ................................ .....................  73 
10.3.1 . Subjects disposition  ................................ ................................ ..... 73 
10.3.2.  Demography and baseline characteristics analyses  .....................  73 
10.3.3.  Immunogenicity analyses  ................................ .............................  73 
10.3.4.  Safety analyses  ................................ ................................ ...........  75 
10.4.  Sequ ence of analyses ................................ ................................ .................  77 
11. REFERENCES  ................................ ................................ ................................ ....... 78 
12. APPENDICES  ................................ ................................ ................................ ........  79 
12.1.  Appendix 1: Abbreviations, glossary of terms and trademarks  ....................  [ADDRESS_368867] of abbreviations  ................................ ................................ ..... 79 
12.1.2.  Glossary of terms  ................................ ................................ .........  81 
12.1.3.  Trademarks  ................................ ................................ .................  85 
12.2.  Appendix 2: Clinical and safety laboratory tests  ................................ ..........  86 
12.3. Appendix 3: Clinical laboratories  ................................ ................................ . 87 
12.4.  Appendix 4: Study governance considerations  ................................ ...........  88 
12.4.1.  Regulatory and ethical considerations  ................................ .........  88 
12.4.2.  Financial disclosure  ................................ ................................ ..... 88 
12.4.3.  Informed consent process  ................................ ............................  89 
12.4.4.  Data protection  ................................ ................................ ............  89 
12.4.5.  Committees structure  ................................ ................................ ... 89 
12.4.6.  Publication policy  ................................ ................................ .........  90 
12.4.7.  Dissemination of clinical study data  ................................ .............  90 
12.4.8.  Data quality assurance  ................................ ................................  91 
12.4.9.  Source documents  ................................ ................................ ....... 91 
12.4.10.  Study and site closure ................................ ................................ .. 92 
12.5.  Appendix 5: Adverse Events: definitions and procedures for 
recording, evaluating, follow -up, and rep orting  ................................ ............  93 
12.5.1.  Definition of AE  ................................ ................................ ............  93 
[IP_ADDRESS].  AE Definition ................................ ...............................  93 
[IP_ADDRESS].  Events Meeting the AE Definition  ...............................  93 
[IP_ADDRESS].  Events NOT Meeting the AE Definition  .......................  94 
12.5.2.  Definition of SAE  ................................ ................................ ..........  94 
12.5.3.  Solicited adverse events  ................................ ..............................  95 
12.5.4.  Unsolicited adverse events  ................................ ..........................  95 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  12 12.5.5.  Clinical laboratory parameters and other abnormal 
assessments qualifying as adverse ev ents or serious 
adverse events  ................................ ................................ ............  96 
12.5.6.  Events or outcomes not qualifying as adverse events or 
serious adverse events  ................................ ................................  96 
[IP_ADDRESS].  Pregnancy  ................................ ................................ .. 96 
12.5.7.  Detecting and recording adverse events, serious adverse 
events and pregnancies  ................................ ...............................  97 
[IP_ADDRESS].  Time period for detecting and recording 
adverse events, serious adverse events and 
pregnancies  ................................ ................................  97 
[IP_ADDRESS].  Evaluation of adverse events and serious  
adverse events  ................................ ...........................  98 
[IP_ADDRESS].1.  Active questioning to detect 
adverse events and serious 
adverse events  ................................ ....... 98 
[IP_ADDRESS].2.  Assessment of adverse events  ...............  99 
[IP_ADDRESS].3.  Medically attended visits  .......................  101 
12.5.8.  Reporting of serious adverse events, pregnancies, and 
other events  ................................ ................................ ...............  102 
[IP_ADDRESS].  Prompt reporting of serious adverse events, 
pregnancies, and other events to [COMPANY_004]  .....................  102 
[IP_ADDRESS].  SAEs requiring expedited reporting to [COMPANY_004]  ..............  102 
[IP_ADDRESS].  Back -up system in case the electronic 
reporting system does not work  ................................  102 
[IP_ADDRESS].  Completion and transmission of pregnancy 
reports to [COMPANY_004] (Amended 09 -APR-2021)  .................  [ADDRESS_368868]‚Äôs eCRF  ................................ ............  103 
12.5.10.  Follow -up of adverse events, serious adverse events, and 
pregnancies  ................................ ................................ ...............  103 
[IP_ADDRESS].  Follow -up during the study  ................................ ........  103 
[IP_ADDRESS].  Follow -up after the subject is discharged from 
the study  ................................ ................................ ... 103 
[IP_ADDRESS].  Follow -up of pregnancies ................................ ..........  104 
12.6.  Appendix 6: Contraceptive guidance and collection of pregnancy 
information  ................................ ................................ ................................  105 
12.6.1.  Definitions  ................................ ................................ ..................  105 
[IP_ADDRESS].  Woman of Childbearing Potential (WOCBP)  .............  105 
[IP_ADDRESS].1.  Women in the following categories 
are not considered WOCBP  ..................  105 
12.6.2.  Contraception guidance  ................................ .............................  105 
12.6.3.  Collection of pregnancy information  ................................ ...........  106 
[IP_ADDRESS].  Female Subjects who become pregnant  ...................  106 
12.7.  Appendix 7: Genetics  ................................ ................................ ................  107 
12.8.  Appendix 8: Country -specific requirements  ................................ ...............  107 
12.9.  Appendix 9: Protocol Amendment/Administrative change History  .............  108 
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368869] of main changes in the protocol and their rationale  ............................  8 
Table 3  Schedule of Activities  ................................ ................................ .............  20 
Table 4  Intervals between study visits  ................................ ................................ . 24 
Table 5  Study objectives and endpoints  ................................ ..............................  27 
Table 6  Study groups, treatment and epochs foreseen in the study  ....................  34 
Table 7  Treatments administered (Part 1)  ................................ ...........................  41 
Table 8  Treatments administered (Part 2)  ................................ ...........................  [ADDRESS_368870] information for emergency unblinding  ................................ ....... 46 
Table 10  Intervals between study visits under Special Circumstances  ..................  51 
Table 11  Biological samples  ................................ ................................ .................  55 
Table 12 Humoral Immunity (Antibody determination)  ................................ ...........  [ADDRESS_368871] information for reporting of serious adverse events 
(SAEs), pregnancies and study holding rules  ................................ .........  [ADDRESS_368872] 95% confidence interval (CI) on the probability of a subject 
with AEs events following vaccination of  50 subjects per group, 
(100 subjects per group in US and ex -US combined) and 400 
subjects with RSVPreF3 groups combined  ................................ .............  71 
Table 19  Precision and power in terms of RSV -A neutralizing antibody 
titers with a sample size of 100 subjects per group and 50 
subjects per group  ................................ ................................ ..................  72 
Table 20  Protocol -Required Safety Laboratory Assessments  ...............................  86 
Table 21  [COMPANY_004] laboratories,  ................................ ................................ ...................  87 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  14 Table 22  Outsourced laboratories  ................................ ................................ .........  87 
Table 23  Solicited local adverse events  ................................ ................................  95 
Table 24  Solicited general adverse events  ................................ ............................  95 
Table 25  Intensity scales for solicited symptoms in adults and children of 6 
years of age or more  ................................ ................................ ..............  99 
Table 26  Highly Effective Contraceptive Methods  ................................ ...............  106 
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368873] OF FIGURES  
PAGE 
Figure 1  Study design overview  ................................ ................................ ...........  30 
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  16 1. SYNOPSIS  
Indication:  
Active immunization of pregnant women during the third trimester of pregnancy to 
prevent respi[INVESTIGATOR_4345] (RSV) - associated lower respi[INVESTIGATOR_301865] 
(LRTI) in infants by [CONTACT_301890] . 
Rationale:  
[COMPANY_004] is developi[INVESTIGATOR_301866] (RSVPreF3) against RSV 
disease in infants through  maternal immunizatio n. In the RSV maternal program to date, 
a Phase 1/2 study (study RSV MAT -001; NCT 03674177) is ongoing in healthy non -
pregnant women 18 -45 years of age (YOA) to det ermine the safety and immunogenicity 
of 3 dose levels of RSVPreF3 (30, 60 and 120 ¬µg) vaccine compared to placebo. 
Preliminary safety and immunogenicity information is available in the investigator 
brochure.  
In many countries, the use of acellular pertussis  vaccination is recommended for women 
during pregnancy to protect young infants against pertussis before they can benefit from 
the infant vaccination series [ Mazzilli, 2018]. Boostrix, a vaccine against diphtheria, 
tetanus and acellular pertussis is administered in the third trimester of pregnancy in many 
countries. Since RSVPreF3 is intended for administration in the third trimester of 
pregnancy, it will be important to evaluate any p otential interference of co -administration 
with Boostrix.  
This study (RSV MAT -011), in healthy non -pregnant women, will be the first to evaluate 
co-administration of  2 dose levels of  RSVPreF3 with Boostrix (dTpa). Selection of th e 60 
and 120¬µg RSVPreF3 doses was based on preliminary results of the ongoing (RSV MAT 
001) Phase 1 / 2 study.  
Two formulations of dTpa vaccine, each containing either 300 micrograms  or 500 
micrograms  of aluminum are licensed in the US and outside the US (ex -US), 
respectively. As s uch, the Boostrix (US formulation) (dTpa_300) will be administered to 
subjects in centers located in the US, while the Boostrix (ex-US formulation ) (dTpa_500) 
will be administered to subjects in centers ex -US [Christy, 1995]. In previous studies 
both, Boostrix formulations have had a similar immunogenicity and safety profiles. 
Therefore, any potential differences in immune response to Boostrix in this study may be 
the result of population differences or immune response in the setting of RSVPreF3 co -
administration  [Theeten, 2005; Melville-Smith, 1983]. 
This will be a Phase II study to evaluate safety and reactogenicity of co -administration of 
RSVPreF3 and dTpa_300  or dTpa_500 in non -pregnant women [ADDRESS_368874] udy will evaluate whether co -administration of dTpa  affects the 
magnitude of the immune response to RSVPreF3 and whether RSVPreF3 affects the 
magnitude of the immune response to dTpa.   209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  17 For those who provide consent, the durability of the response to RSVPreF3 will be 
measured  from 12 to 18 months  following initial vaccination. In addition, a second 
immunization with the RSV Maternal (120¬µg) vaccine will be administered from [ADDRESS_368875] vaccination  to evaluate the immunogenici ty and safety 
profile of RSVPreF3  vaccine second dose .  
Objectives and Endpoints:  
Objectives  Endpoints  
Primary (US + ex -US data to be pooled)  
Safety  
‚Ä¢ To evaluate the safety and reactogenicity of 2 dose 
levels (60 and 120  ¬µg) of RSVPreF3 when given 
alone or co -administered with dTpa from 
Vaccination up to Day 31.   Safety  
‚Ä¢ Occurrence of any Adverse Events (AEs) from 
Vaccination to Day 31:  
‚àí Occurrence of each solicited local AEs at the 
site of injection in both limbs from Vaccination 
to Day 8;  
‚àí Occurrence of s olicited general AEs from 
Vaccination to Day 8;  
‚àí Occurrence of any unsolicited AEs from 
Vaccination to Day 31;  
‚àí Occurrence of Serious Adverse Events (SAEs) 
from Vaccination to Day 31.  
‚Ä¢ To evaluate the safety of a 2nd dose of RSVPreF3 
given from [ADDRESS_368876] 2nd dose vaccination  ‚Ä¢ Occurrence of any AEs from 2nd dose to Day [ADDRESS_368877]-2nd dose vaccination, for all subjects:  
‚Ä¢ Occurrence of each solicited local AE at the site of 
injection in both deltoids from 2nd dose vacci nation 
to Day [ADDRESS_368878] -2nd dose vaccination  
‚Ä¢ Occurrence of solicited general AEs from 2nd dose 
vaccination to Day [ADDRESS_368879] 2nd dose vaccination  
‚Ä¢ Occurrence of any unsolicited AEs from 2nd dose to 
Day [ADDRESS_368880] - 2nd dose vaccination  
‚Ä¢ Occurrence of Serious Adverse Events (SAEs) from 
2nd dose vaccination to Day [ADDRESS_368881] 2nd dose 
vaccination.  
Immunogenicity  
‚Ä¢ To evaluate the humoral immune response to 2 
dose levels (60 and 120 ¬µg) of RSVPreF3 when 
given alone and co -administered with dTpa, at 
Screening, Day [ADDRESS_368882] dose 
vaccination  Immunogenicity  
‚Ä¢ RSV A neutralizing antibody titers at Screening, 
Day 8 and Day 31 in all groups  
‚Ä¢ RSV IgG antibody concentrations at Screening, Day 
8 and Day 31.  
Secondary (US and ex -US data to be considered pooled, then separately)  
Safety  
‚Ä¢ To evaluate the safety and reactogenicity of 2 dose 
levels (60 and 120 ¬µg) of RSVPreF3 when given 
alone or co -administered with dTpa from 1st dose 
vaccination up to Day 31  by [CONTACT_14509] .  Safety  
‚Ä¢ Occurrence of any AEs from Vaccination to Day 31, 
for all subjects:  
‚àí Occurrence of each solicited local AE at the 
site of injection in both limbs from Vaccination 
to Day 8  
‚àí Occurrence of solicited general AEs from 
Vaccination to Day 8  
‚àí Occurrence of any unso licited AEs from 
Vaccination to Day 31  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  18 Objectives  Endpoints  
‚Ä¢ Occurrence of Serious Adverse Events (SAEs) from 
Vaccination to Day 31.  
‚Ä¢ To evaluate the safety of 2 dose levels (60 and 
120 ¬µg) of RSVPreF3 when given alone and co -
administered with dTpa compared to dTpa -Placebo 
groups from 1st dose vaccination  up to Day 181.  ‚Ä¢ Occurrence of SAEs from Vaccination up to Day 
181. 
‚Ä¢ To evaluate the safety of 2 dose levels (60 and 
120 ¬µg) of RSVPreF3 when given alone and co -
administered from Vaccination up to Day 181 by 
[CONTACT_14509].  ‚Ä¢ Occu rrence of SAEs from Vaccination up to Day 
181.  
‚Ä¢ To evaluate the safety of RSVPreF3 (pooled for all 
groups receiving RSVPreF3) for the 1st dose 
vaccination.  ‚Ä¢ Occurrence of SAEs from Vaccination up to Day 
181. 
‚Ä¢ To evaluate the safety of 2nd dose of RSVPreF3 
given from [ADDRESS_368883] 2nd dose vaccination.  ‚Ä¢ Occurrence of SAEs from 2nd dose vaccination up to 
Day [ADDRESS_368884] -2nd dose vaccination.  
Immunogenicity  
‚Ä¢ To evaluate the humoral immune respo nse and 
persistence to 2 dose levels (60 and 120 ¬µg) of 
RSVPreF3 when given alone and co -administered 
with dTpa at Screening, Day 8, and Day [ADDRESS_368885] 
dose vaccination, and at 12 to 18 months by 
[CONTACT_14509].  Immunogenicity  
‚Ä¢ RSV A neutralizing antibody tit ers at Screening, Day 
8, Day 31, a nd a single timepoint between [ADDRESS_368886] vaccination.  
‚Ä¢ RSV IgG antibody concentrations at Screening, Day 
8, Day 31, a nd a single timepoint between [ADDRESS_368887] vaccination.  
‚Ä¢ To evaluate the humoral  immune response to the 
pertussis component of the dTpa vaccine when 
given alone and co -administered with 2 dose levels 
(60 and 120 ¬µg) of RSVPreF3 at Screening and Day 
[ADDRESS_368888] dose vaccination by [CONTACT_14509].  ‚Ä¢ Antibody concentrations against pertussis  toxoid 
(anti-PT), filamentous hemagglutinin (anti -FHA), and 
pertactin (anti -PRN) concentrations  at Screening 
and Day 31.  
‚Ä¢ To evaluate the humoral immune response to the 
diphtheria (D) component of dTpa vaccine when 
given alone and co -administered with 2 dose levels 
(60 and 120 ¬µg) of RSVPreF3 at Screening and Day 
[ADDRESS_368889] dose vaccination by [CONTACT_14509].  ‚Ä¢ Anti-D concentrations at Screening and Day 31.  
‚Ä¢ To evaluate the humoral immune response to the 
tetanus (T) component of dTpa vaccine when given 
alone and co -administered with 2 dose levels (60 
and 120 ¬µg) of RSVPreF3 at Screening and Day [ADDRESS_368890] dose vaccination by [CONTACT_14509].  ‚Ä¢ Anti-T concentrations at Screening and Day 31.  
‚Ä¢ To evaluate the humoral immune response of a 2nd 
dose vaccination of RSVPre F3 (120 ¬µg), following a 
first dose vaccination of either 60 ¬µg or 120 ¬µg.  ‚Ä¢ RSV A neutralizing antibody titers concentrations [ADDRESS_368891] 2nd dose vaccination.  
‚Ä¢ RSV IgG antibody concentrations [ADDRESS_368892] 2nd 
dose vaccination.  
Tertiary  
If necessary, additional testing to further characterize the response to the RSV maternal investigational vaccine will 
be performed.  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7
3URWRFRO$PHQGPHQW)LQDO
$SULO 2YHUDOO'HVLJQ 

Note: study groups labeled X = ex-US; study grou ps labeled U = US. V = visit, C = phone contact 
= Vaccination; N = number of subjects; V = Visit; D = Day; AE = adverse event; UP = Urine pregnancy test;  
CHS = Chemical/Hematological Screening, FU = follow-up 
BSH = blood sample (5 mL) for humoral immune responses (RSV-A neutralization and RSV IgG antibo dy concentrations at Screening, Visit 2, [Day 8] Visit 3, [Day 31], Visit 4, [up to 
D7 prior to 2nd vaccination], and Visit 6 [D31 post 2nd vaccination] 
dTpa ELISAs at Screening and Visit 3 [Day 31])  
* All subject groups will be giv en RSV 120mcg and subjects will be followed in an open labeled study 
** Hematological and biochemical laboratory testing at Visit 4 (D -7 up to and including 2nd dose vaccination) at the investiga tor‚Äôs discretion  
***There will be no follow-up between C1 and V4. New medical histo ry and relevant new safety even ts during this period will be recorded at visit 4 for subjects who agree to the study 
extension and sign the informed consent addendum. 
_3URWRFRO$PHQGPHQW$SU_70)_
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  20 2. SCHEDULE OF ACTIVITI ES (SOA)  
Table 3 Schedule of Activities   
Epoch  Epoch 001  Epoch 002  
(Vaccination 1)  Epoch 
003  
(Follow -
up 1)   Epoch 004  
(Vaccination 2)  Epoch 005  
(Follow -up 2)  
Type of contact  [CONTACT_301891] 
[ADDRESS_368893] -Vacc 2  
Informed consent  ‚óè      ‚óè     
Assign subject number  ‚óè           
Check inclusion/exclusion 
criteria  ‚óè O     ‚óè     
Check contraindications to 
subsequent vaccine(s) 
administration        O O    
Phone contact      ‚óè    ‚óè  ‚óè 
Collect demographic data  ‚óè1           
Medical history  O ‚óè     ‚óè      
Physical examination 2  ‚óè ‚óè ‚óè O   ‚óè   O  
Urine pregnancy test 3  ‚óè ‚óè      ‚óè    
Pre-vaccination body 
temperature and heart rate   ‚óè          
Pre-vaccination v ital sign 
readings4        ‚óè    
Distribution of subject card   O      O    209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  21 Epoch  Epoch 001  Epoch 002  
(Vaccination 1)  Epoch 
003  
(Follow -
up 1)   Epoch 004  
(Vaccination 2)  Epoch 005  
(Follow -up 2)  
Type of contact  [CONTACT_301891] 
[ADDRESS_368894] -Vacc 2  
Hematological and biochemical 
laboratory testing (~5.5 mL)  O      O9     
Blood sampling for humoral 
immune response (~5 mL) 5 ‚óè  ‚óè ‚óè   ‚óè   ‚óè  
Study group and treatment 
number allocation (SBIR)   O          
Treatment number allocation 
(SBIR)         O    
Vaccine administration   ‚óè      ‚óè    
Recording of administered 
treatment number   ‚óè      ‚óè    
[ADDRESS_368895] transcription by 
[CONTACT_301892]    ‚óè ‚óè      ‚óè  
Recording of solicited adverse 
events   ‚óè ‚óè     ‚óè ‚óè   
Recording of unsolicited adverse 
events    ‚óè ‚óè ‚óè    ‚óè ‚óè ‚óè  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  22 Epoch  Epoch 001  Epoch 002  
(Vaccination 1)  Epoch 
003  
(Follow -
up 1)   Epoch 004  
(Vaccination 2)  Epoch 005  
(Follow -up 2)  
Type of contact  [CONTACT_301891] 
[ADDRESS_368896] -Vacc 2  
Recording of AE leading to 
withdrawal   ‚óè ‚óè ‚óè ‚óè   ‚óè ‚óè ‚óè ‚óè 
Recording of serious AE 7 ‚óè ‚óè ‚óè ‚óè ‚óè  ‚óè ‚óè ‚óè ‚óè ‚óè 
Recording of pregnancies   ‚óè ‚óè ‚óè ‚óè  ‚óè ‚óè ‚óè ‚óè ‚óè 
Recording of concomitant 
medications/vaccinations8  ‚óè ‚óè ‚óè ‚óè  ‚óè ‚óè ‚óè ‚óè ‚óè 
Record any intercurrent medical 
conditions    ‚óè ‚óè ‚óè  ‚óè ‚óè ‚óè ‚óè ‚óè 
Screening conclusion  ‚óè           
Investigator sign -off on eCRF 
before analysis  ‚óè   ‚óè ‚óè     ‚óè ‚óè 
COVID -19 eCRFs log page        ‚óè ‚óè ‚óè ‚óè ‚óè 
Study conclusion primary study      ‚óè       
Study conclusion extension            ‚óè 
Vacc: vaccination  
‚óè is used to indicate a study procedure that requires documentation in the individual eCRF.  
‚óã is used to indicate a study procedure that does not require documentation in the individual eCRF  
1 Date of birth (month and year or year only, as per local regulation s), race, ethnicity and childbearing potential (if subject not of childbearing  potential , the specific reason should be 
documented in the eCRF ) (see Section  [IP_ADDRESS].1  for more detail) . 
2 Physical examination including resting vital signs (blood pressure, heart rate and respi[INVESTIGATOR_697], temperature) measured after at least [ADDRESS_368897].  
Screening: Ph ysical exam, vital signs (blood pressure, heart rate and respi[INVESTIGATOR_697], temperature), and weight, height and BMI will be r ecorded in the eCRF.  
Visit 1: History directed physical exam will be performed and the vital signs will be recorded in the eCRF  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  23 Visit 2 Physical examination will be performed only if deemed necessary by [CONTACT_093].  If performed , only vital signs (blood pressure, heart rate and respi[INVESTIGATOR_697]) will be 
required recorded in the eCRF  
Visit 3: Physical examination will be performed only if deemed necessary by [CONTACT_093].   
Visit 4: Perform history directed physical exam will be performed and vital signs (blood pressure, heart rate and respi[INVESTIGATOR_2842], temperature) will be recorde d in the eCRF. Weight, 
height and BMI should also be recorded in the eCRF.  
Visit 6: Physical examination will be performed only if deemed necessary by [CONTACT_093].   
[ADDRESS_368898] (instead of urine test) may be 
performed if required by [CONTACT_1606], local or ethics committee regulations.  
4Pre -vaccination vital signs: At Visit 5, the pre -vaccination vital signs (blood pressu re, heart rate and respi[INVESTIGATOR_697], temperature) will be recorded in the eCRF  
5 Sub-groups, Method, cut -off, and laboratory l ocations will be defined in Sectio n 8.4.3 . 
6 Primary Vaccination: The diary card will be distributed  at the day of vaccination and will be used for recording solicited and unsolicited AEs, and concomitant medications/products on 
the day of vaccination and for 6 subsequent days  and for recording unsolicited AEs and concomitant medications/products and vaccinations from Day 8 to Day 31 .  
Second Vaccination : The diary card will be distributed at the day of vaccination and will be used for recording solicited and unsolicited AEs, an d concomitant medications/products on 
the day of vaccination and for 6 subsequent days and for recording unsolicited AEs and conco mitant medications/products and vaccinations from Day 8 to Day 31 . 
7. For Screening and Visit 1 (prior to study vaccine administration), only those SAEs that are considered related to study par ticipation need to be recorded.  
8 Recording of Concomitant med ications/vaccinations/products w ill be described in Section 7.5 
9 Hematological and biochemical laboratory testing at  Visit 4 ( D -7 up to and includin g 2nd dose vaccination)  at the investigator‚Äôs discretion  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  24 Whenever possible, the investigator  should arrange study visits within the interval s 
described in Table 4. 
Table 4 Intervals between study visits   
Interval  Optimal timing  Allowed interval 
Screening Visit‚Üí Visit 1   ‚â§7 days   -7 - 1 days * 
Visit 1 ‚Üí Visit 2   8 days   7 - 10 days   
Visit 1  ‚Üí Visit 3   31 days  30 - 45 days  
Visit 1  ‚Üí Phone Contact  1 181 days  165 - 195 days   
Visit 4 ‚ÜíVisit 5 ‚â§7 days  -7 to 1 days * 
Visit 1  ‚Üí Visit 5 365 days  365 - 548 days**  
Visit 5  ‚Üí Phone Contact 2  8 days  7 - 10 days  
Visit 5  ‚Üí Visit 6  31 days  30 - 45 days  
Visit 5  ‚Üí Phone Contact 3  181 days  165 - 195 days  
*From 7  days prior to  vaccination up to and including the day of vaccination . 
** For a 6 -month period ‚â• 12 to <[ADDRESS_368899] vaccination  
3. INTRODUCTION  
3.1. Study rationale  
[COMPANY_004] is developi[INVESTIGATOR_301867] (RSVPreF3) against RSV 
disease in infants through  maternal immunizatio n. In the RSV maternal program to date,  
a Phase 1/2 study (study RSV MAT -001; NCT 03674177) is ongoing in healthy non -
pregnant women 18 -45 years of age (YOA) to determine the safety and immunogenicity 
of 3 dose levels of RSVPreF3 (30, 60 and 120 ¬µg) compared to placebo. Preliminary 
safety information is available in the investigator brochure.  
In many countries, the use of acellular pertussis vaccin ation is recommended for women 
during pregnancy to protect young infants against pertussis before they can benefit from 
the infant vaccination se ries [Mazzilli, 2018]. Boostrix, a vaccine against diphtheria, 
tetanus and acellular pertussis is administered in the third trimester of pregnancy in many 
countries. Since RSVPreF3 is intended for administration in the third trimester of 
pregnancy, it will be important to evaluate any potential interference of co-administration 
with Boostrix.  
This study (RSV MAT -011), in healthy non -pregnant women, wil l be the first to evaluate 
co-administration of RSVPreF3 with Boostrix (dTpa). Selection of the 60 and  120ÔÅ≠g 
RSVPreF3 doses was based on preliminary results of the ongoing (RSV MAT 001) Phase 
1/2 study.  
Two formulations of dTpa vaccine, one containing  300 micrograms  and the other 
containing  500 micrograms  of aluminum are licensed in the US and outside the US (ex -
US), respectively. As such, the Boostrix (US formulation) (dTpa_300) will be 
administered to subjects in centers located in the US, while the Boostrix (ex-US 
formulation)  (dTpa_500) will be administered to subjects in centers ex-US. In previous 
studies both, Boostrix formulations have had a similar immunogenicity and safety 
profiles. Therefore, any potential differences in immune response to Boostrix in this study 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  25 may be the result of population differences or immune response in the setting of 
RSVPreF3 co -administration [ Theeten, 2005]. 
This will be a Phase  II study to evaluate safety and reactogenicity of co -administration of 
RSVPreF3 and dTpa_300  or dTpa_500 in non -pregnant women 18 -45 YOA. 
Additionally, this study will evaluate whether co -administration of dTpa  affects the 
magnitude of the immune response  to RSVPreF3 and whether RSVPreF3 affects the 
magnitude of the immune response to dTpa.  
Finally, a second dose  vaccination  of RSVPreF3  (120 ¬µg) will be administered to the  
consenting  subjects from 12 to  18 months  following initial vaccination  to evaluate the 
immunogenicity and safety profile of RSVPreF3 . This extension  of the study will recruit 
the same non-pregnant women as a proxy for women who may require additional dosing 
in successive pregnancies .  
3.2. Background  
Please refer to the current Investigator B rochure for information regarding the pre -
clinical and clinical studies  of the RSV maternal (RSVPreF3) vaccine and background 
information pertaining to maternal immunization and RSV infection . 
3.3. Benefit/Risk a ssessment  
Please refer to the current Investigato r Brochure for the summary of potential risks and 
benefits of the RSV maternal (RSVPreF3) vaccine . 
Please refer to the local Prescribing Information for information regarding the summary 
of potential risks and benefits of Boostrix. 
3.3.1. Risk assessment  
The investigational RSV maternal (RSVPreF3) vaccine is in an early stage of clinical 
development. This is the first time that the RSV maternal (RSVPreF3) and Boostrix 
vaccines will be co -administered.  
Based on the following data, there are currently no kno wn important risks associated with 
the investigational RSV maternal (RSVPreF3) vaccine or its co -administration with 
Boostrix that preclude further development:  
‚Ä¢ Extensive prior experience with Boostrix administered alone . 
‚Ä¢ Results of non -clinical studies of  the RSV maternal (RSVPreF3) vaccine given alone 
and co-administered with Boostrix. 
‚Ä¢ Available safety data from an ongoing Phase I/II study of the RSV maternal 
(RSVPreF3) vaccine administered alone.  
All [ADDRESS_368900] 60 minutes after vaccination.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  26 3.3.2. Benefit a ssessment  
Subjects may or may not benefit from receiving the investigational RSV maternal vaccine 
and / or Boostrix. The efficacy of the RSV maternal vaccine has not yet been evalu ated. 
Subjects who receive Boostrix may have the benefit of being protected against diphtheria, 
tetanus and pertussis diseases [ Mazzilli, 2018]. However , the effect s of administering 
Boostrix together with the  RSV maternal vaccine are unknown.   
At the time of screening , the investigator  will review the potential participant dT pa 
vaccination history. All women  who are not up -to-date with dTpa vaccine based on  local 
recommendations will be informed of  their options : 
1. to participate in the trial and potentially be randomized to receive a dose of Boostrix 
or  
2. to opt out of the study . 
Of these women, those who chose to participate and did not receive Boostrix as part of 
the trial, will counselled on their options to receive the vaccine  at the time of unblinding .  
3.3.3. Overall Benefit:  Risk conclusion  
The balance of anticipated benefits and  apparent risks associated with the RSV maternal 
(RSVPreF3) vaccine, with Boostrix, and with co -administration of the RSV maternal 
(RSVPreF3) vaccine and Boostrix continues to be acceptable following the ongoing 
systematic review of safety data.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  27 4. OBJECTIVE (S) AND ENDPOINT (S) 
Table 5 Study objectives and endpoints   
Objectives  Endpoints  
Primary (US + ex -US data to be pooled)  
Safety  
‚Ä¢ To evaluate the safety and reactogenicity of 2 dose 
levels (60 and 120 ¬µg) of RSVPreF3 when given 
alone or co -administered with dTpa from 
Vaccination up to Day 31.   Safety  
‚Ä¢ Occurrence of any Adverse Events (AEs) from 
Vaccination to Day 31:  
‚àí Occurrence of each solicited local AEs at the 
site of injection in both limbs from Vaccination 
to Day 8;  
‚àí Occurrence of s olicited general AEs from 
Vaccination to Day 8;  
‚àí Occurrence of any unsolicited AEs from 
Vaccination to Day 31;  
‚àí Occurrence of Serious Adverse Events (SAEs) 
from Vaccination to Day 31.  
‚Ä¢ To evaluate the safety of a 2nd dose of RSVPreF3 
given from [ADDRESS_368901] 2nd dose vaccination  ‚Ä¢ Occurrence of any AEs from 2nd dose to Day [ADDRESS_368902]-2nd dose vaccination, for all subjects:  
‚Ä¢ Occurrence of each solicited local AE at the site of 
inject ion in both deltoids from 2nd dose vaccination 
to Day [ADDRESS_368903] -2nd dose vaccination  
‚Ä¢ Occurrence of solicited general AEs from 2nd dose 
vaccination to Day [ADDRESS_368904] 2nd dose vaccination  
‚Ä¢ Occurrence of any unsolicited AEs from 2nd dose to 
Day [ADDRESS_368905] - 2nd dose vacc ination  
‚Ä¢ Occurrence of Serious Adverse Events (SAEs) from 
2nd dose vaccination to Day [ADDRESS_368906] 2nd dose 
vaccination.  
Immunogenicity  
‚Ä¢ To evaluate the humoral immune response to 2 
dose levels (60 and 120 ¬µg) of RSVPreF3 when 
given alone and co -administered with dTpa, at 
Screening, Day [ADDRESS_368907] dose 
vaccination  Immunogenicity  
‚Ä¢ RSV A neutralizing antibody titers at Screening, 
Day 8 and Day 31 in all groups  
‚Ä¢ RSV IgG antibody concentrations at Screening, Day 
8 and Day 31.  
Secondary (US and ex -US data to be considered pooled, then separately)  
Safety  
‚Ä¢ To evaluate the safety and reactogenicity of 2 dose 
levels (60 and 120 ¬µg) of RSVPreF3 when given 
alone or co -administered with dTpa from 1st dose 
vaccination up to Day 31 by [CONTACT_14509].  Safety  
‚Ä¢ Occurrence of any AEs from Vaccination to Day 31, 
for all subjects:  
‚àí Occurrence of each solicited local AE at the 
site of injection in both limbs from Vaccination 
to Day 8  
‚àí Occurrence of solicited general AEs from 
Vaccination to Day 8  
‚àí Occurrence of any unsolicited AEs from 
Vaccination to Day 31  
‚àí Occurrence of Serious Adverse Events (SAEs) 
from Vaccination to Day 31 .  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  28 Objectives  Endpoints  
‚Ä¢ To evaluate the safety of 2 dose levels (60 and 
120 ¬µg) of RSVPreF3 when given alone and co -
administered with dTpa compa red to dTpa -Placebo 
groups from 1st dose vaccination  up to Day 181.  ‚Ä¢ Occurrence of SAEs from Vaccination up to Day 
181. 
‚Ä¢ To evaluate the safety of 2 dose levels (60 and 
120 ¬µg) of RSVPreF3 when given alone and co -
administered from Vaccination up to Day 181 by 
[CONTACT_14509].  ‚Ä¢ Occurrence of SAEs from Vaccination up to Day 
181.  
‚Ä¢ To evaluate the safety of RSVPreF3 (pooled for all 
groups receiving RSVPreF3) for the 1st dose 
vaccination.  ‚Ä¢ Occurrence of SAEs from Vaccination up to Day 
181. 
‚Ä¢ To evaluate the safety of 2nd dose of RSVPreF3 
given from [ADDRESS_368908] 2nd dose vaccination.  ‚Ä¢ Occurrence of SAEs from 2nd dose vaccination up to 
Day [ADDRESS_368909] -2nd dose vaccination.  
Immunogenicity  
‚Ä¢ To evaluate the humoral immune response and 
persistence to 2 dose levels (60 and 120 ¬µg) of 
RSVPreF3 when given alone and co -administered 
with dTpa at Screening, Day 8, and Day [ADDRESS_368910] 
dose vaccination, and at 12 to 18 months by 
[CONTACT_14509].  Immunogenicity  
‚Ä¢ RSV A neutralizing antibod y titers at Screening, Day 
8, Day 31, a nd a single timepoint between [ADDRESS_368911] vaccination.  
‚Ä¢ RSV IgG antibody concentrations at Screening, Day 
8, Day 31, a nd a single timepoint between [ADDRESS_368912] vaccination.  
‚Ä¢ To evaluate the hu moral immune response to the 
pertussis component of the dTpa vaccine when 
given alone and co -administered with 2 dose levels 
(60 and 120 ¬µg) of RSVPreF3 at Screening and Day 
[ADDRESS_368913] dose vaccination by [CONTACT_14509].  ‚Ä¢ Antibody concentrations against pert ussis toxoid 
(anti-PT), filamentous hemagglutinin (anti -FHA), and 
pertactin (anti -PRN) concentrations  at Screening 
and Day 31.  
‚Ä¢ To evaluate the humoral immune response to the 
diphtheria (D) component of dTpa vaccine when 
given alone and co -administered with 2 dose levels 
(60 and 120 ¬µg) of RSVPreF3 at Screening and Day 
[ADDRESS_368914] dose vaccination by [CONTACT_14509].  ‚Ä¢ Anti-D concentrations at Screening and Day 31.  
‚Ä¢ To evaluate the humoral immune response to the 
tetanus (T) component of dTpa vaccine when given  
alone and co -administered with 2 dose levels (60 
and 120 ¬µg) of RSVPreF3 at Screening and Day [ADDRESS_368915] dose vaccination by [CONTACT_14509].  ‚Ä¢ Anti-T concentrations at Screening and Day 31.  
‚Ä¢ To evaluate the humoral immune response of a 2nd 
dose vaccination of  RSVPreF3 (120 ¬µg), following a 
first dose vaccination of either 60 ¬µg or 120 ¬µg.  ‚Ä¢ RSV A neutralizing antibody titers concentrations [ADDRESS_368916] 2nd dose vaccination.  
‚Ä¢ RSV IgG antibody concentrations [ADDRESS_368917] 2nd 
dose vaccination.  
Tertiary  
If necessary, additional testing to further characterize the response to the RSV maternal investigational vaccine will 
be performed.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368918] the dose level for 
further development. Two formulations of Boostrix, one containing  300 
micrograms  (dTpa_300) and the other containing  500 micrograms (dTpa_500) of 
aluminum are l icensed in the US and outside the US (ex -US), respectively. The 
difference between the two formulations being the level of aluminium adjuvant. Both  
formulations will be studied.  
Approximately [ADDRESS_368919] 95% confidence to rule 
out an AE rate greater than 3.6% and there will be at least 90% power to claim non- 
inferiority  with a margin of 1.[ADDRESS_368920] dose  vaccination , and to 
assess the safety and immunogenicity following a second dose vaccination of the 
RSVPreF3 maternal vaccine. This extension  of the study will recruit the same non-
pregnant women as a p roxy for women  who may require additional dosing in  successive 
pregnancies.  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7
3URWRFRO$PHQGPHQW)LQDO
$SULO  2YHUDOOGHVLJQ
)LJXUH 6WXG\GHVLJQRYHUYLHZ
 
Note: study groups labeled X = ex-US; study grou ps labeled U = US. V = visit, C = phone contact 
= Vaccination; N = number of subjects; V = Visit; D = Day; AE = adverse event; UP = Urine pregnancy test;  
CHS = Chemical/Hematological Screening, FU = follow-up 
BSH = blood sample (5 mL) for humoral immune responses (RSV-A neutralization and RSV IgG antibo dy concentrations at Screening, Visit 2, [Day 8] Visit 3, [Day 31], Visit 4, [up to 
D7 prior to 2nd vaccination], and Vi sit 6 [D31 post 2nd vaccination] 
dTpa ELISAs at Screening and Visit 3 [Day 31])  
_3URWRFRO$PHQGPHQW$SU_70)_
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  31 *All subject groups will be given RSV 120mcg and subjects will be followed in an unblinded open label manner  
** Hematological and biochemical laboratory testing at Visit 4 (D -7 up to and including 2nd dose vaccination) at the investigator‚Äôs discretion  
*** There will be no follow -up between C1 and V4. New medical history and relevant new safety events during this period will be recorded at visit 4 for s ubjects who agree to the study 
extension and sign the informed consent addendum.  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  32 The study will be conducted with 2 formulations of dTpa, dTpa_300 (in the US) and 
dTpa_500  (ex-US). 
Approximately 500 eligible subjects (250 in the US and 250 ex -US) will be enrolled. Of 
these, approximately 250 subjects will be randomized to 5 US study groups in a 1:1:1:1:1 
ratio using SBIR, and the remaining approximately 250 will be randomiz ed to 5 ex-US 
study groups in a 1:1:1:1:1 ratio using SBIR.  The randomization algorithm will use a 
minimization pr ocedure by [CONTACT_301893]  (US and ex -US) as a stratification 
factor, and  age at the time of vaccination (18 -32 or 33-45 years of a ge) and center as 
minimization factors.  
Protocol waivers or exemptions are not allowed unless necessary for the management of 
immediate safety concerns. Therefore, adherence to the study design requirements, 
including those specified in the schedule of act ivities (Section 2), are essential and 
required for study conduct.  
‚Ä¢ Type of study: self-contained  
‚Ä¢ Experimental design :  
‚àí Primary Vaccination : multi-centric study, multi-country Phase II, observer -
blind, randomized , with 5 parallel groups  in each formulation  (US, ex-US).  
Study Extension : multi-centric study, multi -country Phase II, open unblinded , with all 5 
parallel groups in each formulation (US, ex -US) receiving the experimental RSV 
maternal (120 ¬µg) vaccine . 
‚Ä¢ Duration of the study : The primary study will be approximately [ADDRESS_368921]  and from 18 up to 24 months for subjects that agree to participate in 
the study extension . 
‚àí Primary Vaccination  
‚Ä¢ Epoch 001: Screening  
‚Ä¢ Epoch 002: Primary vaccina tion starting at Visit 1 (Day 1) and ending just 
before the Visit 3 (Day 31)   
‚Ä¢ Epoch 003: Follow-up after Visit 3 (Day 31)  to Phone Contact 1 on (Day 
181)  
‚àí End of Primary Study : Subjects must  sign the ICF addendum  to join the study 
extension . 
‚àí Study Extension : 6-month period starting at the beginning of 12th month up to 
the beginning of 18th month after Visit 1 (‚â•12 to <18 months)  
‚Ä¢ Epoch 004:  2nd dose vaccination starting from Visit 4 ( up -7 days prior to 
vaccination) to Visit 6 (Day [ADDRESS_368922] 2nd dose vaccination)  
‚Ä¢ Epoch 005:  2nd dose vaccination Study Follow -up 2 starting a fter Visit 6 
(Day [ADDRESS_368923] 2nd dose vaccination) and ending at Phone Contact  3 (Day 
[ADDRESS_368924] 2nd vaccination) . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  33 ‚Ä¢ Primary completion Date (PCD): Visit 3 (Day 31) or last visit of Primary Epoch  
Refer to glossary of terms for the definition of PCD.  
‚Ä¢ End of Study (EoS):  Last testing results release d of samples collected at Visit 6, to 
occur no later than [ADDRESS_368925] visit (LSLV), which occurs with 
phone contact [ADDRESS_368926] 2nd vaccination . 
Refer to glossary of terms  for the definition of EoS.  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  34 ‚Ä¢ Study groups:  
Table 6 Study groups, treatment and epochs foreseen in the study  
Study Groups  Number of 
subjects  Age 
(Min-
Max)  Treatment 
name 1  Treatment 
name 2  Epochs  
(Blinding)    
Epoch 001  
(Screening)  Epoch 002 
(observer -
blind)  Epoch 003  
(single -
blind)  Epoch 
004 (open 
study)  Epoch 00 
5 
 
(open 
study)  
XRSV120_dTpa  50 18 ‚Äì 45 
years RSV MAT 120  
Boostrix -ex-US 
(dTpa_500)  RSV MAT 120  
x x x x x 
Xplacebo_RSV120  50 18 ‚Äì 45 
years RSV MAT 120  
Placebo  RSV MAT 120  x x x x x 
XRSV60_dTpa  50 18 ‚Äì 45 
years  RSV MAT 60  
Boostrix -ex-US 
(dTpa_500)  RSV MAT 120  
x x x x x 
Xplacebo_RSV60  50 18 ‚Äì 45 
years  RSV MAT 60  
Placebo  RSV MAT 120  x x x x x 
Xplacebo_dTpa  50 18 ‚Äì 45 
years  Boostrix -ex-US 
(dTpa_500)  
Placebo  RSV MAT 120  
x x x x x 
URSV120_dTpa  50 18 ‚Äì 45 
years  RSV MAT 120  
Boostrix -US 
(dTpa_300)  RSV MAT 120  
x x x x x 
Uplacebo_RSV120  50 18 ‚Äì 45 
years  RSV MAT 120  
Placebo  RSV MAT 120  x x x x x 
URSV60_dTpa  50 18 ‚Äì 45 
years  RSV MAT 60  
Boostrix -US RSV MAT 120  x x x x x 
Uplacebo_RSV60  50 18 ‚Äì 45 
years  RSV MAT 60  
Placebo  RSV MAT 120  x x x x x 
Uplacebo_dTpa  50 18 ‚Äì 45 
years  Boostrix -US 
(dTpa_300)  
Placebo  RSV MAT 120  
x x x x x 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  35 ‚Ä¢ Control: (active comparator ). 
‚Ä¢ Treatment allocation: (randomised  stratified).  
‚Ä¢ Blinding: As described in  Table 6. 
‚Ä¢ Data collection: standardis ed Electronic Case Report Form ( eCRF). Solicited 
symptoms will be collected using a subject paper Diary ( pDiary). 
‚Ä¢ Safety monitoring  
If the investigator becomes aware of a holding rule being met, he/she will suspend 
vaccination and will inform [COMPANY_004] immediately.  
Refer to section 8.6 for detailed description of holding rules and safety monitoring.  
5.3. Number of subjects 
Approximately 500 subjects wi ll be randomise d such that approximately 475 (based on 
5% drop out rate ) evaluable subjects complete the study.  
Withdrawals will not be replaced.  
5.4. Subject and study c ompletion  
A subject is considered to have completed the study if she is available for the concluding 
phone contact 3 (Day [ADDRESS_368927] second vaccination ) as described in the protocol.  
For those subjects that do not agree to participate in the study extension, the conc luding 
contact [CONTACT_301894] [ADDRESS_368928] as described in previous version of protocol 
(RSV MAT -011 (209141) Protocol Amendment 3 (03 -APR-2020). 
Global completion of the study is required in order to provide sufficient subjects as 
defined in Section  10.1 Sample Size Determination . 
6. STUDY POPULATION  
6.1. Inclusion c riteria for enrolment  (primary study) 
Deviations from inclusion criteria are not allowed because they can potentially jeopardi se 
the scientific integrity, regulatory acceptability of the study or subject safety. Therefore, 
adherence to the criteria as specified in the protocol is essential.  
All subjects must satisfy ALL the following criteria at study entry:  
‚Ä¢ Subjects who, in the opi[INVESTIGATOR_144457], can and will comply with the 
requirements of the protocol (e.g. completion of the diary card, return for follow -up 
visits).  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  36 ‚Ä¢ Written or witnessed/thumb printed  informed consent obt ained from the subject prior 
to performance of any study specific procedure.  
‚Ä¢ Healthy female subjects; as established by [CONTACT_301895], 
aged [ADDRESS_368929] vaccination;  
‚Ä¢ Female subjects of childbearing potential may be enrolled in the study, if the subject:  
‚àí has practiced adequate contraception for 30 days prior to  primary vaccination, 
and 
‚àí has a negative pregnancy test on the day of primary vaccination, and  
‚àí has agreed to continue adequate contraception for 90 days after comp letion of 
the vaccination.   
‚àí No local condition precluding injection in both left and right deltoid muscles.  
6.2. Exclusion c riteria for enrolment  (primary study)  
Deviations from exclusion criteria are not allowed because they can potentially 
jeopardize the scientific integrity, regulatory a cceptability of the study or subject safety. 
Therefore, adherence to the criteria as specified in the protocol is essential.  
The following criteria should be checked at the time of study entry. If ANY exclusion 
criterion applies, the subject must not be in cluded in the study.  
6.2.1. Medical conditions  
‚Ä¢ History of any reaction or hypersensitivity likely to be exacerbated by [CONTACT_301896];  
‚Ä¢ Any confirmed or suspected immunosuppressive or immunodeficient condition, 
based on medical history and physical examination (no laboratory testing required);  
‚Ä¢ Hypersensitivity to latex;  
‚Ä¢ Major congenital defects, as assessed by [CONTACT_093];  
‚Ä¢ Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal 
functional abnormality, as determined by [CONTACT_9870], physical examination or 
laboratory screening tests;  
‚Ä¢ Significant or uncontrolled psychiatric illness;  
‚Ä¢ Recurrent hi story or un -controlled neurological disorders or seizures;  
‚Ä¢ Documented HIV -positive subject;  
‚Ä¢ History of or current autoimmune disease;  
‚Ä¢ Body mass index (BMI) > 40 kg/m2; 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  37 ‚Ä¢ Any clinically significant hematological parameter (hemoglobin level, white blood 
cell, lymphocyte, neutrophil, eosinophil, platelet red blood cell count and erythrocyte 
mean corpuscular volume) and/or biochemical (alanine aminotransferase [ALT], 
aspartate aminotransferase [AST], creatinine, blood urea nitrogen) laboratory 
abnormality.  
‚àí The investigator should use his/her clinical judgement to decide which 
abnormalities are clinically significant.  
‚Ä¢ Any other clinical condition that, in the opi[INVESTIGATOR_871], might pose 
additional risk to the subject due to participation in the study.  
6.2.2. Prior/Concomitant t herapy 
‚Ä¢ Use of any investigational or non -registered product (drug, vaccine or medical 
device) other than the study vaccines during the period starting [ADDRESS_368930] dose of study vaccines (Day -29 to Day 1), or planned use dur ing the study 
period; 
‚Ä¢ Administration of long -acting immune -modifying drugs at any time during the study 
period (e.g. infliximab);  
‚Ä¢ Administration of immunoglobulins and/or any blood products or plasma derivatives 
during the period starting [ADDRESS_368931] dose of study vaccines or planned 
administration during the study period;  
‚Ä¢ Chronic administration (defined as more than 14 days in total) of 
immunosuppressants or other immune -modifying drugs during the period starting [ADDRESS_368932] v accine dose(s). For corticosteroids, this will mean 
prednisone  ÔÇ≥5 mg/day, or equivalent. Inhaled and topi[INVESTIGATOR_14271];  
‚Ä¢ Planned administration/administration of a vaccine not foreseen by [CONTACT_301897] 30 days befo re and ending 30 days after study 
primary vaccination, with the exception of any licensed influenza vaccine which may 
be administered ‚â• 15 days before or after study vaccination;  
‚Ä¢ Administration of a vaccine containing diphtheria, tetanus or pertussis antigens or 
diphtheria and tetanus toxoids within the previous 5 years  (by [CONTACT_163400]) ; 
‚Ä¢ Previous experimental vaccination against RSV;  
6.2.3. Prior/Concurrent clinical study e xperienc e 
‚Ä¢ Concurrently participating in another clinical study, at any time during the study 
period, in which the subject has been or will be exposed to an investigational or a 
non-investigational vaccine/product (drug or medical device);  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  38 6.2.4. Other exclusions  
‚Ä¢ Pregnant or lactating female;  
‚Ä¢ Female planning to become pregnant or planning to discontinue contraceptive 
precautions;  
‚Ä¢ History of alcoholism, drug abuse and/or use disorder within the past two years (as 
defined in DSM -5 Diagnostic Criteria) [ Camargo, 1984; Christy, 1995; Hasin, 2013]; 
‚Ä¢ Any study personnel or their immediate dependents, family, or household member s. 
6.3. Inclusion criteria for study extension  
Deviations from inclusion criteria are not allowed because they ca n potentially jeopardise 
the scientific integrity, regulatory acceptability of the study or subject safety. Therefore, 
adherence to the criteria as specified in the protocol is essential.  
‚Ä¢ Completed in primary study and received 1st dose vaccination of a study vaccine 
(RSVPreF3 or Boostrix). 
‚Ä¢ Written or witnessed/thumb printed informed consent obtained from the subject prior 
to performance of any study specific procedure to the study extension . 
Are eligible if they meet the following criteria below 
All subjects must satisfy ALL the following criteria:  
‚Ä¢ Subjects who, in the opi[INVESTIGATOR_871], can and will comply with the 
requirements of the protocol (e.g. completion of the diary card, return for follow -up 
visits).  
‚Ä¢ Female subjects  remain healthy ; as established by [CONTACT_301898], aged [ADDRESS_368933] vaccination;  
‚Ä¢ Female subjects of childbearing potential are eligible for the extension , if the subject:  
‚àí has practiced adequate contraception for 30 day s prior to 2nd vaccination  
‚àí has a negative pregnancy test with results available on the day of 2nd vaccination  
‚àí has agreed to continue adequate contraception for [ADDRESS_368934] not be included in the extension . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  39 6.4.1. Medical conditions  for extension  
‚Ä¢ History of any reaction or hypersensitivity likely to be  exacerbated by [CONTACT_301896];  
‚Ä¢ Any confirmed or suspected immunosuppressive or immunodeficient condition, 
based on medical history and physical examination (no laboratory testing required);  
‚Ä¢ Hypersensitivity to latex;  
‚Ä¢ Acute or chronic clinic ally significant pulmonary, cardiovascular, hepatic or renal 
functional abnormality, as determined by [CONTACT_9870], physical examination or 
laboratory screening tests;  
‚Ä¢ Significant or uncontrolled psychiatric illness;  
‚Ä¢ Recurrent history or un -controlled neurological disorders or seizures;  
‚Ä¢ Documented HIV -positive subject;  
‚Ä¢ History of or current autoimmune disease;  
‚Ä¢ Body mass index (BMI) > 40 kg/m2; 
‚Ä¢ Participants who experience d any SAE judged to be possibly or probably related to 
first dose vaccination  of RSVPreF3, including hypersensitivity reactions.  
‚Ä¢ Any other clinical condition that, in the opi[INVESTIGATOR_871], might pose 
additional risk to the subject due to participation in the study.  
6.4.2. Prior/Concomitant therapy  for extension  (Amended 09-APR-2021) 
‚Ä¢ Use of any investigational or non -registered product (drug, vaccine or medical 
device) other than the study vaccines during the period starting 30 days before the 
second dose of study vaccin e (Day -29 to Day 1), or planned use during the 6 month 
study extension period; 
‚Ä¢ Administration of long -acting immune -modifying drugs at any time during the study 
period (e.g. infliximab);  
‚Ä¢ Administration of immunoglobulins and/or any blood products or plasma derivatives 
during the period starting [ADDRESS_368935] dose of study vaccines or planned 
administration during the study period;  
‚Ä¢ Chronic administration (defined as more than 14 days in total) of 
immunosuppressants or other immune -modifying drugs during the period starting [ADDRESS_368936] vaccine do se(s). For corticosteroids, this will mean 
prednisone  ÔÇ≥5 mg/day, or equivalent. Inhaled and topi[INVESTIGATOR_14271];  
‚Ä¢ Planned administration/administration of a vaccine not foreseen by [CONTACT_301897] 30 days before and en ding 30 days after study 2nd 
dose vaccination *, with the exception of any licensed influenza vaccine which may 
be administered ‚â•15 days before or after study vaccination . 
*Note: In case an emergency mass vaccination for an unforeseen public health 
threat (e.g.: a pandemic) is organised by [CONTACT_43068], outside the  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368937] Ch aracteristics (SmPC) or Prescribing Information and according to the 
local governmental recommendations.  
6.4.3. Prior/Concurrent clinical study experience  for extension  
‚Ä¢ Concurrently participating in another clinical study, at any time during the study 
period, in which the subject has been or will be exposed to an investigational or a 
non-investigational vaccine/product (drug or medical device);  
6.4.4. Other exclusions  for extension  
‚Ä¢ Pregnant or lactating female  at the time of V isit 4; 
‚Ä¢ Female planning to become pregnant or  planning to discontinue contraceptive 
precautions;  
‚Ä¢ History of alcoholism, drug abuse and/or use disorder within the past two years (as 
defined in DSM -5 Diagnostic Criteria) [ Camargo, 1984; Christy, 1995; Hasin, 2013]; 
‚Ä¢ Any study personnel or their immediate dependents, family, or household memb ers. 
6.5. Criteria for temporary  delay for enrolment and vaccination   
Vaccination  may be postponed within the allowed time interval until transient 
circumstances cited below have been resolved:  
‚Ä¢ Haematological/biochemical values out of normal range at screening,  if expected to 
be temporary. Subjects must be re -screened at a later date within the allowed time 
interval. 
‚Ä¢ Acute disease and/or fever at the time of  enrollment ; 
‚àí Fever is defined as body temperature ‚â• 38‚óãC/100.4‚óãF. The preferred location for 
measuring temperature in this study will be the oral cavity. 
‚àí For subjects with acute disease and/or fever at the time of enrollment, Visit 1  for 
primary vaccination and Visit 5, the 2nd vaccination  will be rescheduled within 
the allowed window for the visit.  
‚àí Screening hematological/ biochemical do not need to be repeated if obtained 
within 30 days of each vaccination . 
Subjects with a minor illness (such as mild diarrhea, mild upper respi[INVESTIGATOR_28945]) without fever may be enr olled at the discretion of the investigator . 
6.6. Screen and baseline failures  
‚ÄúScreening failures‚Äù are subjects who withdraw or are withdrawn from the study after 
giving informed consent, but before study eligibility (presence of all inclusion and 
absence of all exclusion criteria) is confirmed.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368938] udy eligibility should also be considered a 
screening failure. Limited data for screening failures (including reason for screening 
failure and any SAEs that occurred at the visit) will be collected and reported in the 
eCRF. 
The development of such conditio ns (after Visit 1) does not constitute screening failure 
and should be captu red on the eCRF, as applicable . 
6.7. Screen failures to the extension  
‚ÄúScreening failures‚Äù for the extension are subjects who withdraw or are withdrawn from 
the extension after giving informed consent to the extension, but before extension 
eligibility (presence of all inclusion and absence of all exclusion criteria) is confi rmed. 
Limited data for screening failures (including reason for screening failure and any SAEs 
that occurred at the visit) will be collected and reported in the eCRF.  
7. TREATMENTS  
Study treatment is defined as a set of investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject . 
7.1. Treatments administered  
Table 7 Treatments administered  (Part 1) 
 RSV MAT 120  RSV MAT 60  Boostrix -ex-
US 
(dTpa_500)  Boostrix -US 
(dTpa_300)  
 Placebo  
Vaccines 
/Products  RSVPreF3 high 
dose  RSVPreF3 mid 
dose  dTpa  dTpa  NaCl  
NaCl  NaCl  
Presentation  Powder for 
suspension for 
injection (vial)  
(174mcg/vial)  Powder for 
suspension for 
injection (vial)  
(87mcg/vial)  Suspension for 
injection 
(syringe)  Suspension for 
injection 
(syringe)  Solution for 
injection; vial)  
Solution for solution 
for injection; (vial)  Solution for 
solution for 
injection; (vial)  
Formulation  RSVPreF3(120 
¬µg)/Trehalose(12.73 
mg).  
NaCl solution (4.5 
mg/0.5 mL, ~150 
mM) RSVPreF3(60 
¬µg)/Trehalose(6.42 
mg).  
NaCl solution (4.5 
mg/0.5 mL, ~150 
mM) Diphtheria 
toxoid (‚â• 2 IU) 
adsorbed on 
aluminium 
hydroxide and 
aluminium 
phosphate; 
Tetanus toxoid 
(‚â• 20 IU) Diphtheria 
toxoid (‚â• 2 IU) 
adsorbed on 
aluminium 
hydroxide; 
Tetanus toxoid 
(‚â• 20 IU) 
adsorbed on 
aluminium NaCl solution 
(4.5 mg/0.5 
mL, ~150 
mM) 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  42  RSV MAT 120  RSV MAT 60  Boostrix -ex-
US 
(dTpa_500)  Boostrix -US 
(dTpa_300)  
 Placebo  
adsorbed on 
aluminium 
hydroxide and 
aluminium 
phosphate; 
Pertussis 
toxoid (8 ¬µg) 
adsorbed on 
aluminium 
hydroxide and 
aluminium 
phosphate; 
Filamentous 
haemagglutinin 
(8 ¬µg) 
adsorbed on 
aluminium 
hydroxide and 
aluminium 
phosphate; 
Pertactin (69 
kDa outer 
membrane 
protein) (2.5 
¬µg) adsorbed 
on aluminium 
hydroxide and 
aluminium 
phosphate; 
Aluminium 
hydroxide (0.3 
mg Al¬≥+); 
Aluminium 
phosphate (0.2 
mg Al¬≥+); 
Sodium 
chloride; Water 
for injections 
q.s. 0.5 mL  hydroxide; 
Pertussi s 
toxoid (8 ¬µg) 
adsorbed on 
aluminium 
hydroxide; 
Filamentous 
haemagglutinin 
(8 ¬µg) 
adsorbed on 
aluminium 
hydroxide; 
Pertactin (69 
kDa outer 
membrane 
protein) (2.5 
¬µg) adsorbed 
on aluminium 
hydroxide; 
Aluminium 
hydroxide (0.3 
mg Al¬≥+); 
Sodium 
chloride (4.4 
mg); Water for 
injections q.s. 
0.5 mL  
Route of 
Administration  Intramuscular use  Intramuscular use  Intramuscular 
use Intramuscular 
use Intramuscular 
use 
Administration site  
Location  Deltoid  Deltoid  Deltoid  Deltoid  Deltoid  
Laterality  Refer to  Table 8. 
No of doses  2 1 1 1 1 
Dose volume  0.5 ml 0.5 ml 0.5 ml 0.5 ml 0.5 ml  
Packaging and 
Labelling  Refer to the SPM  Refer to the SPM  Refer to the 
SPM  Refer to the 
SPM  Refer to the 
SPM  
Manufacturer  RSVPreF3: [COMPANY_004] 
Biologicals  
NaCl: [COMPANY_004]  
Biologicals  RSVPreF3: [COMPANY_004] 
Biologicals  
NaCl: [COMPANY_004] 
Biologicals   [COMPANY_004] 
Biologicals  [COMPANY_004] 
Biologicals  [COMPANY_004] 
Biologicals  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  43 The vaccinations will be administered in each arm as follows:  
Table 8 Treatments administered  (Part 2) 
Primary Vaccination  
Group  Formulation  N  Laterality   Laterality  
XRSV120_dTpa  
ex-US 50 RSVPreF3=120¬µg  Left Arm dTpa 500 Right  Arm 
Xplacebo_RSV120  50 RSVPreF3=120¬µg  Left Arm Placebo  Right Arm  
XRSV60_dTpa  50 RSVPreF3=60¬µg  Left Arm dTpa 500 Right  Arm 
Xplacebo_RSV60  50 RSVPreF3=60¬µg  Left Arm Placebo  Right  Arm 
Xplacebo_dTpa  50 Placebo  Left Arm  dTpa 500 Right  Arm 
URSV120_dTpa  
US 50 RSVPreF3=120¬µg  Left Arm dTpa 300 Right  Arm 
Uplacebo_RSV120  50 RSVPreF3=120¬µg  Left Arm Placebo  Right Arm  
URSV60_dTpa  50 RSVPreF3=60¬µg  Left Arm dTpa 300 Right  Arm 
Uplacebo_RSV60  50 RSVPreF3=60¬µg  Left Arm Placebo  Right Arm 
Uplacebo_dTpa  50 Placebo  Left Arm  dTpa 300 Right  Arm 
2nd Vaccination  
Group s in primary 
vaccination  Formulation  
in primary 
vaccination  N Groups in 2nd 
vaccination  Laterality  
XRSV120_dTpa  
ex-US 50 RSVPreF3=120¬µg  Non-Dominant  
Xplacebo_RSV120  50 RSVPreF3=120¬µg  Non-Dominant  
XRSV60_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
Xplacebo_RSV60  50 RSVPreF3=120¬µg  Non-Dominant  
Xplacebo_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
URSV120_dTpa  
US 50 RSVPreF3=120¬µg  Non-Dominant  
Uplacebo_RSV120  50 RSVPreF3=120¬µg  Non-Dominant  
URSV60_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
Uplacebo_RSV60  50 RSVPreF3=120¬µg  Non-Dominant  
Uplacebo_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
Note: study groups labeled X = ex-US; study groups labeled U = US.  
Refer to the Study Procedures Manual (SPM) for detailed instructions on study vaccine 
reconstitution.  
After completing all prerequisite procedures prior to vaccination  (refer to Section 7.7 
regarding the contraindications to subseque nt vaccination) , the assigned study vaccines 
(Table 9) will be administered as shown in Table 7and Table 8. 
If the investigator or delegate determines that the subject‚Äôs health on the day of 
administra tion temporarily precludes vaccine(s)  administration, the visit will be 
rescheduled within the allowed interval for this visit (refer to  Table 4). 
The subjects will be o bserved closely for at least [ADDRESS_368939] ration 
of the vaccine(s) , with appropriate medical treatment readily available in case of 
anaphylaxis and syncope.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368940]  identification  number will be the 
same in the  study extension. No new subjects will be recruited . 
[IP_ADDRESS]. Randomisation of supplies  
The randomisation of supplies within blocks will be performed at [COMPANY_004], using MATerial 
Excellence ( MatEx), a program developed for use in Statistical Analysis System (SAS) 
(Cary, NC, [LOCATION_003])  by [CONTACT_23983]. Entire blocks will be shipped to the study centres/warehouse.  
[IP_ADDRESS]. Treatment allocation to the subject  
The treatment numbers will be allocated by [CONTACT_301899]  ([ADDRESS_368941] ‚Äì one for each vaccine/product administe red).  
For the second vaccination, [ADDRESS_368942].  
[IP_ADDRESS].1.  Study group and treatment number allocation  
The target will be to enrol approximately 500 eligible subjects (250 in the US and 250 ex -
US). Of these, 250 subjects will be randomized to 5 study groups in a 1:1:1:1:1 ratio 
using SBIR in the US, and the other a pproximately 250 will also be randomized to 5 
study groups in a 1:1:1:1:[ADDRESS_368943] to a study group  at the investigator site will be performed using 
a randomisation system on internet (SBIR). The randomisation algorithm will use a 
minimisation procedure  by [CONTACT_301893]  (US and ex -US) as a stratification 
factor, and  age at the time of vaccination (18 -32 or 33-45 years of age) and center as 
minimization factors.  
When SBIR is not available, please refer to the SBIR user guide or the Study Procedures 
Manual (SPM) for specific instructions.  
After obtaining the signed or witnessed/thumb printed and dated ICF from the subject 
and having checked the eligibility of the subject, the study staff in charge of the vaccine  
administration will access SBIR. Upon providing the formulation  (US or ex-US), age, 
centre and the subject identification number, the randomisation system will determine the 
study group and will provide the treatment number to be used for each dose . 
The number of each administered treatm ent must be recorded in the eCRF  on the Va ccine 
Administration screen . 
Note that as soon as the target number of approximately 250 subjects in the US or 250 
subjects ex -US has been reached, the enrolment will be frozen for this formulation . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368944] sequentially  at each centre . 
7.3. Blinding  and unblinding  
Data will be collected in an observer -blind manner  during the primary study . By 
[CONTACT_43049]-blind, it is meant that during the cour se of the study, the vaccine(s)  recipi[INVESTIGATOR_301868] (e.g. safety, reactogenicity) 
will all be unaware of which vaccine s were administered. To do so, vaccine  preparation 
and administration will be done by [CONTACT_301900] w ho will not participate 
in any of the study clinical evaluation assays.  
Investigators will remain blinded to each subject‚Äôs assigned study treatment until 
completion of the primary vaccination day [ADDRESS_368945] (C1) for a given subject, the investigator will b e 
informed of the subject‚Äôs treatment assignment and will communicate this to the 
subject. The study extension will then be conducted as an open label study . 
Unblinded monitors and in the event of a Quality Assurance audit, the auditor(s) will be 
allowed access to un -blinded study treatment records at the site(s) to verify that 
randomisation/dispensing has been done accurately.  Please refer to the SPM for details 
on blinding of the vaccine .  
7.3.1. Emergency unblinding  
Unblinding of a subject‚Äôs individual treatme nt code should occur only in the case of a 
medical emergency when knowledge of the treatment is essential for the clinical 
management or welfare of the subject.  
The emergency unblinding process consists of the automated Internet -based system 
(SBIR) that al lows the investigator to have unrestricted, immediate and direct access to 
the subject‚Äôs individual study treatment.  
As back up process, the investigator has the option of contact[CONTACT_30697] a [COMPANY_004] Helpdesk (refer 
to Table 9) if he/she needs support to perform the unblinding (i.e. he/she cannot access 
the automated Internet -based system).  
Non-investigator physician (e.g. physician from emergency room) or subject/care 
giver/family  member can also request emergency unblinding either via the investigator 
(preferred option) or via the [COMPANY_004] Helpdesk (back up process). Contact [CONTACT_301901]/subject card.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368946] information for emergency unblinding  
[COMPANY_004] Helpdesk  
24/24 hour and 7/7 day availability  
The Helpdesk is available by [CONTACT_648], fax and email  
Phone: [PHONE_6282].04  
For Canada, US and  Puerto Rico   
Toll-free number: [PHONE_6278]  
Fax: [PHONE_6283].75  
email: [EMAIL_5930]  
[COMPANY_004] policy (which incorporates ICH E2A guidance, EU Clinical Trial Directive and US 
Federal Regulations) is to unblind the report of any SAE which is unexpected and 
attributable/suspected to be attri butable to the study vaccine(s) , prior to regulatory 
reporting. Vaccine s Clinical Safety and Pharmacovigilance (VCSP) is responsible for 
unblinding the treatment assignment in accordance with the specified timeframes for 
expedited reporting of SAEs (refer to Section 12.5.8). 
A subject should continue in the study if that subject‚Äôs treatment assignment is unblinded.  
[COMPANY_004] Vaccines Clinical Safety and Pharmacovigilance (VCSP)  staff may unblind the 
treatment assignment for any subject in case of Suspected Unexpected Serious Adverse 
Reaction (S[LOCATION_003]R) as well as in case of fatal or life -threatening cases. If the SAE 
requires that an expedited regulatory report be sent to [ADDRESS_368947]‚Äôs treatment assignment, may be sent to 
investigators in accordance with local regulations and/or [COMPANY_004] policy.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  47 7.4. Handling , storage and  replacement of study 
vaccine(s)/product(s)  
7.4.1. Storage and handling of study vaccine(s)  
The study vaccine(s)  must be stored at the respective label storage temperature conditions 
in a safe and locked place. Access to the storage space should be limited to authori sed 
study personnel. The storage conditions will be assessed during pre -study activities under 
the responsibility of the sponsor study contact. The storage temperature should be 
continuously monitored with calibrated (if not validated) temperature monitoring 
device(s) and recorded. Refer to the Module on Cl inical Trial Supplies in the SPM for 
more details on storage  of the study vaccine(s) . 
A temperature excursion is any temperature that is not in range of the label storage 
temperature conditions. Temperatures outside the range of label storage temperature 
conditions must be reported and/or documented. Temperature excursion impacting study 
vaccine(s) must be reported and/or documented.  
In the frame of the reporting, the lack/absence of temperature monitoring documentation 
from a device meeting [COMPANY_004] requirement s has to be considered as a temperature 
excursion.  
Study vaccine(s) that are impacted by a temperature excursion may not be used and must 
be quarantined at label storage conditions until usage approval has been obtained 
from/via the local study contact (e. g. Site Monitor).  
Refer to the Module on Clinical Trial Supplies in the SPM for details and instructions on 
the temperature excursion reporting and usage decision process, packaging and 
accountability of the st udy vaccine(s) . 
7.4.2. Replacement of unusable vaccin e(s) doses 
In addition to the vaccine  doses provided for the planned number of subjects (including 
over-randomisation when applicable), at least 10% additional vaccine  doses will be 
supplied to replace those that are unusable.  
The investigator will use SB IR to obtain the replacement product number. The 
replacement numbers will be allocated by [CONTACT_301899]. The system will ensure, in a 
blinded manner, that the replacement product matches the formulation the subject was 
assigned to by [CONTACT_17975].  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  48 7.5. Concomitant  medication(s)/product(s) and concomitant 
vaccinations  
7.5.1. Recording of concomitant medications/products and 
concomitant vaccinations  
At each study visit/contact, the investigator or delegate should question the subject  about 
any medications/products taken and  vaccinations received by [CONTACT_423].  
The following concomitant medication(s)/product(s)/vaccine(s ) must be recorded in the 
eCRF. 
‚Ä¢ All concomitant medications/products, except vitamins and dietary supplements, 
administered during the period of [ADDRESS_368948] primary vaccination  and 2nd 
vaccination . 
‚Ä¢ Any concomitant vaccination administered in the period starting 30 days before the  
dose of study vaccine(s)  and ending at the last  study visit/ contact (Day -[ADDRESS_368949] 2nd vaccination ). 
‚Ä¢ Prophylactic medicat ion (i.e. medication administered in the absence of ANY 
symptom and in anticipation of a reaction to the vaccination).  
An anti-pyretic is considered to be prophylactic when it is given in the absence of fever 
and any other symptom, to prevent fever from oc curring fever is defined as temperature.  
38.0¬∞C/100.4¬∞F regardles s the location of measurement . The preferred location for 
measuring temperature in this study will be the oral cavity . 
‚Ä¢ Any concomitant medications/products/vaccines leading to the withdrawal or non-
eligibility of the subject from the study . 
‚Ä¢ Any concomitant medications/products/vaccines relevant to a n SAE to be reported as 
per protocol or administered at any time during the study period for the treatment of 
an SAE. In addition, concomitant medi cations relevant to SAEs  need to be recorded 
on the expedited Adverse Event report.  
‚Ä¢ Any antipyretic administered in the period starting 6 hours before vaccination and 
ending 12 hours after vaccination need s to be recorded on the specific page of the 
eCRF. 
‚Ä¢ The Medical Monitor should be contact[CONTACT_61519].  
7.5.2. Concomitant medications/products/vaccines that may lead to the 
elimination of a subject from per -protocol analyses  
The use of the following concomita nt medications/products/vaccines will not require 
withdrawal of the subject from the study but may determine a subject‚Äôs evaluability in the 
per-protocol analysis. See Section 10.2 for populations to be analysed.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368950] (drug or vaccine) other than the study 
vaccine(s ) used during the study period.  
‚Ä¢ Immunosuppressants or other immune -modifying drugs administered chronically 
(i.e. more than 14 days in total) during the study period. For corticosteroids, this will 
mean prednisone  ÔÇ≥5 mg/day (for adult subjects) or  ÔÇ≥0.5 mg/kg/day (for paediatric 
subjects), or equivalent. Inhaled and topi[INVESTIGATOR_14271] . 
‚Ä¢ Long-acting immune -modifying drugs administered at any time during the study 
period (e.g. infliximab).  
‚Ä¢ A vaccine not foreseen by [CONTACT_301902] 
30 days before the dose  and ending 30 days after each dose of vaccine(s). 
Note: In case an emergency mass vaccination for an unforeseen public health threat 
(e.g.: a pandemic ) is organised by [CONTACT_43068], outside the routine 
immunisation program, the time period described above can be reduced if necessary  
for that vaccine provided it is licensed and used according to its Summary of Product 
Characteristics (SmPC) or Prescribing Information and according to the local 
governmental recommendations and provided a written approval of the Sponsor is 
obtained. 
‚Ä¢ Immunoglobulins and/or any blood products administered during the study period.  
‚Ä¢ Drug and/or alcohol abuse . 
7.6. Intercurrent medical conditions that may lead to elimination 
of a subject from per -protocol analyses  
At each study visit subsequent to the vaccination v isit, it must be verified if the subject 
has experienced or is experiencing any intercurrent medical condition  that may lead to 
elimination from per protocol analysis . If it is the case, the condition(s) m ust be recorded 
in the eCRF . 
For example, s ubjects may be eliminated from the per -protocol set for immunogenicity if, 
during the study, they incur a condition that has the capability of altering their immune 
response (i.e. varicella) or are confirmed to have an alteration of their initial immune 
status. 
7.7. Contraindications to subsequent vaccin e(s) administration  
N/A  
7.8. Warnings and precautions  
Warnings and precautions to vaccination must be checked at the beginning of each  
vaccination visit.  
Refer to the local approved product Prescribing Information for Boostrix. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368951]‚Äôs clinical management to determine the  medical care 
needed as per local/regional practices (such as re -vaccination of  the subject (s)). 
8. STUDY ASSESSMENTS AN D PROCEDURES  
Study procedures and their timing are described  in the SoA  (Section 2). 
Protocol waivers or exemptions are not allowed unless necessary for the management of 
immediate safety concerns.  
Immediate s afety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the subject (s) should discontinue study 
treatment . 
Adherence to the study design requirements, including those specified in the SoA, is 
essential a nd required for study conduct.  
‚Ä¢ All screening evaluations must be completed and reviewed to confirm that potential 
subjects meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for 
screening failure, as applicable. The lab results will be considered valid for a period 
of [ADDRESS_368952]‚Äôs routine clinica l management (e .g. blood 
count) and obtained before signing of ICF may be utili sed for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and was performed  
within the time frame defined in the SoA.  
8.1. Study Procedures Du ring Special Circumstances  
During special circumstances (e.g., the COVID -19 pandemic), the specific guidance 
from local public health and other competent authorities regarding the protection of 
individuals‚Äô welfare must be applied.  
For the duration of suc h special circumstances : 
‚Ä¢ Reconsent of subjects for the study extension may be placed on hold.  Decisions on 
re-starting will be made in a manner consistent with guidance from public health and 
other competent authorities.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  51 ‚Ä¢ Informed consent must take place i n a face to face contact [CONTACT_301903].  
‚Ä¢ Certain procedures may be performed at an alternate location.  This includes, signing 
of informed consent, physical examination and vaccine dosing.  If vaccinating in an 
alternate location, it must be assured that trained staff and equipment are available to 
manage an acute vaccine r eaction. Biological samples may be collected at a different 
location* other than the study site or at participant‚Äôs home . Biological samples should 
not be collected if they cannot be processed in a timely manner or appropriately 
stored until the intended u se. 
‚Ä¢ Safety follow -up may be made by a telephone call, other means of virtual contact [CONTACT_227249], if appropriate.  
‚Ä¢  ‚ÄúMedically attended visits‚Äù include instances where, due to the special 
circumstances, the subject cannot seek medical advice for symptoms/ an illness by 
[CONTACT_156995] a medical facility or arranging for a home visit, and seeks this advice instead 
via telephone, SMS, email, videotelephony or telemedicine, or other means.  
‚Ä¢ The paper Diary card provided to the subject may be transmitted from and to t he site 
by [CONTACT_301904] . 
‚Ä¢ If despi[INVESTIGATOR_301869] (see Table 4), then the interval may be extended 
up to a maximum length described in  Table 10, however efforts should be made to 
adhere as closely as possible to the optimal timing .  
‚Ä¢ If despi[INVESTIGATOR_301870] (see Table 4), a maximum dose interval described in Table 10 
may be used, however efforts should be made to adhere as closely as possible to the 
optimal timing.  
Table 10 Intervals between study visits under Special Circumstances  
Interval  Optimal timing  Allowed interval Adapted interval 
under special 
circumstances  
Screening Visit  ‚ÜíVisit 1  ‚â§7 days  -7- 1 days  -30 to 1 days  
Visit 1 ‚Üí Visit 2  8 days  7- 10 days  7- 10 days  
Visit 1 ‚ÜíVisit 3  31 days  30- 45 days  30 ‚Äì 60 days  
Visit 1  ‚Üí Phone Contact  1 181 days  165- 195 days  165 ‚Äì 195 days  
Visit 4  ‚Üí Visit 5   -7 to 1 days  -30 ‚Äì 1 days * 
Visit 1  ‚Üí Visit 5  365 days  365-548 days **  
Visit [ADDRESS_368953] 2  8 days  7- 10 days  7- 10 days  
Visit 5  ‚ÜíVisit 6  31 days  30- 45 days  30 ‚Äì 90 days  
Visit 5  ‚ÜíPhone Contact 3  181 days  165- 195 days  165 ‚Äì 195 days  
*From 30 days prior to vaccination up to and including the day of vaccination.  
** For a 6 -month period ‚â•12 to <[ADDRESS_368954] on the per protocol set for immunogenicity will be determined on a case by [CONTACT_17878].  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  52 ‚Ä¢ Any impact of above-mentioned  measures on the study results will be described in 
the clinical study report. 
 * It is the investigator‚Äôs responsibility to identify an alternate location. The investigator should ensure that this alterna te 
location meets ICH GCP requirements, such as adequate facilities to perform study procedures, appropriate training of 
the staff and documented delegation of responsibilities in this location. This alternate location should be covered by 
[CONTACT_301905] a site other than the designated study 
site.  
8.2. General s tudy aspects  
Supplementary study conduct information not mandated to be present in this protocol is 
provided in the accompanying SPM. The SPM provides the investigator and the site 
personnel with administrative and detailed technical information that does not impact the 
safety of the subjects.  
8.3. Pre-vaccination procedures  
8.3.1. Collection of demographic data  
Record demographic data such as date of  birth, sex, race and ethnicity  in the subject‚Äôs 
eCRF. 
8.3.2. Medical and vaccination  history (Amended  09 APR 2021) 
Obtain the subject‚Äôs medical and vaccination history by [CONTACT_10393]/or review of the 
subject‚Äôs medical records and record any pre -existing conditions or signs and/or 
symptoms present in a subject prior to the study vaccination in the eCRF.  Significant 
medical condi tions and vaccinations that occurred during the C1 -V4 will be reviewed 
during the screening for the second vaccination and reported as medical history  and 
concomitant medications, respectively .  
8.3.3. Physical examination   
‚Ä¢ Perform a full physical examination of the subject at screening visit, including 
assessment of axillary or oral body temperature and resting vital signs: 
systolic/diastolic blood pressure, heart rate and respi[INVESTIGATOR_163484] [ADDRESS_368955].  
‚Ä¢ Perform a history directed physical ex am plus vital signs at Visit 1 [Day 1]   
‚Ä¢ Perform a history directed physical exam plus vital signs at Visit  4 [D-7 2nd 
vaccination to  2nd vaccination ]. Note that laboratory assessments of haematology  and 
biochemistry may be made on the investigator ‚Äôs discretion.  
‚Ä¢ Physical examination s at each study visit subsequent to  the vaccination visit, will be 
performed only if the subject indicates during questioning that there might be some 
underlying pathology(ies) or if deemed necessary by [CONTACT_29517] d elegate.  
‚Ä¢ Any vital signs measured at Visit 2 [Day 8] and Visit 5 [2nd Vaccination] should be 
recorded in the eCRF.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  53 ‚Ä¢ Collected information  needs to be recorded in the eCRF . 
‚Ä¢ If the investigator determines that the subject‚Äôs health on the day of vaccination 
temporarily precludes vaccination, the visit will be rescheduled  within the acceptable 
range. 
‚Ä¢ Treatment of any abnormality observed during this examination has to be performed 
according to local medical practice outside this study or by [CONTACT_43053].  
8.3.4. Pregnancy test  
Female subjects of childbearing potential are to have a urine pregnancy test prior to any 
study vaccine administration. The study vac cine(s) may only be administered if the 
pregnancy test is negative.   
A serum pregnancy test instead of a urine pregnancy test should be performed if required 
by [CONTACT_1606], local or ethics committee regulations.  
The results of the applicable test will be recorded in the eCRF. The study vaccine may 
only be administered if the pregna ncy test is negative.  
Note: Pregnancy test must be performed even if the subject is menstruating at the time of 
the study visit.  
8.3.5. Pre-vaccination body temperature  
The body temperature (oral preferred) of each subject needs to be measured prior to any 
study vaccine(s) administration. If the subject has fever [temperature  ÔÇ≥38.0¬∞C/100.4¬∞F 
regardless of the location of measurement  on the day of vaccination, the vaccination visit 
will be rescheduled within the allowed interval for this visit (see Section  6.5). 
8.3.6. Pre-vaccination Vital Signs  
Pre-vaccination vital signs: At Visit 5, the pre -vaccination vital signs (blood pressure,  
heart rate and respi[INVESTIGATOR_697], temperature) will be recorded in the eCRF.  
8.4. Immunogenicity assessments  
Please refer to the SPM for details on biospecimen management (handling, storage and 
shipment).  
The laboratory in charge of the laboratory testing will be blinded to the treatment,  and 
codes will be used to link the subject and study (without any link to the treatment 
attributed to the subject) to each sample.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368956] . 
Refer also to the Investigator Agreement , where it is noted that the investigator cannot 
perform any other biological assays except those described in the protocol or its 
amendment(s).  
If additional testing is performed, the marker priority ranking given in Section 8.4.[ADDRESS_368957] es will be stored for a maximum of 20 years (counting from when the last 
subject performed the last study visit), unless local rules, regulations or guidelines require 
different timeframes or different procedures, which will then be in line with the subjec t 
consent. These extra requirements need to be communicated formally to and discussed 
and agreed with [COMPANY_004].  
8.4.1. Use of specified study materials  
When materials are provided by [CONTACT_23983], it is MANDATORY  that all clinical samples 
(including serum samples) be collected  and stored exclusively using those materials in 
the appropriate manner. The use of other materials could result in the exclusion of the 
subject from the per -protocol analysis (See Section 10.2 for the definition of populations  
for analyses ). The investigator must ensure that his/her personnel and the laboratory(ies) 
under his/her supervision comply with this requirement. However, when [COMPANY_004] does not 
provide material for collecting and storing clinical samples, appropriate materials from 
the investigator‚Äôs site must be used. Refer to the Module on Clinical Trial Supplies in the 
SPM. 
8.4.2. Biological samples  
Biological samples to evaluate immunogenicity and safety will be collected as specified 
in Section  2, Schedule of Activities (SoA). Table 11 summarizes biological samples and 
minimum  total blood volumes to be collected from study subjects.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368958]  Unit Time point  Additional Information  
Whole blood for 
hematology, 
biochemistry and 
immune response  10.5 ml screening visit  Hematology, chemistry: 5.5 m L. 
Immune response: 5 mL (~ 2 mL 
serum).  
Whole blood for 
immune response  5  ml Visit 2 (Day 8)  Immune response  : 5 mL (~ 2 mL 
serum).  
Whole blood for 
immune response  5 ml Visit 3 (Day  31) Immune response  : 5 mL (~ 2 mL 
serum) . 
Whole blood for 
hematology, 
biochemistry*  
Whole blood for 
immune response  10.5 or 5 ml Visit 4 ( up Day -7 prior 
to 2nd vaccination ) Hematology, chemistry: 5.5 mL.  
Immune response: 5 mL (~ 2 mL 
serum).  
Whole blood for 
immune response  5 ml Visit 6 (Day  [ADDRESS_368959] 2nd 
vaccination ) Immune response  : 5 mL (~ 2 mL 
serum) . 
 36 or 30.5 ml Minimum Total, not including repeat or unscheduled 
samples  
Urine for Pregnancy  - - screening visit  
Visit 1 (Day 1) and Visit 
5 (2nd Vaccination)   
*Hematological and biochemical laboratory testing at Visit 4 (D -7 up to and including 2nd dose vaccination) at the 
investigator‚Äôs discretion  
8.4.3. Laboratory assays  
Protocol-required hematology/biochemistry assays are listed in Section 12.2. Assays 
performed by [CONTACT_301906].  
Please refer to  Section 12.3 for the address of the clinical labora tories used for sample 
analysis. 
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  56 Table 12 Humoral Immunity (Antibody determination)   
Sampling 
time points  System  Component  Method  Kit/ 
Manufacturer  Unit Cut-off Groups  Number of 
subjects  Laboratory *** 
Screening  Serum  Respi[INVESTIGATOR_14250] A Ab 
neutralizing  NEU  In house  ED60 and/or 
IU 
(international 
unit) 18 for ED60 
56 for IU  All 500 [COMPANY_004]  
Serum  Respi[INVESTIGATOR_301871]3 Ab.IgG concentration  ELI In house  ELU/mL  25 All 500 Nexelis  
Serum  Bordetella pertussis.Filamentous 
Hemaglutinin Ab.IgG  ELI In house  IU/mL  2.046  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Serum  Bordetella pertussis.Pertactin 
Ab.IgG  ELI In house  IU/mL  2.187  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Seru m Bordetella pertussis.Pertussis 
Toxin Ab.IgG  ELI  In house  IU/mL  2.693  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Serum  Corynebacterium 
diphtheriae.Diphtheria Toxoid 
Ab.IgG  ELI In house  IU/mL  0.030  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Serum  Clostridium tetani.Tetanus 
Toxoid Ab.IgG  ELI In house  IU/mL  0.037 XRSV120_dTpa, 
XRSV60_dTpa, 300 [COMPANY_004]  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  57 Sampling 
time points  System  Component  Method  Kit/ 
Manufacturer  Unit Cut-off Groups  Number of 
subjects  Laboratory *** 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  
Day 8  Serum  Respi[INVESTIGATOR_14250] A  Ab 
neutralizing  NEU  In house  ED60 and/or 
IU 
(international 
unit) 18 for ED60 
56 for IU  All 500 [COMPANY_004]  
Serum  Respi[INVESTIGATOR_301871]3 Ab.IgG concentration  ELI In house  ELU/mL  25 All 500 Nexelis  
Day 31  Serum  Respi[INVESTIGATOR_14250] A Ab 
neutralizing  NEU  In house  ED60 and/or 
IU 
(international 
unit) 18 for ED60 
56 for IU  All 500 [COMPANY_004]  
Serum  Respi[INVESTIGATOR_301871]3 Ab.IgG concentration  ELI In house  ELU/mL  25 All 500 Nexelis  
Serum  Bordetella pertussis.Filamentous 
Hemaglutinin Ab.IgG  ELI In house  IU/mL  2.046  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Serum  Bordetella pertussis.Pertactin 
Ab.IgG  ELI In house  IU/mL  2.187  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Serum  Bordetella pertussis.Pertussis 
Toxin Ab.IgG  ELI  In house  IU/mL  2.693  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 300 [COMPANY_004]  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  58 Sampling 
time points  System  Component  Method  Kit/ 
Manufacturer  Unit Cut-off Groups  Number of 
subjects  Laboratory *** 
URSV60_dTpa, 
Uplacebo_dTpa  
Serum  Corynebacterium 
diphtheriae.Diphtheria Toxoid 
Ab.IgG  ELI In house  IU/mL  0.030  XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Serum  Clostridium tetani.Tetanus 
Toxoid Ab.IgG  ELI In house  IU/mL  0.037 XRSV120_dTpa, 
XRSV60_dTpa, 
Xplacebo_dTpa, 
URSV120_dTpa, 
URSV60_dTpa, 
Uplacebo_dTpa  300 [COMPANY_004]  
Day -7 up to 
2nd 
vaccination  Serum  Respi[INVESTIGATOR_14250] A Ab 
neutralizing  NEU  In house  ED60 and/or 
IU 
(international 
unit) 18 for ED60 
56 for IU  All 500 [COMPANY_004]  
Serum  Respi[INVESTIGATOR_301871]3 Ab.IgG concentration  ELI In house  ELU/mL  [ADDRESS_368960] 2nd 
vaccination  Serum  Respi[INVESTIGATOR_14250] A Ab 
neutralizing  NEU  In house  ED60 and/or 
IU 
(international 
unit) 18 for ED60 
56 for IU  All 500 [COMPANY_004]  
Serum  Respi[INVESTIGATOR_301872]3 Ab.IgG concentration  ELI In house  ELU/mL  25 All 500 Nexelis  
Ab = antibody; ELI = Enzyme -linked immunosorbent assay (ELISA) ; ELU=ELISA unit ; IgG = immunoglobulin G; RSV = respi[INVESTIGATOR_4345]; ED60 = serum dilution inducing 60% 
inhibition in plaque forming units; IU/ml = International units/milliliter , IU= International units ; TBD = to be determined  
Assay cut -off and unit might be subject to change before starting of testing  (e.g. in case of requalification, revalidation or standardisation). I n this case, this will be documented in the 
clinical report.  
***[COMPANY_004] laboratory refers to the Clinical Laboratory Sciences (CLS) in Rixensart, Belgium; Wavre, Belgium; Marburg, [LOCATION_013].  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  59 Other assays may be performed with the aim to explore tertiary objectives of the study. 
The research may include, but is not limited to:  
Additional testing on the vaccine and/or on the disease u nder study may be performed 
within the framework of the study if deemed necessary for accurate interpretation of the 
data or should such assay(s) become available at [COMPANY_004] . These assays may not be 
represented in the objectives/endpoints of the study protocol . 
The [COMPANY_004] clinical laboratories have established a Quality System supported by 
[CONTACT_43056]. The activities of [COMPANY_004] clinical laboratories are audited regularly for quality 
assessment by [CONTACT_43057] (sponsor -dependent) but laboratory -independent Quality 
Department. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  60 8.4.4. Biological samples evaluation  
[IP_ADDRESS]. Immunological read -outs 
Table [ADDRESS_368961] 
and timepoint * Sampling 
timepoint  
Screening visit  Pre-Vacc  All 500 RSV-A neutralizing 
antibody  1 
All 500 RSVPreF3 IgG antibody 
concentration  2 
Boostrix*  
recipi[INVESTIGATOR_840]  300 Bordetella 
pertussis.Filamentous 
Hemaglutinin Ab.IgG  3 
Boostrix  
recipi[INVESTIGATOR_840]  300 Bordetella 
pertussis.Pertactin Ab.IgG  3 
Boostrix  
recipi[INVESTIGATOR_840]  300 Bordetella 
pertussis.Pertussis Toxin 
Ab.IgG  3 
Boostrix  
recipi[INVESTIGATOR_840]  300 Corynebacterium 
diphtheriae.Diphtheria 
Toxoid Ab.IgG  4 
Boostrix  
recipi[INVESTIGATOR_840]  300 Clostridium tetani.Tetanus 
Toxoid Ab.IgG  5 
Visit 2 (Day 8)  Post-Vacc  All 500 RSV-A neutralizing 
antibody  1 
All 500 RSVPreF3 IgG antibody 
concentration  2 
Visit 3 (Day 31)  Post-Vacc  All [ADDRESS_368962]-Vacc  All 500 RSV-A neutralizing 
antibody  1 
 All 500 RSVPreF3 IgG antibody 
concentration  2 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  61 *Boostrix  recipi[INVESTIGATOR_840] = subjects in the following study groups: -XRSV120_dTpa, XRSV60_dTpa , Xplacebo_dTpa , 
URSV120_dTpa , URSV60_dTpa , Uplacebo_ dTpa. 
In case of insufficient blood sample volume to perform assays for all antibodies, the 
samples will be analysed according to priority ranking provided in  Table 13. 
8.4.5. Immunological correlates of protection  
[IP_ADDRESS]. RSV 
No generally accepted immunological correlate of protection has been established so far 
for the antigen used in the RSV maternal (RSVPreF3) vaccine.  
[IP_ADDRESS]. Boostrix  
The following cut -offs are accepted as immunological correlates of protection:  
‚Ä¢ Specific antibodies against diphtheria toxoid (anti -diphtheria) and tetanus toxoid 
(anti-tetanus) will be measured by [CONTACT_301907] -linked immunosorbent assay (ELISA). 
Subjects with antibody concentration s of at least 0.1 International Units per ml 
(IU/ml) by [CONTACT_301908] [Camargo, 1984; Melville-Smith, 
1983]. In this study, the booster response will be defined by [CONTACT_301909] ‚â• 1.0 IU/mL.  
‚Ä¢ No serological correlate of protection against pertussis has been established [Vidor, 
2008]. Antibodies against the pertussis components pertussis toxoid (PT), 
filamentous haemagglutinin (FHA) and pertactin (PRN) will be measured by [CONTACT_6428]. 
The current seropositivity cut -off is 2.693 IU/ml for anti -PT, 2.046 IU/ml for anti -
FHA and 2.187 IU/ml for a nti-PRN (see Table 12). Subjects with antibody 
concentration below the cut -off will be considered seronegative.  
The immunological assay results will be communicated to the investigator within [ADDRESS_368963] to discontinue the study .  
8.5.1. Safety definitions  
Please refer to Section 12.5 for safety definitions.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  62 8.5.2. Time period and frequency for collecting AE and serious adverse 
event (S AE) information  
An overview of the protocol -required reporting periods for AEs, SAEs, and pregnancies 
is given in  Table 14 . Refer to the Section [IP_ADDRESS] for details on the time period for 
recording safety information.  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6 Final  
9 April 2021  63 Table 14 Reporting periods for collecting safety information  
Event  Pre- 
V1*  V1  V2  V3 C1  C1 to 
V4** V4 V5*  C2  V6 C3 
D1 D7 D8 D30 D31 D181   D -[ADDRESS_368964] 2nd 
vaccination  
Solicited local and 
general AEs                  
                
                
Unsolicited AEs                  
                
                
AEs leading to 
withdrawal from the 
study                 
                
                
SAEs **                 
                
                
SAEs related to study 
participation  
or concurrent [COMPANY_004] 
medication/vaccine                  
                
                
Pregnancies ***                 
                
                
* i.e. consent  obtained. Pre -V: pre -vaccination; V: vaccination; Post -V: post -vaccination; D: Day, M: Month  
** There will be no follow -up between C1 and V4. New medical history and relevant new safety events during this period will be recorded at visit 4 for subjects who  agree to the  study 
extensio n and sig n the informed consent addendum . In addition, SAE related to vaccination are reported during the period C1 -V4 will be reported to the Investigator at the time of 
awareness.  
***Pregnancies that occurred during the C1 -V4 period will be reported as medical hi story  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  64 All SAEs will be recorded and reported  via Expedited AE Reporting Form  to the sponsor 
or designee immediately and under no circumstance should this exceed 24 hours after the 
investigator became aware of it , as indicated in  Section 12.5. The investi gator will submit 
any updated SAE data to the sponsor within 24  hours of it being available.  
8.5.3. Method of d etecting AEs and SAEs  
The method of recording, evaluating, and assessing intensity , causality and outcome  of 
AEs and SAEs and the procedures for completing and transmitting SAE reports are 
provided in  Section 12.5.7. 
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the subjects is the preferred method to inquire about 
AE occurrence.  
8.5.4. Reporting of serious adverse events, pregnancies, and other -
events (Amended 09 -APR-2021  
Table 15 Timeframes for submitting serious adverse event, pregnancy and 
other events reports to [COMPANY_004] 
Type of Event  Initial Reports  Follow -up of Relevant Information on a 
Previous Report  
Timeframe  Documents  Timeframe  Documents  
SAEs  24 hours* ‚Ä° electronic Expedited 
Adverse Events Report  24 hours*  electronic Expedited Adverse 
Events Report  
Pregnancies  2 weeks*  Paper pregnancy notification 
report/electronic pregnancy 
report  24 hours * electronic pregnancy report  
* Timeframe allowed after receipt or awareness of the information . 
‚Ä° The investigator will be required to confirm review of the SAE causality by [CONTACT_43078] ‚Äòreviewed‚Äô box in the electronic 
Expedited Adverse Events Report within [ADDRESS_368965]-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
reporting period defined in Table 14. Investigators are not obligated to actively seek AEs 
or SAEs in former study participants. However, if the investigator learns of any SAE at 
any time after a subject has been discharged from the study, and he/she considers the 
event reasonably related to the investigational vaccine/product, the investigator will 
promptly notify the Study Contact [CONTACT_43075].  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  65 [IP_ADDRESS]. Contact [CONTACT_301910] (SAEs), 
pregnancies  and study holding rules  (Amended 09 APR 2021)  
Table [ADDRESS_368966] information for reporting of serious adverse events (SAEs), 
pregnancies and study holding rules  
Study contact [CONTACT_301911], pregnancies and study holdi ng rules 
Refer to the local study contact [CONTACT_301912] a holding rule is met, he/she must  immediately  
inform the local contact .  
Back-up Study Contact [CONTACT_43075], pregnancies and study holding rules  
24/24 hour and 7/7-day availability:  
[COMPANY_004] Clinical Safety & Pharmacovigilance  
Outside US & Canada sites : 
Fax: [PHONE_6284] 16 or +32 2  656 80 09  
Email address: [EMAIL_5931]  
US sites only:  
Fax: [PHONE_6279] 
Canadian sites only:  
Fax: [PHONE_6280] 
8.5.6. Follow-up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
subject at subsequent visits/contacts. All SAEs, will be followed until the event is 
resolved, stabili sed, otherwise  explained, or the subject is lost to follow -up. Further 
information on follow -up procedures is given in  Section 12.5.10. 
8.5.7. Treatment of adverse events  
Treatment of any AE is at the sole discretion of the investigator and according to current 
good medical practice.  Any medication adminis tered for the treatment of a SAE should 
be recorded in Expedited Adverse Ev ent Report of the subject‚Äôs eCRF (refer to Section 
7.5). 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368967] of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency.  
‚Ä¢ The investigator must review the laboratory report, document this review, and record 
any clinically relevant changes occurring during the st udy in the AE section of the 
eCRF. The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are associated with an 
underlying dise ase, unless judged by [CONTACT_301913]‚Äôs condition. All laboratory tests with values considered 
clinically significant abnormal during participation in the study or within [ADDRESS_368968] dose of study  treatment should be repeated until the values return to 
normal or baseline or are no longer considered significantly abnormal by [CONTACT_63200].  Refer to the Section 12.5.5 for clinical laboratory 
abnormal assessments qualified as AEs or SAEs.  
‚Ä¢ If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be iden tified and the sponsor 
notified. 
All protocol -required laboratory  safety assessments, as defined in Section 12.2, must be 
conducted in accordance with the laboratory manual and the SoA.  
8.5.9. Subject card  
Study subjects must be provided with the address and telephone number of the main 
contact [CONTACT_43089].  
The investigator (or designate) must therefore provide a ‚Äúsubject card‚Äù  to each subject. In 
an emergency situation , this card serves to inform the responsible attending physician 
that the subject is in a clinical study and that relevant information may be obtained by 
[CONTACT_21947].  
Subjects must be instructed to  keep subject cards in their possession at all times during 
the study duration.  
8.6. Holding rules and safety monitoring  
The safety holding rules are defined in Table 17. Holding rules 1a -b will be assessed by 
[CONTACT_30036] a continuous basis . Meeting any of these holding rules will trigger a 
hold of vaccination irrespective of number of subjects enrolled.  
Table 17 Study holding rules  
Holding 
Rule  Event  Number of Subjects  
1a Death or any life -threatening SAE occurring within 30 days from 
vaccination  ‚â•1 
1b Any SAE that ca n be reasonably  attributed to the vaccination  ‚â•1 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  67 The investigator is not permitted to start the administration of the next dose until receipt 
of the favourable outcome of the safety evaluation, documented and provided in writing, 
authorising the investigator to proceed. While vaccinations are on hold, th e investigator 
should not consent subjects into the study.  
Moreover, if the investigator becomes aware of a holding rule being met, he/she will 
suspend vaccination and will inform [COMPANY_004] immediately (e.g. meeting of holding rules 1a -
b). 
The below flow of comm unication has to be followed:  
‚Ä¢ The concerned site staff has to put vaccination  and enrolment  on hold. 
‚Ä¢ The concerned site staff must immediately inform their local contact [CONTACT_301914] 16. 
‚Ä¢ The local contact [CONTACT_301915] y to the central study team  
(ie SDL and CRDL) . 
‚Ä¢ The central study team will ensure SBIR is blocked and all vaccinating centres are 
informed. 
‚Ä¢ [COMPANY_004] Safety Review Team ( SRT) will further evaluate the case and escalate to [COMPANY_004] 
VSMB for making the decision to stop or to restart the vaccination. All site staff will 
be informed about that final decision by [CONTACT_301916].  
If the Central Team becomes aware of a holding rule  being met, the below flow of 
communication must be followed:  
‚Ä¢ CRDL inform the  local Study team ( Table 16) 
‚Ä¢ The LML/delegate of each country confirm the reception of the h olding rule to the 
CRDL and inform all the investigators.  
‚Ä¢ The concerned site staff has to put vaccination and enrolment on hold.  
‚Ä¢ The central study team will ensure SBIR is blocked and all vaccinating centres are 
informed.  
‚Ä¢ [COMPANY_004] Safety Review Team (SRT) will further evaluate the case and escalate to [COMPANY_004] 
VSMB for making the decision to stop or to restart the vaccination. All site staff will 
be informed about that final decision by [CONTACT_301916].  
8.7. Genetic Research (Pharmacogenetics)  
Genetics are not evaluated in this study.  
8.8. Biomarkers and p harmacogenomics  
Not applicable.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  68 8.9. Economic a ssessment  
Not applicable.  
8.9.1. Regulatory reporting requirements for SAEs  
Prompt notification of an SAE by [CONTACT_301917] a 
study treatment under clinical investigation.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safet y of a study treatment under clinical 
investigation. The sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary.  
An investigator who receives an investigator safety report describing a SAE or other 
specific safety information (e.g. summary or listing of SAE) from the sponsor will review 
and then file it along with the Investigator‚Äôs Brochure and will notify the IRB/IEC, if 
appropriate according to local requirements.  
9. DISCONTINUATION CRIT ERIA 
9.1. Discontinuation from the study   
Subjects will complete the study at day [ADDRESS_368969]. For the subjects that 
enroll in the study extension , the conclusion of the study will be on Day 181 following 
the second immunization  as described in the protocol.  
From an analysis perspective, a ‚Äòwithdrawal‚Äô from the study refers to any subject was not 
available for the concluding contact [CONTACT_91313].  
All data and samples collected until the date of  withdrawal/last contact [CONTACT_301918].  
A subject is considered a ‚Äòwithdrawal‚Äô from the study when no study procedure has 
occurred, no follow -up has been performed and no further information has been collected 
for this subjec t from the date of withdrawal/last contact.  
Investigators will make [ADDRESS_368970] those subjects 
who do not return for scheduled visits or follow -up. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368971] himself/herself , or by [CONTACT_093], as well as which of the following 
possible reasons was responsible for withdrawal:  
‚Ä¢ Adverse event s requiring expedited reporting  
‚Ä¢ Unsolicited non -serious adverse event  
‚Ä¢ Solicited adverse event  
‚Ä¢ Protocol deviation  
‚Ä¢ Withdrawal by [CONTACT_1130], not due to an adverse event*  
‚Ä¢ Migrated/Moved from the study area  
‚Ä¢ Lost to follow -up 
‚Ä¢ Sponsor study termination  
‚Ä¢ Other (specify)  
*In case a subject is withdraw n from the study because she has withdrawn consent, the 
investigator will document the reason for withdrawal of consent, if specified by [CONTACT_301919] . 
Subjects who are withdrawn from the study because of SAEs/A Es must be clearly 
distinguished from subjects who are withdrawn for other reasons. Investigators will 
follow subjects who are withdrawn from the study as result of a SAE/AE until resolution 
of the event (see Section 12.5.10). 
9.2. Discontinuation of study vaccine(s)   
‚ÄòDiscontinuation‚Äô of study intervention  refers to any participant who has not received all 
planned doses of study intervention. A participant who discontinued study intervention 
may continue other study procedures (e.g. safety or immunogenicity), planned in the 
study protocol at the discretion o f the investigator.  
The primary reason for premature discontinuation of the study intervention  will be 
documented on the eCRF as follows:  
‚Ä¢ Adverse event requiring expedited reporting to [COMPANY_004]  
‚Ä¢ Unsolicited non -serious adverse event  
‚Ä¢ Solicited adverse event  
‚Ä¢ Not willing to be vaccinated  
‚Ä¢ Other (specify).  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368972] fails to return to the clinic for a required 
study visit:  
‚Ä¢ The site must attempt to contact [CONTACT_301920]/or should 
continue in the study.  
‚Ä¢ Before a subject is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_368973]‚Äôs last known mailing address or local 
equivalent methods). These contact [CONTACT_9300]‚Äôs 
medical record.  
‚Ä¢ Should the subject continue to be unreachable, he/she will be considered to ha ve 
withdrawn from the study with a primary reason of lost to follow -up. 
10. STATISTICAL C ONSIDERATIONS  
10.1. Sample size determination  
10.1.1. Hypotheses related to primary and secondary objectives  
No hypothesis driven sample size calculation was conducted due to the descriptive nature 
of the study . 
10.1.2. Sample size calculation  
The sample size of [ADDRESS_368974] 95% confidence to rule out an AE incidence greater 
than 7.1%, and a total of [ADDRESS_368975] 
95% confidence to rule out an AE rate greater than 3.6%. A combined [ADDRESS_368976] 95% confidence to 
rule out an AE incidence rate greater than 0.9% . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  71 Furthermore, a sample size of 50 subjects per group and 100 subjects per group in the 
combined formulations  would provide a probability of 92% or 99% to  observe at least 
one AE respectively, if the true AE rate is 5%. In addition, a sample size of 400 when 
combining the RSVPreF3 groups would provide a probability of 98% to observe at least 
one AE if the true AE rate is only 1%.  
Table [ADDRESS_368977] 95% confidence interval (CI) on the probability of a subject 
with AEs events following vaccination of 50 subjects per group, (100 
subjects per group in US and ex -US combined) and 400 subjects 
with RSVPreF3 groups combined  
Number of subjects per  
group  Number (%) of subjects with 
an AE  Exact 95% CI  
Lower  Limit (%)  Upper  Limit (%)  
50 0 (0%)  0 7.1 
50 5 (10%)  3.3 21.8 
50 10 (20%)  10 33.7 
50 15 (30%)  17.9 44.6 
50 20 (40%)  26.4 54.8 
50 25 (50%)  35.5 64.5 
100 0 (0%)  0 3.6 
100 5 (5%)  1.6 11.3 
100 10 (10%)  4.9 17.6 
100 15 (15%)  8.6 23.5 
100 20 (20%)  12.7 29.2 
100 25 (25%)  16.9 34.7 
400 0 (0%)  0 0.9 
400 5 (1.25%)  0.4 2.9 
400 10 (2.5%)  1.2 4.5 
400 15 (3.75%)  2.1 6.1 
400 20 (5%)  3.1 7.6 
400 25 (6.25%)  4.[ADDRESS_368978] 95% CI computed based on Clopper/Pearson formula  
In order to evaluate the humoral response to 2 dose levels (60 and 120  ÔÅ≠g) of RSVPreF3 
when given alone, and co -administered with dTpa, the difference between co -
administration with dTpa (RSVPreF3 dTpa) and RSVPreF3 alone (RSVPre F3 placebo) in 
terms of RSV -A neutralizing antibody (Nab) titers will be evaluated at Day [ADDRESS_368979] vaccination .  
Table 19 presents the precision estimation on the ratio of the Geometric Mean of RSV -A 
Nab titers (GMT) with their 90% CI between two study groups, and the power to claim 
non-inferiority , when the samp le size is [ADDRESS_368980] deviation (SD) of RSV -A Nab titers 0.3 -0.5 on its log10 
transformation  and non-inferiority margin of 1.5 between RSVPreF3 alone and 
RSVPreF3 dTpa.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  72 If a SD of log10 transf ormed RSV -A Nab of 0.4 is assumed, when the sample size is 50 
subjects per group, the half width of the 90% CI on the log ratio of GMT between co -
administration with dTpa and RSVPreF3 alone is 0. 133. With an observed GMT ratio of 
1, its 90% CI will be ( 0.74, 1.36). With subjects in US and ex -US combined, there will be 
at least 90% chance that the upper bound of one -sided 95% CI for the ratio of GMT of 
RSV-A Nab titer between RSVPreF3 alone and co-administration with dTpa is under 1.5 -
fold. 
Table 19 Precision and power in terms of RSV -A neutralizing antibody titers 
with a sample size of 100 subjects per group and 50 subjects per 
group 
Number of 
subjects per 
group  Ratio of GMT 
between two 
groups  SD* 90% CI  90% CI  Power for non-
inferiority test (%) ***  
LL UL 
50 0.9 0.3 0.71 1.13 97.9 
50 0.9 0.4 0.66 1.22 86.6 
50 0.9 0.5 0.61 1.32 71.2 
50 1.0 0.3 0.79 1.26 89.8 
50 1.0 0.4 0.74 1.36 70.5 
50 1.0 0.5 0.68 1.47 54.1 
50 1.1 0.3 0.87 1.38 72.0 
50 1.1 0.4 0.81 1.49 51.0 
50 1.1 0.5 0.75 1.61 37.9 
100 0.9 0.3 0.77 1.06 100 
100 0.9 0.4 0.73 1.11 98.8 
100 0.9 0.5 0.69 1.18 93.1 
100 1.0 0.3 0.85 1.17 99.4 
100 1.0 0.4 0.81 1.24 92.7 
100 1.0 0.5 0.76 1.31 79.8 
100 1.1 0.3 0.94 1.29 93.5 
100 1.1 0.4 0.89 1.36 76.6 
100 1.1 0.5 0.84 1.44 60.0 
*Standard deviation of log [ADDRESS_368981] deviation observed 30 days after vaccination in a 
previous [COMPANY_004] RSV study was 0.4.  
**Precision estimation for log GMT ratio using PASS 12.0.2 (CI for two means), LL: Lower Limit, UL: Upper Limit  
***PASS: Non-Inferiority Tests for Two Means using Differences with one -sided alpha 5% and Non -Inferiority Margin 
0.176 on log 10 scale (corresponding to Non -Inferiority  Margin 1.5 for GMT ratio).  
10.2. Populations for a nalyses 
For purposes of analysis, the following analysis sets are defined:  
Analysis Set  Description  
Enrolled  Subjects  who agreed to participate in a clinical study after completion of the 
informed consent process. And subject is not a screen failure .  
Exposed  All subjects who received at least [ADDRESS_368982] 1 dose of the study treatment (Exposed Set) 
who have solicited safety data  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  73 10.3. Statistical  analyses 
10.3.1. Subjects d isposition  
The number of screened, enrolled, and vaccinated subjects  included in each group or in 
total for a given age category or for all age categories will be described. These might be 
additionally broken down by [CONTACT_301921]/or by [CONTACT_3725].  
10.3.2. Demography and baseline characteristics analyses  
Demographic characteristics (age at first study vaccination in weeks, or months or years, 
gender, race and ethnicity [where applicable]), vaccination history, will be summarised 
by [CONTACT_301922]:  
‚Ä¢ Frequency tables will be generated for categorical variables such as centre.  
‚Ä¢ Mean, standard deviation, median, minimum and maximum will be provided for 
continuous data such as age, height, weight and body mass index (BMI).  
10.3.3. Immunogenicity analyses  
The primary analysis will be based on the Per Protocol set for analysis of 
immunogenicity. If, in any study group and at any timepoint, the perce ntage of enrolled 
or vaccinated  subjects with serological results excluded from the Per Protocol set f or 
analysis of immunogenicity is 5% or more, a second analysis based on the  Exposed Set 
will be performed to complement the Per Protocol analysis.  
Endpoint  Statistical Analysis Methods  
Primary  (US + ex -US data to be pooled  for the first vaccination ) 
For each group, at each time point that blood samples are collected for humoral immune 
response and for each assay (unless otherwise specified):  
‚Ä¢ GMCs/GMTs and their 95% CI will be tabulated and represented graphically pooled . 
‚Ä¢ Geometric mean of ratios of antibo dy titer/concentrations at each individual post -
vaccination time point over pre -vaccination (screening) will be tabulated with 95% CI 
pooled . 
‚Ä¢ Antibody titer/concentration will be displayed using reverse cumulative curves pooled . 
‚Ä¢ The kinetics of GMT/GMCs wi ll be plotted as a function of time for subjects with results 
available at all time points pooled . 
‚Ä¢ The GMT/GMCs ratio and their 90% CI between RSVPreF3 dTpa and RSVPreF3 alone in 
terms of RSV -A Nab titers and RSV IgG antibody concentrations may be calculat ed at 
Screening, and/or Day 8 , and/or Day 31 pooled for all subjects.  
‚Ä¢ A further exploratory between -groups analysis will be performed at Day 8 or Day 31 using 
an ANCOVA model by [CONTACT_301923], study formulation  (US and ex -US), age 
category, and level of antibodies at Scr eening as covariates.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  74 Endpoint  Statistical Analysis Methods  
Secondary  (US and ex -US data to be considered pooled, then separately  for the first vaccination)  
For each group, at each time point that blood samples are collected for hum oral immune 
response and for each assay (unless otherwise specified):  
‚Ä¢ GMCs/GMTs and their 95% CI will be tabulated and represented graphically by 
[CONTACT_14509]  (US and ex -US) Geometric mean of ratios of antibody titer/concentrations at 
each individual post -vaccination time point over pre -vaccination (screening) will be 
tabulated with 95% CI by [CONTACT_14509]  (US and ex -US). 
‚Ä¢ Antibody titer/concentration will be displayed using reverse cumulative curves by 
[CONTACT_14509]  (US and ex -US). 
‚Ä¢ The kinetics of GMT/GMCs will be plotted as a function of time for subjects with results 
available at all time points by [CONTACT_14509]  (US and ex -US). 
‚Ä¢ Booster response rates for PT, FHA and PRN (with exact 95% CI) will be calculated by 
[CONTACT_301924]  (US and ex -US). 
For the data collected for the second vaccination, the humoral immune response of RSV PreF3 
will be summarized based on 2 dose level ( 60 and 120 ¬µg ) from the first vaccination.  
‚Ä¢ GMCs/GMTs and their 95% CI will be tabulated and represented graphically for pr ior and 
post 2nd dose  vaccination  
‚Ä¢ Geometric mean of ratios of antibody titer/concentrations at individual post - 2nd dose 
vaccination time point (visit 6) over prior 2nd dose  vaccination  time point (visit 4) will be 
tabulated with 95% CI  
‚Ä¢ Antibody titer/concentration will be displayed using reverse cumulative curves on prior and 
post 2nd vaccination  
‚Ä¢ The kinetics of GMT/GMCs will be plotted as a function of time for subjects with results 
available at all time points including the visits from the firs t vaccination.  
Booster responses to PT, FHA and PRN antigens are defined as:  
‚Ä¢ For subjects with pre -vaccination antibody concentration below the assay cut -offs: post -
vaccination antibody concentration ‚â•  4 times the assay cut -offs, 
‚Ä¢ For subjects with pre -vaccination antibody concentration between the assay cut -offs and 
below 4 times the assay cut -offs: post -vaccination antibody concentration ‚â•  4 times the 
pre-vaccination antibody concentration, and  
‚Ä¢ For subjects with pre -vaccination antibody concentration ‚â•  4 times the assay cut -offs: 
post-vaccination antibody concentrati on ÔÇ≥2 times the pre -vaccination antibody 
concentration.  
‚àí The percentage of subjects with anti -D antibody concentrations ‚â•1.0 IU/mL by 
[CONTACT_301925] -T antibody con centrations ‚â•1.0 
IU/mL by [CONTACT_6428] (with exact 95% CI) will be calculated by [CONTACT_301924]  
(US and ex -US). 
‚àí The GMT/GMCs ratio and their 90% CI between RSVPreF3 dTpa and dTpa  placebo 
in terms of anti-PT, anti -FHA, anti -PRN, anti -D, anti -T will be calculated at Screening  
and Day 31 pooled for all subjects and by [CONTACT_14509]  (US and ex -US). 
‚àí A further exploratory between -groups analysis will be performed at Day 31 using an 
ANCOVA model by [CONTACT_301923], study formulation  (US and ex -US), age 
category, and level of antibodies at Screening as covariates.  
‚àí For Boostrix  booster response to antigens PT, FHA and PRN, the two -sided 
standardized asymptotic 95% CI for the group differences in the percentage of 
subjects with a booste r response to each antigen in the RSVPreF3 dTpa vaccine 
group and (minus) the dTpa Placebo vaccine group on Day [ADDRESS_368983] vaccination will 
be calculated for each formulation . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  75 Endpoint  Statistical Analysis Methods  
‚àí For Boostrix  seroprotection rate (percentage of subjects with antibody 
concentratio ns ‚â• 0.1 IU/mL by [CONTACT_6428]) for antigens D and T, the two -sided 
standardized asymptotic 95% CI for the group differences in the percentage of 
subjects with antibody concentrations ‚â•0.1 IU/mL in the RSVPreF3 dTpa vaccine 
group and (minus) the dTpa Placebo vacc ine group at Day [ADDRESS_368984] vaccination will 
be calculated for each formulation . 
Tertiary  Will be described in a  Statistical Analysis Plan finali sed before database unblinding/freezing . 
10.3.4. Safety analyses  
The primary safety analyses will be performed on the Exposed Set. The following safety 
analyses will be performed based on the Exposed Set . The following safety analysis will 
be performed on the pooled formulations , the US and ex -US separately.  
Endpoint  Statistical Analysis Methods  
Primary  (US + ex -US data to be pooled)  
For each  group  with 1st dose vaccination of RSVPreF3 (two dose level s) when given alone or 
co-ad with dTpa ; the following points will be analysed for 1st and 2nd dose  vaccination . 
The percentage of subjects with at least one local AE with at least one general AE and with any 
(‚Äúsolicited or unsolicited‚Äù)  AE during the [ADDRESS_368985] 95% CI b y study group. The same 
computations will be done for Grade 3 AEs, for any AEs considered related to vaccination, for 
Grade 3 AEs considered related to vaccination and for AEs resulting in medically attended visits.  
The percentage of subjects reporting eac h individual solicited local AE (any grade, Grade  3 and 
those resulting in a medically attended visit) and solicited general AE (any grade, Grade 3, any 
related, Grade 3 related and those resulting in a medically attended visit) during the 7 -day 
follow -up period (i.e. on the day of vaccination and 6 subsequent days) will be tabulated based 
on maximum intensity for each group.  
For fever, the number and percentage of subjects reporting fever by [CONTACT_227259] (¬∞C) cumulative 
increments during the 7 -day follow -up period will be tabulated for each group. Similar tabulations 
will be performed for any fever with a causal relationship to vaccination, Grade 3 or above 
(> 39.0¬∞C/102.2¬∞F) causally  related fever, and fever resulting in a medically attended visit. In 
addit ion, the prevalence of any and Grade 3 fever will be presented graphically over time after 
each vaccination.  
The percentage of subjects with any unsolicited AEs during the 30 -day follow -up period (i.e. on 
the day of vaccination and 29 subsequent days) with  its exact 95% CI will be tabulated by [CONTACT_301926] (MedDRA) SOC and preferred  term. Similar 
tabulation will be done for Grade [ADDRESS_368986] 95% CI. 
SAEs will also be described in detail.  
The percentage of subjects using concomitant medication (any medication, any antipyretic and 
any antipyretic taken prophylactically, respectiv ely) during the 7 -day follow -up period and during 
the 30 -day follow -up period will be summarized by [CONTACT_301927].  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  76 Endpoint  Statistical Analysis Methods  
Secondary  (US and ex -US data to be considered pooled, then separately)  
For each group with 1st dose vaccination of RSVPreF3 (two do se level) when given alone or co -
ad with dTpa ; the following points will be analysed for 1s t and 2nd dose  vaccination . 
The percentage of subjects with at least one local AE with at least one general AE and with any 
(‚Äúsolicited or unsolicited‚Äù)  AE during the [ADDRESS_368987] 95% CI by [CONTACT_301928]. The same computations will be done for Grade [ADDRESS_368988] 
95% CI for each formulation (US and ex -US).  
The percentage of subjects reporting each individual solicited local AE (any grade, Grade  3 and 
those resulting in a medically attended visit) and solicited general AE (any grade, Grade 3, any 
related, Grade 3 related and those resulting in a medically attended visit) during the 7 -day 
follow -up period (i.e. on the day of vaccination and 6 subsequent days) will be tabulated based 
on maximum intensity for each group for each formulation  (US and ex -US). 
For fever, the number and percentage of subjects reporting fever by [CONTACT_227259] (¬∞C) cumulative 
increments during the 7 -day follow -up period will be tabulated for each group  for each 
formulation  (US and ex -US). Similar tab ulations will be performed for any fever with a causal 
relationship to vaccination, Grade 3 or above (>  39.0¬∞C/102.2¬∞F) causally  related fever, and 
fever resulting in a medically attended visit. In addition, the prevalence of any and Grade 3 fever 
will be presented graphically over time after each vaccination.  
For each formulation  (US and ex -US), t he percentage of subjects with any unsolicited AEs 
during the 30 -day follow -up period (i.e. on the day of vaccination and 29 subsequent days) with 
its exact 95% C I will be tabulated by [CONTACT_301929] 
(MedDRA) SOC and preferred term. Similar tabulation will be done for Grade 3 unsolicited AEs, 
for any causally related unsolicited AEs, for Grade 3 causally related unsolicited AEs and for 
unsolicited AEs resulting in a medically attended visit. The verbatim reports of unsolicited AEs 
will be reviewed by a physician and the signs and symptoms  will be coded according to the 
MedDRA Dictionary for Adverse Reaction Termin ology.  
Tertiary  Will be described in a  Statistical Analysis P lan finali sed befo re database unblinding/freezing . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  77 10.4. Sequence of analyses  
Analyses to evaluate objectives and endpoints will be performed in steps . 
‚Ä¢ A first analysis  will be performed on all data available and as clean as possible, 
when data for at least primary and secondary endpoints pertaining to safety and 
immunogenicity up to Day 31 are available. At this point, the statistician will be 
unblinded (i.e. individual  subject treatment assignments will be available), but no 
individual listings will be provided to the study team. Given that summary safety 
results may unblind some specific subjects, the study will be considered as single -
blind from this point onwards, wi th subjects and investigators remaining blinded up 
to study end. The investigators will not be provided with the individual data listings 
or with the randomization listings until the end of study analysis.   
‚Ä¢ The second analysis  will evaluate  safety data and will be performed when all 
subjects have completed visits up to (and including) C1 (Day 181) and the data are 
available.  From this point the study is unblinded.   
‚Ä¢ The third analysis  will evaluate safety and immunogenicity data and will be 
performed when  all subjects  have completed visits up to (and including) Visit 6 
(Day [ADDRESS_368989] 2nd dose vaccination ) and the data are available. At this time, any 
available safety data will also be provided.  
‚Ä¢ The final end -of-study will be performed when all data for at least primary and 
secondary endpoints up to study conclusion  at Day [ADDRESS_368990] 2nd dose vaccination  
(C3) are available. An integrated clinical study report containing all available data 
will be written and made available to the investigators   
The final study report will contain at least the final analyses of all primary and secondary 
endpoints.  If the data for tertiary endpoints become available at a later stage, (an) 
additional analysis/ analyses will be performed. These analyses will be documented in 
annex(es) to the study report.  
If the data for tertiary endpoints become available at a later stage, (an) additional 
analysis/ analyses will be performed. These data will be documented in annex(es) to the 
study report and will be made available to the investigato rs at that time.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368991];20(4):[ADDRESS_368992] of Gender, Ra ce, and Parental Education on 
Immunogenicity and Reported Reactogenicity of Acellular and Whole -Cell Pertussis Vaccines.  
Pediatrics  (1995), 96(3) 
EMA Guideline on the exposure to medicinal products during pregnancy: need for post -
authorization data (Doc. R ef. EMEA/CHMP/313666/2005 ) ‚Äòadopted at Community level 
in May 2006);  
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_g
uideline/2009/11/WC500011303.pdf  
Hasin DS, O‚ÄôBrien CP, Auriacombe M, et al. DSM-5 Criteria for Substance U se 
Disorders: Recommendations and Rationale. The American journal of psychiatry . 
2013;170(8):834 -851. Doi:10.1176/appi.ajp.2013.12060782.  
Mazzilli S, Tavoschi L, Lopalco PL. Tdap vaccination during pregnancy to protect 
newborns from pertussis infection. Ann Ig. 2018 Jul-Aug;30(4):346 -363. Doi: 
10.7416/ai.2018.2226.  
Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme -linked 
immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for 
the estimation of tetanus antitoxin in human sera. J Biol Stand . 1983 Apr;11(2):137 -44. 
Theeten H, Van Damme  P, Hoppenbrouwers K, et al. Effects of lowering the aluminium 
content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a 
booster to adolescents. Vaccine 23(2005) 1515 ‚Äì1521. 
Vidor E, Plotkin SA. Immunogenicity of a two -component (PT  & FHA) acellular 
pertussis vaccine in various combinations  Hum Vaccin . [ADDRESS_368993];4(5):328 -40. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  79 12. APPENDICES  
12.1. Appendix 1: Abbreviations , glossary of terms  and 
trademarks  
12.1.1. List of abbreviations   
Ab Antibody  
AE Adverse Event  
AE(s) Adverse Event(s)  
Anti- Antibodies against  
BS H Blood Sample Humoral  
CDC Centers for Disease Control  
CI Confidence Interval  
CLS Clinical Laboratory Sciences  
CoP Correlate of Protection  
COVID Severe acute respi[INVESTIGATOR_103948]  2 
D Diphtheria  
dTpa Diphtheria, Tetanus and acellular Pertussis  
eCRF electronic Case Report Form  
ELISA Enzyme-Linked Immunosorbent Assay  
EoS End of Study  
eTDF Electronic Temperature excursion Decision Form  
Ex-US Outside the US  
FDA Food and Drug Administration, [LOCATION_002] of America 
FHA Filamentous Hemagglutinin  
FU Follow-up 
GCP Good Clinical Practice  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368994] Visit  
MACDP Metropolitan Atlanta Congenital Defects Program  
MedDRA  Medical Dictionary for Regulatory Activities  
Nab Neutralizing antibody  
PCD Primary Completion Date  
pI[INVESTIGATOR_301873] -Mediated Disease  
PP Per protocol  
PRN Pertactin 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  81 PRO Patient Related Outcomes  
PT Pertussis Toxoid  
RRA Recruitment/Randomisation Agreement  
RSV Respi[INVESTIGATOR_301874]3  RSV maternal vaccine  
SAE Serious Adverse Event  
SAE Serious Adverse Event  
SBIR Source data Base for Internet Randomisation  
SD Standard Deviation  
SDV Source Document Verification  
SmPC Summary of Product Characteristics  
SPM Study Procedures Manual  
SRT Safety Review Team  
T Tetanus 
UP Urine Pregnancy Test  
VSMB Vaccine Safety Monitoring Board  
12.1.2. Glossary of terms  
Adverse event:  Any untoward medical occurrence in a patient or clinical 
investigation subject, temporally associated with the use 
of a medicinal product, whether or not considered related 
to the medicinal product.  
An adverse event (AE) can therefore be any unfavourable 
and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a med icinal product. 
For marketed medicinal products, this also includes 
failure to produce expected benefits (i.e. lack of efficacy), 
abuse or misuse.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  82 Blinding:  A procedure in which [ADDRESS_368995] and the site and sponsor 
personnel involved in the clinical evaluation of the 
subjects are blinded while other study personnel may be 
aware of the treatment assignment (see Section 7.3 for 
details on observer -blinded studies).  
Certified copy:  A copy (irrespective of the type of media used) of the 
original record that has been verified (i.e. by a dated 
signature [INVESTIGATOR_4388] [CONTACT_97214] a validated process) to 
have the same information, including data that describe 
the context, c ontent, and structure, as the original.  
Child in care:  A child who has been placed under the control or 
protection of an agency, organisation, institution or entity 
by [CONTACT_285135], the government or a government body, 
acting in accordance with powers confe rred on them by 
[CONTACT_6617]. The definition of a child in care can 
include a child cared for by [CONTACT_301930] a 
care home or institution, provided that the arrangement 
falls within the definition above. The definition of a child 
in care does not include a child who is adopted or has an 
appointed legal guardian.  
Eligible: Qualified for enrolment into the study based upon strict 
adherence to inclusion/exclusion criteria.  
End of Study (EoS):  
(Synonym of End of 
Trial) For studies with coll ection of human biological samples 
and/or imaging data, the EoS is defined as Last subject 
last visit (Visit X) or Last testing results released of 
samples collected at Visit X*  
* In this case EoS must be achieved no later than 8 
months after LSLV.  
Enrolled: Subjects who agreed to participate in a clinical study after 
completion of the informed consent process. and subject 
is not a screen failure.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  83 Epoch: Interval of time in the planned conduct of a study. An 
epoch is associated with a purpose (e.g. screening, 
randomisation, treatment, follow -up), which applies 
across all arms of a study. NOTE: Epoch is intended as a 
standardised term to replace: period, cy cle, phase, stage.  
Essential documents:  Documents which individually and collectively permit 
evaluation of the conduct of a study and the quality of the 
data produced.  
eTrack: [COMPANY_004]‚Äôs tracking tool for clinical trials.  
Evaluable:  Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, 
included in the per -protocol analysis (see Section 10.2 for 
details on criteria for evaluability).  
Immunological correlate 
of protection:  The defined immune response above which there is a high 
likelihood of protection in the absence of any host factors 
that might increase susceptibility to the infectious agent. 
Investigational vaccine:  
(Synonym of 
Investigational Medicinal 
Product)  A pharmaceutical form of an active ingredient being 
tested in a clinical trial, including a product with a 
marketing authorisation when used in a way different 
from the approve d form, or when used for an unapproved 
indication, or when used to gain further information about 
an approved use.  
Investigator:  A person responsible for the conduct of the clinical trial 
at a trial site. If a trial is conducted by a team of 
individuals at a trial site, the investigator is the 
responsible leader of the team and may be called the 
principal investigator.  
The investigator can delegate trial -related duties and 
functions conducted at the trial site to qualified individual 
or party to perform t hose trial-related duties and functions  
Legally acceptable 
representative:  
(The terms legal 
representative or legally 
authorised 
representative are used 
in some settings.)  An individual or juridical or other body authorised under 
applicable law to consent , on behalf of a prospective 
subject, to the subject's participation in the clinical trial.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  84 Primary completion 
date: The date that the final subject was examined or received 
an intervention for the purpose of final collection of data 
for all primary outcomes, whether the clinical trial was 
concluded according to the pre -specified protocol or was 
terminated.  
Protocol administrative 
change: A protocol administrative change addresses changes to 
only logistical or administrative aspects of the study.  
Protocol amendment:  The International Council on Harmonisation (ICH) 
defines a protocol amendment as: ‚ÄòA written description 
of a change(s) to or formal clarification of a protocol.‚Äô 
[COMPANY_004] further details this to include a change to an 
approved protocol that affects the safety of subjects, 
scope of the investigation, study design, or scientific 
integrity of the study.  
Randomisation:  Process of random attribution of treatment to subjects in 
order to reduce bias of selection.  
Self-contained study:  Study with o bjectives not linked to the data of another 
study. 
Site Monitor:  An individual assigned by [CONTACT_301931] 1 or 
more investigational sites.  
Solicited adverse event:  AEs to be recorded as e ndpoints in the clinical study. The 
presence/occurrence/intensity of these events is actively 
solicited from the subject or an observer during a 
specified post -vaccination follow -up period.  
Source data:  All information in original records and certified copi[INVESTIGATOR_163503], observations, or other 
activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data are 
contained in source documents (original records or 
certified copi[INVESTIGATOR_014]).  
Source documents:  Original documents, data, and records (e.g. hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, 
memoranda, subjects' diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from 
automated instruments, copi[INVESTIGATOR_014] o r transcriptions certified 
after verification as being accurate copi[INVESTIGATOR_014], microfiches, 
photographic negatives, microfilm or magnetic media, x -
rays, subject files, and records kept at the pharmacy, at 
the laboratories and at medico -technical departments 
involved in the clinical trial).  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  85 Study vaccine/product:  Any investigational vaccine/product being tested and/or 
any authorised use of a vaccine/product/placebo as a 
reference or administered concomitantly, in a clinical trial 
that evaluates the use of an inves tigational 
vaccine/product.  
Sub-cohort: A group of subjects for whom specific study procedures 
are planned as compared to other subjects or a group of 
subjects who share a common characteristic (e.g. ages, 
vaccination schedule‚Ä¶) at the time of enrolment.  
Subject: Term used throughout the protocol to denote an 
individual who has been contact[CONTACT_43031], either as a recipi[INVESTIGATOR_285098](s) or as a control.  
Subject number:  A unique number identifying a subject, assigned to each 
subject consenting to participate in the study.  
Treatment:  Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject.  
Treatment number:  A number identifying a treatment to a subject, according 
to treatment allocation.  
Unsolicited adverse 
event: Any AE reported in addition to those solicited during the 
clinical study. Also, any ‚Äòsolicited‚Äô symptom with onset 
outside the specified period of follow -up for solicited 
symptoms will be reported as an unsolicited adverse 
event. 
12.1.3. Trademarks  
Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Generic description  
Boostrix    Combined diphtheria, tetanus and acellular 
pertussis vaccine (adsorbed)  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  86 12.2. Appendix  2: Clinical  and safety laboratory tests 
The tests detailed in  Table 20 will be performed by [CONTACT_12082].  
All clinical and safety laboratory tests will be perfo rmed by [CONTACT_12117](ies). All 
assessments of immune response ( Section 8.4) will be performed centrally (by [CONTACT_301932] 
a [COMPANY_004]-designated laboratory).  
Protocol-specific requirements for inclusion or exclusion of subjects are detailed in 
Section 6 of the protocol.  
The investigator is not allowed to do extra testing on samples outside of what has been 
agreed upon by [CONTACT_301933] s committees. 
Table 20 Protocol -Required Safety Laboratory Assessments  
System  Discipline  Component  Method  Scale  Laboratory  
Whole 
blood  Haematology1 Leukocytes (White Blood Cells)  
As per local 
practice  Quantitative  
At 
investigator‚Äôs 
laboratory  Lymphocytes  
Eosinophils  
Basophils  
Haemoglobin  
Platelets  
Neutrophils  
Serum  Biochemistry  Alanine Aminotransferase (ALT)  
As per local 
practice  Quantitative  Aspartate Aminotransferase 
(AST)  
Creatinine  
Blood Urea Nitrogen 
(BUN)/urea]* 
Urine1  Pregnancy  As per local 
practice; dipstick 
provided by [CONTACT_301934]‚Äôs 
laboratory  
* Sites not able to directly test for BUN, will test for urea and then convert urea values into BUN using the applicable  
established conversion factor(s). 
1 In certain  labs a complete blood counts will be required per local lab practice (more than just those  listed in table)  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  87 12.3. Appendix 3: Clinical laboratories  
Table 21 [COMPANY_004] laboratories , 
Laboratory  Address  
[COMPANY_004] Biological‚Äôs Clinical Laboratory Sciences, 
Rixensart  Biospecimen Reception -B7/44  
Rue de l'Institut, 89 -B-1330 Rixensart -Belgium  
[COMPANY_004] Biological‚Äôs Clinical Laboratory Sciences, 
Wavre -Nord Noir Epi[INVESTIGATOR_301875], [ADDRESS_368996] Laval  
Quebec Canada H7V 3S8  
Nexelis  Inc. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  88 12.4. Appendix  4: Study governance c onsiderations  
12.4.1. Regulatory and e thical considerations  
‚Ä¢ This study will be conducted in accordance with the protocol and with:  
‚àí Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organi sations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
‚àí Applicable ICH Good Clinical Practice (GCP) Guidelines  
‚àí Applicable laws and regulations  
‚Ä¢ The protocol, protocol amendments, Informed Consent Form (ICF) or Informed 
Assent Form (IAF), Investigator Brochure, and other relevant documents (e .g. 
advertisements) must be submitted , to an IRB/IEC by [CONTACT_301935]. These documents will be  signed and dated by [CONTACT_301936].  
‚Ä¢ Any amendments to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study subjects.  
‚Ä¢ [COMPANY_004] will provide full details of the above procedures to the investigator, either 
verbally, in writing, or both.  
‚Ä¢ The investigator will be responsible for the fo llowing: 
‚àí Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/EC . 
‚àí Notifying the IRB/IEC of SAE (s) or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures . 
‚àí Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other a pplicable local 
regulations . 
12.4.2. Financial d isclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disc losure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interest prior 
initiation of the cent re and at the end of the study. Investigators are responsible for 
providing an update of Financial Disclosure if their financial interest changes at any point 
during their participation in a study and for 1 year after completion of the study.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  89 12.4.3. Informed consent process  
The investigator or his/her representative will explain the nature of the s tudy to the 
subject or his/her legally authorised representative and answer all questions regarding the 
study.  
Subjects must be informed that their participation is voluntary.  
Freely given and written or witnessed/thumb printed informed consent must  be obtained 
from each subject , as appropriate, prior to participation in the study.  
The content of informed consent form must meet the requirements of [ADDRESS_368997] 
(HIPAA) re quirements, where applicable, and the IRB/IEC or study centre.  
The medical record must include a statement that written informed consent was obtained 
before the subject was enrolled in the study and the date the written consent was 
obtained. The authorised  person obtaining the informed consent must also sign the ICF.  
Subjects must be re -consented to the most current version of the ICF(s) or an ICF 
addendum during their participation in the study.  
A copy of the ICF(s) must be provided to the subject . 
Subjects who are rescreened are required to sign a new ICF.  
12.4.4. Data protection  
Subject will be assigned a unique identifier by [CONTACT_456]. Any subject records or 
datasets that are transferred to the sponsor will contain the identifier only; subject ‚Äôs 
names or any information which would make the subject identifiable will not be 
transferred.  
The subject must be informed that his/her personal study -related data will be used by [CONTACT_20004].  
The subject must be infor med that his/her medical records may be examined by [CONTACT_301937], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].  
[COMPANY_004] will also ensure the protecti on of personal data of investigator and the site staff 
which will be collected within the frame and for the purpose of the study.  
12.4.5. Committees structure  
Safety oversight will be provided by a blinded safety review team (SRT) composed of 
[COMPANY_004] RSV team members , and by [CONTACT_161698], internal safety review  committee 
composed of [COMPANY_004] personnel not affiliated with the RSV program . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  90 12.4.6. Publication policy 
[COMPANY_004] aims to publish the results of this study in searchable, peer reviewed scientific 
literature. [COMPANY_004] will target to s ubmit within 18 months from LSLV for interventional 
studies and from the completion of the analysis for non -interventional studies and follows 
the guidance from the International Committee of Medical Journal Editors.  
12.4.7. Dissemination of clinical study d ata 
The key design elements of this protocol will be posted on the [COMPANY_004] Clinical Study 
Register and on publicly accessible registers including ClinicalTrials.gov. Where 
required, protocol summaries will also be posted on national or regional clinical trial 
registers or databases (e.g. EudraCT database) in compliance with the applicable 
regulations.  
[COMPANY_004] also assures that results will be submitted to ClinicalTrials.gov within the required 
time-frame, in compliance with the current regulations  mentioned in the table below.  
At the time of study results posting, the full study protocol and statistical analysis plan 
will also be posted on ClinicalTrials.gov.  
In addition, for studies that are in scope of the EU Clinical Trial Directive, summaries of 
the results of [COMPANY_004] i nterventional studies (phase I -IV) in adult population will be posted 
within defined timelines on the publicly available EU Clinical Trial Register.   
If it is not possible to submit a summary of the results within the required timelines in the 
concerned EU  member state, the summary of results shall be submitted as soon as it is 
available. In this case, the protocol shall specify when the results are going to be 
submitted, together with a justification.   
 Clinicaltrial.gov  EU 
Protocol summary  Before enrolment of subjects  As per CTA submission /Before 
enrolment of subjects  
Results summary  Within 12 months of PCD (Primary 
and safety endpoint results) /Within 
12 months of LSLV* (for secondary 
endpoint results)  Within 6 months (for paediatric 
population st udies) /Within 12 months 
(for adult population studies) of EoS*.  
* As defined in the study protocol.  
Under the framework of the SHARE initiative, anonymi sed patient -level data from [COMPANY_004] 
sponsored interventional studies that evaluate products will be made av ailable within [ADDRESS_368998].com.  
Where required by [CONTACT_301938], an investigator signatory will be 
identified for the approval of the study report, provided reasonable access to statistical 
tables, figures, and relevant reports. [COMPANY_004] will also provide the investigator with the full 
summary of the study result s. The investigator is encouraged to share the summary 
results with the study subjects, as appropriate.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_368999] of the location(s) of their respective essential 
documents including source documents . The storage system used during the trial and for 
archiving (irrespective of the type of media used) should provide for document 
identification, version history, search, and retrieval.  
Essential documents for the trial may be added or reduced where justifi ed (in advance of 
trial initiation) based on the importance and relevance to the trial. When a copy is used to 
replace an original document (e.g. source documents, CRF), the copy should fulfil the 
requirements for certified copi[INVESTIGATOR_014] .  
All subject data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e .g. laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189] /eCRF.  
The investigator must maintain adequate and accurate source documents and trial records 
that include all pertinent observations on each of the site‚Äôs trial subjects  that supports th e 
information entered in the  eCRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents or certified 
copi[INVESTIGATOR_014].  
The sponsor or designee is responsible for the data management of t his study including 
quality checking of the source da ta.  
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_301939], legible, contemporaneous, 
original, accurate, an d complete . Changes to source data should be traceable, should not 
obscure the original entry, and should be explained if necessary (e.g. via an audit trail). 
Safety and rights of subjects must be protected and study be conducted in accordance 
with the cur rently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
Trial records and source documents, including signed ICF, pertaining to the conduct of 
this study must be retained by [CONTACT_1732] 25 years from the issue of the final 
Clinical Study Report (CSR) /equivalent summary  unless local regulations or institutional 
policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of t he sponsor. No records may be 
transferred to another location or party without written notification to the sponsor.  
12.4.9. Source d ocuments  
Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Investigator should maintain a record of the location(s) of 
their source documents.   209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369000] be available.  
Definition of what constitutes source data  and source documents  can be found in  the 
glossary of terms . 
12.4.10. Study and s ite closure 
[COMPANY_004] or its designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole disc retion of [COMPANY_004] , provided there is sufficient notice given 
to account for patient‚Äôs safe exit from study participation . Study sites  regular closure  will 
be upon study completion. A study site is considered closed when all required 
data/documents and study supplies have been collected and a study -site closure visit has 
been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_103086]:  
‚Ä¢ Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
‚Ä¢ Inadequate recruitment of subjects by [CONTACT_093]  
‚Ä¢ Discontinuation of further study treatment development  
The investigator will:  
‚Ä¢ Review data collected to ensure accuracy and completeness  
‚Ä¢ Complete the Study Conclusion screen in the/eCRF . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  93 12.5. Appendix 5: Adverse Events: definitions and procedures for 
recording, evaluating, follow -up, and r eporting  
12.5.1. Definition of AE  
[IP_ADDRESS].  AE Definition  
An AE is any untoward medical occurrence in a clinical study subject, temporally 
associated with the use of a study treatment, whether or not considered related to the 
study treatment.  
NOTE: An AE can therefore be any unfavo urable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use o f a study treatment.  
[IP_ADDRESS].  Events Meeting  the AE Definition  
‚Ä¢ Significant or unexpected worsening or exacerbation of the condition/indication 
under study.  
‚Ä¢ Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency a nd/or intensity of the condition.  
‚Ä¢ New conditions detected or d iagnosed after study vaccine(s)  administration even 
though they may have been present prior to the start of the study.  
‚Ä¢ Signs, symptoms, or the clinical sequelae of a suspected interaction.  
‚Ä¢ Signs, symptoms, or the clinical sequelae of a suspected overdose of  either study 
vaccine(s)  or a concurrent medication (overdose per se should not be reported as an 
AE/SAE).  
‚Ä¢ Signs, symptoms temporally a ssociated with study vaccine(s) administration.  
‚Ä¢ Significan t failure of expected pharmacological or biological action.  
‚Ä¢ Pre- or post-treatment events that occur as a result of protocol -mandated procedures 
(i.e. invasive procedures, modification of subject‚Äôs previous therapeutic regimen).  
‚Ä¢ Medically attended visits related to adverse events (e.g. Hospi[INVESTIGATOR_7959], physician 
visits and emergency room visits).  
AEs to be recorded as endpoints (solicited AEs) are described in Section  12.5.3. All other 
AEs will be recorded as UNSOLICITED AEs.  
The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfil the definition o f an AE or SAE.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  94 [IP_ADDRESS].  Events NOT Meeting the AE Definition  
‚Ä¢ Situations where an untoward medical occurrence did not occur (e.g. social and/or 
convenience admission to a hospi[INVESTIGATOR_307], admission for routine examination).  
‚Ä¢ Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
‚Ä¢ Pre-existing conditions or signs and/or symptoms present in a  subject prior to the 
study vaccination. These events will be recorded in the med ical history s ection of the 
eCRF. 
12.5.2. Definition of SAE  
A SAE is any untoward medical occurrence that:  
a. Results in death,  
b. Is life-threatening,  
Note: The term ‚Äòlife -threatening‚Äô in the definition of ‚Äòserious‚Äô refers to an event in 
which the subject was at risk of death at the  time of the event. It does not refer to an 
event, which hypothetically might have caused death, had it been more severe.  
c. Requires hospi[INVESTIGATOR_15574],  
Note: In general, hospi[INVESTIGATOR_301876]/or treatment that would not have 
been appropriate in the physician‚Äôs office or in an out -patient setting. Complications 
that occur during hospi[INVESTIGATOR_301877]. If a com plication prolongs 
hospi[INVESTIGATOR_222663], the event will also be considered 
serious. When in doubt as to whether ‚Äòhospi[INVESTIGATOR_11956]‚Äô occurred , or was necessary, 
the AE should be considered serious.  
Hospi[INVESTIGATOR_301878] a pre -existing condition (known or 
diagnosed prior to informed consent signature) that did not worsen from baseline is 
NOT considered an AE.  
d. Results in disability/incapacity, OR  
Note: The term disability means a substantial disruption of a pe rson‚Äôs ability to 
conduct normal life functions. This definition is not intended to include experiences 
of relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhoea, influenza like illness, and accidental trauma (e.g . sprained 
ankle) which may interfere or prevent everyday life functions but do not constitute a 
substantial disruption.  
e. Is a congenital anomaly/birth defect in the offspring of a study subject . 
f. Medical or scientific judgement should be exercised in decidi ng whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_301879] p revent one of the 
other outcomes listed in the above definition. These should also be considered 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  95 serious. Examples of such events are invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_11956].  
12.5.3. Solicited adverse events  
a. Solicited local (injection -site) adverse events  
The following local (injection -site) AEs will be solicited:  
Table 23 Solicited local adverse events  
Pain at injection site  
Redness  at injection site  
Swelling at injection site  
b. Solicited general adverse events  
The following general AEs will be solicited:  
Table 24 Solicited general adverse events  
Fatigue  
Fever  
Gastrointestinal symptoms ‚Ä† 
Headache  
‚Ä†Gastrointestinal symptoms include nausea, vomiting, diarrhoea and/or abdominal pain.  
Note: subjects will be instructed to measure and record the axillary or oral  body 
temperature in the evening. Should additional temperature measurements be performed at 
other times of day, subjects will be instructed to record the highest temperature in the 
diary card.  
12.5.4. Unsolicited  adverse events  
An unsolicited adverse event is an adverse event that was not solicited using a  Subject 
Diary and that was spontaneously communicated by a subjects who has signed the 
informed consent . 
Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses 
requiring hospi[INVESTIGATOR_73256], or emergency room visit, or visit to/by a health care provider), 
or were of concern to the subjects. I n case of such events, subjects  will be instructed to 
contact [CONTACT_43070](s). The detailed information about 
the reported unsolicited AEs will be collected by [CONTACT_301940]‚Äôs records.  
Unsolicited AEs that are not medically attended nor perceived a s a concern by [CONTACT_301941].  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  96 12.5.5. Clinical laboratory parameters and other abnormal assessments 
qualifying as adverse events or serious adverse events  
In absence of diagnosis, abnormal laboratory  findings (e.g. clinical chemistry, 
haematology, urinalysis) or other abnormal assessment that are judged by [CONTACT_301942] (refer to Sections 12.5.1 and 12.5.2). Clinically significant abno rmal 
laboratory findings or other abnormal assessments that are present at baseline and 
significantly worsen following the start of the study will also be reported as AEs or 
SAEs. However, clinically significant abnormal laboratory findings or other abnorm al 
assessments that are associated with the disease being studied,  unless judged by [CONTACT_301943]‚Äôs condition, or that are present 
or detected at the start of the study and do not worsen, will not be reported as AEs or 
SAEs. 
The investigator will exercise his or her medical  and scientific judgement in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant.  
12.5.6. Events or outcomes not qualifying as adverse events or serious 
adverse events  
[IP_ADDRESS].  Pregnancy  
Female subjects who become pregnant  after the vaccination may continue the study at the 
discretion of the investigator.  
While pregnancy is not considered an AE or SAE, any adverse pregnancy outcome or 
complication or elective termination of a pregnancy for medical reasons will be recorded 
and reported as an AE or a SAE.  
Note: The pregnancy should always be recorded on an electronic pregnancy report.  
The following should always be considered as SAE and will be reported as described in 
Sections [IP_ADDRESS] and [IP_ADDRESS]: 
‚Ä¢ Spontaneous pregnancy loss, including:  
‚àí spontaneous abortion, (spontaneous pregnancy loss before/at 22 weeks of 
gestation)  
‚àí ectopic and molar pregnancy  
‚àí stillbirth (intrauterine death of foetus after 22 weeks of gestation).  
Note: the 22 weeks ‚Äô cut-off in gestational age is based on WHO -ICD 10 noted in the 
EMA Guideline  on pregnancy exposure [ EMA, 2006]. It is recogni sed that national 
regulations might be different.  
‚Ä¢ Any early neonatal death (i.e. death of a live born infant occurring within the first 7 
days of life).  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  97 ‚Ä¢ Any congenital anomaly or birth defect identified in the offspring of a study subject 
(either during pregnancy, at birth or later) regardless of whether  the foetus is 
delivered dead or alive. This includes anomalies identified by [CONTACT_301944], 
amniocentesis or examination of the products of conception after elective or 
spontaneous abortion.  
Furthermore, any SAE occurring as a result of a post -study pregnancy AND considered 
by [CONTACT_301945](s)  will be reported to 
[COMPANY_004] as described in Section  12.5.8. While the investigator is not obligated to actively 
seek this information from former s ubjects, he/she may learn of a pregnancy through 
spontaneous reporting.  
12.5.7. Detecting and recording adverse events, serious adverse events 
and pregnancies  
A Paper Diary (pDiary) hereafter referred to as Subject Diary will be used in this study to 
capture solicited or unsolicited adverse events . The subject should be trained on how and 
when to complete each field of the Subject Diary.  
The subjects will be instructed to con tact the investigator immediately should the subject  
manifest any signs or symptoms they perceive as serious.  
Subject Diary training should be directed at the individual(s) who will perform the 
measurements of adverse events and who will enter the information into the Subject 
Diary. This individual may not be the subject, but if a person other than the subject ent ers 
information into the Subject Diary, this person‚Äôs identity must be documented in the 
Subject Diary. Any individual that makes entries into the Subject Diary must receive 
training on completion of the Subject Diary at the time of the visit when Subject Diary is 
dispensed. This training must be documented in the subject‚Äôs source record.  
At the vaccination visit, the diary card will be provided to the subject. The subject/ will 
be instructed to measure and record the body temperature (oral preferred), and any 
solicited local/general AEs (i.e. on the day of vaccination and during the next 6 days) or 
any unsolicited AEs (i.e. on the day of vaccination and during the next [ADDRESS_369001] to the investigator at the next study visit.  
[IP_ADDRESS].  Time period for detecting and recording adverse events, serious 
adverse events and pregnancies  
All AEs during  7 days following administration of each dose vaccination of study 
vaccine(s) (Day [ADDRESS_369002] 2nd 
vaccination ) must be recorded into the appropriate section of the eCRF, irrespective of 
intensity or whether or not they are considered vaccination -related. 
All AEs/SAEs leading to withdrawal from the study will be collected and recorded from 
the time of the receipt of study vaccine(s)/product(s) . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  98 SAEs that are related to the study vaccine(s)  will be collected and recorded from the time 
of the receipt of study  vaccine(s)  until the subject is discharged from the study . 
In addition to the above -mentioned reporting requirements and in order to fulfil 
international reporting obligations, SAEs that are related to study participation (i.e. 
protocol-mandated procedure s, invasive tests, a change from existing therapy) or are 
related to a concurrent [COMPANY_004] medication/vaccine will be collected and recorded from the 
time the subject consents to participate in the study until she/he is discharged from the 
study. 
The time perio d for collecting and recording pr egnancies will begin at the receipt of study 
vaccine(s) and will end 181 days following administration of the  dose of study 
vaccine(s). See section 12.5.8 for instructions on reporting of pregnancies.  
[IP_ADDRESS].  Evaluation of adverse events and serious adverse events  
[IP_ADDRESS].1.  Active questioning to detect adverse events and serious adverse 
events 
As a consistent method of collecting AEs, the subject should be asked a non -leading 
question such as:  
‚ÄòHave you felt different in any way  since receiving the vaccine(s)  or since the previous 
visit?‚Äô 
When an AE/SAE occurs, it is the responsibility of the in vestigator to review all 
documentation (e.g. hospi[INVESTIGATOR_1088], laboratory and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE in the eCRF . The investigator is not allowed to send photocopi[INVESTIGATOR_5189]‚Äôs medical records to [COMPANY_004] instead of appropriately completing the eCRF . 
However, there may be instances when copi[INVESTIGATOR_31784]. In this instance, all subject identifiers will be blinded on the copi[INVESTIGATOR_301880].  
The investigator will attempt to establish a diagnosis pertaining to the event based on 
signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs/symptoms.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW )LQDO
$SULO   $VVHVVPHQWRIDGYHUVHHYHQWV 
$VVHVVPHQWRILQWHQVLW\ 
7KHLQWHQVLW\RIWKHIROORZLQJVRO LFLWHG$(VZLOOEHDVVHVVHGD VGHVFULEHG 
7DEOH,QWHQVLW\VFDOHVIRUVROLFLWHGV\P SWRPVLQDGXOWVDQGFKLOGUHQRI
\HDUVRIDJHRUPRUH 
Adults/Child ( tt6 years)  
Adverse Event Intensity grade Parameter 
Pain at injection site  
Redness at injection site 
Swelling at injection site 
Temperature* 
Headache  
Fatigue  
Gastrointestinal symptoms  
(nausea, vomiting, diarrhoea and/or
abdominal pain)  
7KHPD[LPXPLQWHQVLW\RIORFDOLQMHF WLRQVLWHUHGQHVVVZHOOLQJZLOO EHVFRUHGDW*6.
%LRORJLFDOVDFFRUGLQJWR WKHVWDQGDUG*6.%LRORJLFDOV¬∂VFRULQJ V\VWHPIRUDGXOWV 
7KHLQYHVWLJDWRU ZLOODVVHVVWKHPD[LPXPLQWHQVLW\WKDWRFFXUUHGRYHUWKHGXUDWL RQRIWKH
HYHQWIRUDOOXQVROLFLWHG$(VLQFOXGLQJ 6$(VUHFRUGHGGXULQJ WKHVWXG\7KHDVVHVVPHQW
ZLOOEHEDVHGRQWKHLQYHVWLJDWRU¬∂VFOLQLFDOMXGJHPHQW _3URWRFRO$PHQGPHQW$SU_70)_
CCI - This section contained Clinical Outcome Assessment data 
collection questionnaires or indices, which are protected by [CONTACT_14561].
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by [CONTACT_14561].
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by [CONTACT_14561].
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW )LQDO
$SULO  7KHLQWHQVLW\VKRXOGEHDVVLJQHGWR RIWKHIROORZLQJFDWHJRULHV 
$Q$(WKDWLVDVVHVVHGDV* UDGH VKRXOGQRWEHFRQIXVHGZLWKD6$(*UDGH
LVDFDWHJRU\XVHGIRUUDWLQJWKHLQWHQVLW\RIDQHYHQWDQG ERWK$(VDQG6$(VFDQEH
DVVHVVHGDV*UDGH$QHYHQWL VGHILQHGDV¬µVH ULRXV¬∂ZKHQLWP HHWVRIWKHSUH GHILQHG
RXWFRPHVDVGHVFULEHG LQ6HFWLRQ 
$VVHVVPHQWRIFDXVDOLW\ 
7KHLQYHVWLJDWRULVREOLJD WHGWRDVVHVVWKHUHODWLRQVKLSEHWZHH QVWXG\YDFFLQHVDQGWKH
RFFXUUHQFHRI HDFK$(6$(XVLQJFOLQLFDOM XGJHPHQW,QFDVHRIFRQFRPLWDQW
DGPLQLVWUDWLRQRIPXOWLSO HYDFFLQHVSURGXFWVLISRVVLEOHWKH LQYHVWLJDWRUVKRXOGVSHFLI\
LIWKH$(FRXOGEHFDXVDOO\UHOD WHGWRDVSHFLILFYDFFLQHSURGX FWDGPLQLVWHUHGLH 
LQYHVWLJDWLRQDOF RQWUROSODFHERRUFR DGPLQLVWHUHGYDFFLQH:KHQFDXVDOUHODWL RQVKLSWR
DVSHFLILFYDFFLQHV FDQQRWEH GHWHUPLQHG WKHLQYHVWLJDWRUVKRXOGLQGLFDWHWKH$(WREH
UHODWHGWRDOOSURGXFWV 
$OWHUQDWLYHSODXVLEOHFDXVHVVXFKD VQDWXUDOKLVWRU\RIWKHXQ GHUO\LQJGLVHDVHV
FRQFRPLWDQWWKHUDS\RWKHUU LVNIDFWRUVDQGWKHWHPSRUDOUHODW LRQVKLSRIWK HHYHQWWRWKH
VWXG\YDFFLQHV ZLOOEHFRQVLGHUHGDQGLQYHVWLJD WHG7KHLQYHVWLJDWRUZLOODOVR FRQVXOW
IRUWKH569 PDWHUQDOYDFFLQH WKH,%DQGIRUWKH %RRVWUL[9DFFLQHWKH6P3&DQGRU
3UHVFULELQJ,QIRUPDWLRQWRGHWHUPLQHKLVKHUDVVHVVPHQW 
7KHUHPD\EHVLWXDWLRQVZKHQD 6$(KDVRFFXUUHGDQGWKHLQYHVWL JDWRUKDVPLQLPDO
LQIRUPDWLRQWRLQFOXGHLQWKHLQLWL DOUHSRUWWR*6.+RZHYHUL WLVYHU\LPSRUWDQWWKDWWKH
LQYHVWLJDWRUDOZD\VPDNHVDQDVVHVVPHQWRI FDXVDOLW\IRUHYHU\ HYHQWSULRUWRVXEPLVVLRQ
RIWKH([SHGLWHG$GYHUVH(YH QWV5HSRUWWR*6.7KHLQYHVWLJDWRU PD\FKDQJHKLVKHU
RSLQLRQRIFDXVDOLW\LQOLJKWRIIROORZ XSLQIRUPDWLRQDQGXSGDWHWKH 6$(LQIRUPDWLR Q
DFFRUGLQJO\7KHFDXVDOLW\DVVHVVPHQWLV RQHRIWKHFULWHULDXVHGZKHQGHWHUPLQLQJ
UHJXODWRU\UHSRUWLQJUHTXLUHPHQWV 
$OOVROLFLWHGORFDOLQMHFWLRQVLWHUHDFWLRQVZLOOEHFRQVLGHU HGFDXVDOO\UHODWHGWR
YDFFLQDWLRQ&DXVDOLW\RIDOORWKHU$(VVKRXOGEH DVVHVVHGE\WKHLQYHVWLJDWRUXVLQJWKH
IROORZLQJTXHVWLRQ _3URWRFRO$PHQGPHQW$SU_70)_
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or 
indices, which are protected by [CONTACT_14561].
CCI
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369003] b een caused by [CONTACT_106365] ? 
YES : There is a reasonable possibility that the  study vaccine(s)  contributed to 
the AE.  
NO : There is no reasonable possibility that the AE is causally related to the 
administration of the  study vaccine(s) . There are other, more likely 
causes and adminis tration of the study vaccine(s)  is not suspected to 
have contributed to the AE.  
If an event meets the criteria to be determined as ‚Äòserious‚Äô (see Section  12.5.2), additional 
examinations/tests will be performed by [CONTACT_301946].  
Possible contributing factors include:  
‚Ä¢ Medical history.  
‚Ä¢ Other medication.  
‚Ä¢ Protocol required procedure.  
‚Ä¢ Other procedure not required by [CONTACT_760].  
‚Ä¢ Lack of efficacy of the vaccine(s)/product(s) (delete as applicable ), if applicable.  
‚Ä¢ Erroneous administration.  
‚Ä¢ Other cause (specify).  
Assessment of outcomes  
The investigator will assess the outcome of all unsolicited AEs (including SAEs) 
recorded during the study as:  
‚Ä¢ Recovered/resolved.  
‚Ä¢ Recovering/resolving.  
‚Ä¢ Not recovered/not resolved.  
‚Ä¢ Recovered with sequelae/resolved with sequelae.  
‚Ä¢ Fatal (SAEs only).  
[IP_ADDRESS].3.  Medically attended visits  
For each solicited and unsolicited symptom the s ubject experiences, the subject  will be 
asked if she  received medical attention defined as hospi[INVESTIGATOR_11956], or an otherwise 
unscheduled visit to or from medical personnel for any reason, including emergency 
room visits. This information will be recorded in the eCRF.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  102 12.5.8. Reporting of serious adverse events, pre gnancies, and other 
events 
[IP_ADDRESS].  Prompt reporting of serious adverse events, pregnancies, and other 
events to [COMPANY_004]  
SAEs that occur in the time period defined in Section 12.5.7 will be reported promptly to 
[COMPANY_004] within the timeframes described in  Table 15, once the investigator det ermines that 
the event meets the protocol definition of a SAE.  
Pregnancies that occur in the time period defined in Section 12.5.7 will be reported 
promptly to [COMPANY_004] within the timeframes described in  Table 15, once the investigator 
becomes aware of the pregnancy.  
[IP_ADDRESS].  SAEs requiring expedited reporting to  [COMPANY_004] 
Once an investigator becomes aware that a SAE has occurred in a study subject, the 
investigato r (or designate) must complete the information in the electronic Expedited 
Adverse Events Report WITHIN [ADDRESS_369004] all information regarding a SAE, the report should still be completed within 24 
hours. Once additional relevant information is received, the report should be updated 
WITHIN 24 HOURS.  
The investigator will always provide an assessment of causality at the ti me of the initial 
report. The investigator will be required to confirm the review of the SAE causality by 
[CONTACT_43078] ‚Äòreviewed‚Äô box in the electronic Expedited Adverse Events Report within 72 
hours of submission of the SAE.  
[IP_ADDRESS].  Back-up system in case the elec tronic reporting system does not work  
If the electronic reporting system does not work, the investigator (or designate) must 
complete, then date and sign a paper Expedited Adverse Events Report and fax it to the 
Study Contact [CONTACT_43075] (refer to t he Sponsor Information ) or to [COMPANY_004] Clinical 
Safety and Pharmacovigilance department within 24 hours.  
This back -up system should only be used if the electronic reporting system is not working 
and NOT if the system is slow. As soon as the electronic reporting system is working 
again, the investigator (or designate) must complete the electronic Expedited Adverse 
Events Report within 24 hours. The final valid information for regulatory reporting will 
be the information reported through the electronic SAE reporting system.  
[IP_ADDRESS].  Completion and transmission of pregnancy reports to [COMPANY_004] (Amended 
09-APR-2021) 
Once the investigator becomes aware that a subject  is pregnant, the investigator (or 
designate) must complete the required information onto the electronic pregnancy report 
WITHIN 24 HOURS . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  103 Note: Conventionally, the estimated gestational age (EGA) of a pregnancy is dated from 
the first day of the last mens trual period (LMP) of the cycle in which a woman conceives. 
If the LMP is uncertain or unknown, dating of EGA and the estimated date of delivery 
(EDD) should be estimated by [CONTACT_301947]. 
12.5.9. Updating of SAE, preg nancy, information after removal of write 
access to the subject‚Äôs eCRF  
When additional SAE  and pregnancy information is received after removal of the write 
access to the subject‚Äôs eCRF, new or updated information should be recorded on the 
appropriate paper  report, with all changes signed and dated by [CONTACT_093]. The 
updated report should be faxed to the Study Contact [CONTACT_43075] (refer to the 
Sponsor Information ) or to [COMPANY_004]  Clinical Safety and Pharmacovigilance department 
within the designated reporting time frames specified in  Table 15. 
12.5.10. Follow-up of adverse events, serious adverse events, and 
pregnancies  
[IP_ADDRESS].  Follow-up during the study  
After the initial AE/SAE report, the investigator is required to proactively follow each 
subject and provide additional relevant information on the subject‚Äôs condition to [COMPANY_004] 
(within 24 hours for SAEs; refer to  Table 15). 
All SAEs  (serious or non -serious) documented at a previous visit/contact [CONTACT_301948]/not resolved or recovering/resolving will be reviewed at subsequent 
visits/contacts until the last visit of the subject.  
All AEs documented at a previous visit/contact [CONTACT_301949]/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until [ADDRESS_369005] vaccination.  
[IP_ADDRESS].  Follow-up after the subject is discharged from the study  
The investigator will follow subjects:  
‚Ä¢ with SAEs, or subje cts withdrawn from the study as a result of an AE, until the event 
has resolved, subsided, stabilised, disappeared, or until the event is otherwise 
explained, or the subject is lost to follow -up.  
If the investigator receives additional relevant information on a previously reported SAE, 
he/she will provide this information to [COMPANY_004] using a paper/electronic Expedited Adverse 
Events Report and/or pregnancy report as applicable.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369006] of additional 
clinical examinations/tests and/or evaluations to elucidate as fully as possible the nature 
and/or causality of the AE or SAE. The investigator is obliged to assist. If a subject dies 
during participation in the study or during a recognised foll ow-up period, [COMPANY_004] will be 
provided with any available post -mortem findings, including histopathology.  
[IP_ADDRESS].  Follow-up of pregnancies  
Pregnant subjects will be followed to determine the outcome of the pregnancy. At the end 
of the pregnancy, whether full -term or premature, information on the status of the mother 
and child will be forwarded to [COMPANY_004] using the electronic pregnancy report and the 
Expedited Adverse Events Report if applicable. Generally, the follow -up period doesn‚Äôt 
need to be longer than 6 to 8 weeks after the estimated date of delivery.  
Regardless of the reporting period for SAEs for this study, if the pregnancy outcome is a 
SAE, it should always be reported as SAE  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  105 12.6. Appendix  6: Contraceptive guidance and collection of 
pregnancy i nformation  
12.6.1. Definitions  
[IP_ADDRESS].  Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile (see below)  
[IP_ADDRESS].1.  Women in the following categories are not considered WOCBP  
‚Ä¢ Premenarchal  
Menarche is the onset o f menses for the first time in a young female and is preceded 
by [CONTACT_301950]. Menarche usually occurs within [ADDRESS_369007] development (palpable glandular breast ti ssue). 
‚Ä¢ Premenopausal female with ONE of the following:  
‚àí Documented hysterectomy  
‚àí Documented bilateral salpi[INVESTIGATOR_1656]  
‚àí Documented bilateral oophorectomy  
Note: Documentation can come from the site personnel‚Äôs: review of subject‚Äôs medical 
records, medical examina tion, or medical history interview.  
‚Ä¢ Postmenopausal female  
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a postmenopausal state in women not 
using hormonal contraception or hormonal replacement therapy (HRT). However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
‚Ä¢ Females on HRT and whose menopausal status is in doubt wi ll be required to use [ADDRESS_369008] discontinue HRT to allow 
confirmation of postmenopausal status before study enrolment.  
12.6.2. Contraception g uidance  
‚Ä¢ Female subjects of childbearing potential are eligible to participate if they agree to 
use an adequate contraception consistently and correctly according to the methods 
listed in [COMPANY_004] list of highly effective contraceptive methods pro vided in Table 26. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  106 Table 26 Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent a 
Failure rate of <1% per year when used consistently and correctly.  
Combined ( oestrogen - and progestogen -containing) hormonal contraception associated with inhibition of ovulation  
‚Ä¢ oral 
‚Ä¢ intravaginal  
‚Ä¢ transdermal  
Progestogen -only hormonal contraception associated with inhibition of ovulation  
‚Ä¢ injectable  
Highly Effective Methods That Are User Independent  
‚Ä¢ Implantable progestogen -only hormonal contraception associated with inhibition of ovulation  
‚Ä¢ Intrauterine devi ce (IUD)  
‚Ä¢ Intrauterine hormone -releasing system (IUS)  
‚Ä¢ bilateral tubal occlusion  
Vasectomi sed partner  
(A vasectomi sed partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used. )  
Male partner sterilisation prior to the female subject‚Äôs entry into the study, and this male is the sole partner for that 
subject,  
(The informati on on the male sterility can come from the site personnel‚Äôs review of the subject‚Äôs medical records; 
medical examination and/or semen analysis, or medical history interview provided by [CONTACT_163596]).  
Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence 
needs to be evaluated in relation to  the duration of the study and the preferred and usual lifestyle of the subject .)  
NOTES:  
a. Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contracep tive methods for subject s in clinical studies.  
12.6.3. Collection of pregnancy i nformation  
[IP_ADDRESS].  Female Subjects who become pregnant  
‚Ä¢ Investigator will collect pregnancy information on any female subject, who becomes 
pregnant while participating in this study.  
‚Ä¢ Information will be recorded on the appropriate form and submitted to [COMPANY_004] within [ADDRESS_369009]'s pregnancy.  
‚Ä¢ Subject will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on subject and neonate, which will be 
forwarded to [COMPANY_004] Generally, follow -up will not be required for longer than 6 to 8 
weeks beyond the estimated delivery date.  
‚Ä¢ Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of ano malies) or indication for procedure.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  107 ‚Ä¢ While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.  
‚Ä¢ A spontaneous abortion is always considered to be an SAE  and will be reported as 
such. 
‚Ä¢ Any SAE occurring as a result of a post -study pregnancy which is considered 
reasonably related to the study treatment by [CONTACT_093], will be reported to [COMPANY_004] 
as described in 12.5.8. While the investigator is not obligated to actively seek this 
information in former study subjects, she may learn of an SAE through spontaneous 
reporting.  
Any female subject who becomes pregnant while participating will continue the study .  
12.7. Appendix  7: Genetics   
Not applicable  
12.8. Appendix  8: Country -specific requirements  
Not applicable.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  108 12.9. Appendix 9: Protocol Amendment/Administrative change 
History 
The Protocol Amendment/Administrative change Summary of Changes Table for the 
current amendment/administrative change is located directly before the Table of Contents 
(TOC). 
DOCUMENT HISTORY  
Document  Date of Issue  
Amendment [ADDRESS_369010]-2019 
Original Protocol  23-Aug-2019 
Overall Rationale for Amendment 1: The current holding rules do not include death or 
life-threatening SAEs considered related to vaccination that occur > [ADDRESS_369011] 
vaccination. In order to ensure inclusion of such events as triggers for study hold, the 
phrase ‚Äúnon -life-threatening‚Äù has b een removed from holding rule 1b.  
Detailed description of Protocol Amendment 1  
Table 16 Study holding rules  
Holding 
Rule  Event  Number of Subjects  
1a Death or any life -threatening SAE occurring within 30 days from 
vaccination  ‚â•1 
1b Any non-life-threatening  SAE that can be reasonably attributed to 
the vaccination  ‚â•[ADDRESS_369012] dosing. 
Long term persistence data will be useful to inform the boosting schedule for women 
entering successive pregnancies.  Unblinding a fter Day 181 will still occur and the 
extended study (epoch 4) will be open labe l. 
In addition, several discrepancies with the protocol with the study procedures manual 
were align ed. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW )LQDO
$SULO  'HWDLOHGGHVFULSWLRQRI3URWRFRO$PHQGPHQW 
&RQWULEXWLQJDXWKRUV&RQW 
x 2YHUVLJKW'DWD0DQDJHU 
x 6DIHW\6FLHQWLVW 
x 6WXG\6WDWLVWLFLDQ 
2EMHFWLYHVDQG(QGSRLQWV 
x To evaluate the safety of 2 dose levels (60 and 
120 Œºg) of RSVPreF3 when given alone and co-
administered with dTpa compared to dTpa- Placebo 
groups from Vaccination up to Day 181 365. x Occurrence of SAEs from Vaccination up to Day 181 
365. 
x To evaluate the safety of 2 dose levels (60 and 
120 Œºg) of RSVPreF3 when given alone and co-
administered from Vaccination up to Day 181 365 by 
[CONTACT_14509]. x Occurrence of SAEs from Vaccination up to Day 
181365.  
x To evaluate the safety of RSVPreF3 (pooled for all 
groups receiving RSVPreF3). x Occurrence of SAEs from Vaccination up to Day 
181365. 
Immunogenicity 
x To evaluate the humoral immune response to 2 
dose levels (60 and 120 Œºg) of RSVPreF3 when 
given alone and co-administered with dTpa at 
Screening, Day 8, and Day [ADDRESS_369013] vaccination by [CONTACT_14509].  Immunogenicity 
x RSV A neutralizing antibody titers at Screening, Day 
8, and Day 31 , Day 181, and Day 365  
x RSV IgG antibody concentrations at Screening, Day 
8, and Day 31 , Day 181, and Day 365  
)LJXUH6WXG\'HVLJQRYHUYL HZ
Note: study groups labeled X = ex -US; study groups labeled U = US.  
x = Vaccination; N = number of subjects; CHS= Chem ical/Hematological Screening Visit; D = Day; AE = 
adverse event; UP = Urine pregnancy test; FU = follow -up; BSH = blood sample (5 mL) for humoral immune responses 
(RSV -A neutralization and RSV IgG an tibody concentrations at Screening, Visit 2 [Day 8], and Visit 3 [Day 31], Visit 4 
[Day 181], and Visit 5 [Day 365] , and dTpa ELISAs at Screening and Visit 3 [Day 31])  
For the participants that sign the informed consent adde ndum, the conclusion of the study will be on Day [ADDRESS_369014].  
7DEOH6FKHGXOHRI$FWLYLWLHV 
Epoch  Epoch 
001 Epoch 002  
(Vaccination) Epoch 003  
(Follow-up)8 Epoch 004  
(Extension Study)[ADDRESS_369015] Vacc 
Physical examination 2  ‚óè ‚óè ‚óè O  O O 
Informed consent for extension 
study      ‚óè  
Phone contact     ‚óè   _3URWRFRO$PHQGPHQW$SU_70)_
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  110 Epoch  Epoch 
001 Epoch 002  
(Vaccination)  Epoch 003   
(Follow -up)8 Epoch 004   
(Extension Study)8 
Blood sampling for humoral 
immune response (~5 mL) 4 ‚óè  ‚óè ‚óè  ‚óè ‚óè 
Recording of AE leading to 
withdrawal   ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè8 
Recording of serious AE 6 ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè8 
Recording of pregnancies   ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè8 
Recording of concomitant 
medications/vaccinations   ‚óè ‚óè ‚óè ‚óè 7 ‚óè ‚óè 7, [ADDRESS_369016] any intercurrent medical 
conditions    ‚óè ‚óè ‚óè ‚óè ‚óè8 
Screening conclusion  ‚óè       
Investigator sign -off on eCRF 
before analysis  ‚óè    ‚óè8  ‚óè8 
Study conclusion        ‚óè8 
2 Physical examination including resting vital signs (blood pressure, heart rate and respi[INVESTIGATOR_697], temperature) after 
at least [ADDRESS_369017]. Weight, height and BMI will only be collected at Screening. Physical examination at  
Visit 2,  Visit 3, Visit 4 and Visit 5 , will be performed only if deemed necessary by [CONTACT_093]. For Visit 1 and 
Visit 2,  (if performed ), only vital signs will be collected in the eCRF.  
[ADDRESS_369018] . 
Table 4 Intervals between study visits  
Interval  Optimal timing  Allowed interval 
 Screening Visit  ‚ÜíVisit 1  ‚â§7 days  -7- 1 days  
Visit 1  ‚ÜíVisit 2  8 days  7- 10 days  
Visit 1  ‚ÜíVisit 3  31 days  30- 45 days  
Visit 1‚ÜíPhone Contact   [ADDRESS_369019] ‚Üí Visit 4   0-30 days  
Visit 1 ‚ÜíVisit 5  365 days  335-395 days  
5.2 Overall design  
‚Ä¢ Duration of the study: Approximately [ADDRESS_369020] 
approximately 6 months.  
‚àí Epoch 001: Screening  
‚àí Epoch 002: Primary (i.e., vaccination phase) starting at Visit 1 (Day 1) and 
ending just before the Visit 3 (Day 31)   
‚àí Epoch 003: Follow -up Phone Ccontact [CONTACT_2006] 181)   
‚àí Epoch 004: Follow Visit 4 (Day 181) to Visit 5 (Day 365)  
‚Ä¢ Primary completion Date (PCD): Visit 3 (Day 31) or last visit of Primary Epoch  
Refer to glossary of terms  for the definition of PCD.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  111 ‚Ä¢ End of Study (EoS):  Last testing resul ts released of samples collected at Visit  [ADDRESS_369021] visit (LSLV), which occurs with 
Visit [ADDRESS_369022] 1  on Day 365 181. 
Table 6 Study groups, treatment and epochs foreseen in the study  
Study Groups  Number 
of 
subjects  Age 
(Min-
Max)  Treatment 
name  [CONTACT_301959]  
(Blinding)  
Epoch 001  
(Screening)  Epoch 002 
(observer -
blind)  Epoch 003  
(single -
blind)  Epoch 
004 
(open 
study)  
XRSV120_dTpa  50 18 - 
45 
years RSV MAT 
120  
Boostrix -ex-
US 
(dTpa_500)  x x x x 
XPlacebo_RSV120  50 18 - 
45 
years RSV MAT 
120 
Placebo  x x x x 
XRSV60_dTpa  50 18 - 
45 
years  RSV MAT 
60 
Boostrix -ex-
US 
(dTpa_500)  x x x x 
XPlacebo_RSV60  50 18 - 
45 
years  RSV MAT 
60 
Placebo  x x x x 
XPlacebo_dTpa  50 18 - 
45 
years  Boostrix -ex-
US 
(dTpa_500)  
Placebo  x x x x 
URSV120_dTpa  50 18 ‚Äì 
45 
years  RSV MAT 
120 
Boostrix -US 
(dTpa_300)  x x x x 
UPlacebo_RSV120  50 18 ‚Äì 
45 
years  RSV MAT 
120 
Placebo  x x x x 
URSV60_dTpa  50 18 - 
45 
years  RSV MAT 
60 
Boostrix -US x x x x 
UPlacebo_RSV60  50 18 - 
45 
years  RSV MAT 
60 
Placebo  x x x x 
UPlacebo_dTpa  50 18 ‚Äì 
45 
years  Boostrix -US 
(dTpa_300)  
Placebo  x x x x 
5.[ADDRESS_369023] completed the study if he/she is available for the 
concluding contact [CONTACT_765] (Visit 5 , Day 181365) as described in the protocol. For those 
participants that do not sign the ICF amendment the EOS will be the Day [ADDRESS_369024] as described in previous version of protocol  (RSV MAT -011 (209141) 
Protocol Amendment 1 ([ADDRESS_369025]-2019). 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369026]‚Äôs treatment assignment and will communicate this to the 
subject. For Visit 4 (Day 181) and Visit 5 (Day 365), the study will continue during 
the extended follow -up phase as an open study.  
7.5.1 Recording of concomitant medications/products and concomitant vaccinations  
‚Ä¢ Any concomitant vaccination administered in the period starting 30 days before the 
dose of study vaccine(s) and ending at the last  study visit/contact  (Day -30 to Day 
181 365). 
8.0 Study assessments and procedures  
For subjects consenting to the extended follow -up phase, 2 additional evaluations 
will be performed at Day 181 (Visit 4) and Day 365  (Visit 5). The subject will be 
queried for th e occurrence of  SAE and associated concomitant medication, 
pregnancy, and vaccinations received . In addition, approximately [ADDRESS_369027], including assessment of axillary or oral 
body temperature and resting vital signs: systolic/diastolic blood pressure, heart rate and 
respi[INVESTIGATOR_163484] [ADDRESS_369028] at screening visit, including 
assessment of axillary or oral body temperature and resting vital signs: 
systolic/diastolic blood pressure, heart rate and respi[INVESTIGATOR_163484] [ADDRESS_369029].  
Perform a history directed physical exam plus vital s igns at Visit 1 [Day 1]  
Physical examinations at each study visit subsequent to the vaccination visit, will be 
performed only if the subject indicates during questioning that there might be some 
underlying pathology(ies) or if deemed necessary by [CONTACT_301951].  Any 
vitals signs measured at Visit 2 (Day 8) should be recorded in the eCRF).  
8.3.Immunogenicity assessments  
Any sample testing will be done in line with the consent of the individual 
subject/subject‚Äôs parent(s)/LAR(s).  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369030]  Unit Time point  Additional Information  
Whole blood for 
immune response*  5 ml Visit 4 (Day  181) Immune response: 5 mL (~ 2 mL 
serum) . 
Whole blood for 
immune response*  5 ml Visit 5 (Day  365) Immune response: 5 mL (~ 2 mL 
serum) . 
 3020.5* ml Minimum Total, not including repeat or unscheduled 
samples  
*For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 
as described in the protocol and 30.5 mL of blood will be collected  in total during the study . Participant‚Äôs 
that do not sign the informed consent addendum  will complete the study at day [ADDRESS_369031] 
and 20.5 m of blood will be collecte d in total during the study . 
Table 11 Humoral Immunity (Antibody determination)  
Sampli
ng time 
points  Syste
m Component  Metho
d Kit/ 
Manufactur
er Unit Cut-
off* Group
s Numbe
r of 
subjec
ts Laborato
ry 
Screeni
ng Serum  Respi[INVESTIGATOR_301881]3 
Ab.IgG 
concentratio
n ELI In house  ELU/mL  25 
All 500 Nexelis  
Neomed  
Serum  Respi[INVESTIGATOR_301881]3 
Ab.IgG 
concentratio
n ELI In house  ELU/mL  25 
All 500 Nexelis  
Neomed   
Day 31           
Serum  Respi[INVESTIGATOR_301881]3 
Ab.IgG 
concentratio
n ELI In house  ELU/mL  25 
All 500 Nexelis  
Neomed   
Day 
181* Seru
m Respi[INVESTIGATOR_301882] A Ab 
neutralizing  NEU  In house  ED60 
and/or IU 
(internatio
nal unit)  18 
for 
ED6
0 
TBD 
for 
IU All 500 [COMPANY_004]  
Seru
m Respi[INVESTIGATOR_301881]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  114 Sampli
ng time 
points  Syste
m Component  Metho
d Kit/ 
Manufactur
er Unit Cut-
off* Group
s Numbe
r of 
subjec
ts Laborato
ry 
Day 
365* Seru
m Respi[INVESTIGATOR_301882] A Ab 
neutralizing  NEU  In house  ED60 
and/or IU 
(internatio
nal unit)  18 
for 
ED6
0 
TBD 
for 
IU All 500 [COMPANY_004]  
Seru
m Respi[INVESTIGATOR_301881]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  
Ab = antibody; ELI = Enzyme -linked immunosorbent assay (ELISA); IgG = immunoglobulin G; RSV = respi[INVESTIGATOR_14256]; ED60  = serum dilution inducing 60% inhibition in plaque forming units; IU/ml = International 
units/milliliter, IU= International units; TBD = to be determined  
Assay cut -off and unit might be subject to change before starting of testing (e.g. in case of requalification, revalidation 
or standardisation). In this case, this will be documented in the clinical report.  
* For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 
as described in the protocol. Participant‚Äôs that do not sign the informed consent addendum  will complete the 
study at day [ADDRESS_369032].  
***[COMPANY_004] laboratory refers to the Clinical Laboratory Sciences (CLS) in Rixensart, Belgium; Wavre, Belgium; Marburg, 
[LOCATION_013].  
Table 12 Immunol ogical read -outs 
Blood sampling timepoint  Subset name  [CONTACT_301960]. subjects  Component  Components 
priority rank  
Visit 4 (Day 
181)***  Post -Vacc  All 500 RSV-A neutralizing 
antibody  1 
All 500 RSVPreF3 IgG antibody 
concentration  2 
Visit 5 (Day 
365)***  Post -Vacc  All 500 RSV-A neutralizing 
antibody  1 
All 500 RSVPreF3 IgG antibody 
concentration  2 
*** For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 
365 as described in the protocol. Participant‚Äôs that do not sign the informed consent addendum  will 
complete the study at day [ADDRESS_369033] . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  115 Table 13 Reporting periods for collecting safety information  
Event  Pre- 
V1*  V1  V2  V3 Phone contact 1   V4** V5 (Study 
Conclusion  
D1 D7 D8 D30 D31 D181  D181  D365  
Solicited local and general 
AEs           
          
          
Unsolicited AEs            
          
          
AEs leading to withdrawal from 
the study            
          
          
SAEs            
          
          
SAEs related to study 
participation  
or concurrent [COMPANY_004] 
medication/vaccine            
          
          
Pregnancies            
          
          
* i.e. consent obtained. Pre -V: pre -vaccination; V: vaccination; Post -V: post -vaccination; D: Day, M: Month  
**For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 
365 as described in the protocol.  Participant‚Äôs that do not sign the informed consent addendum  will 
complete the study at day [ADDRESS_369034] be followed:  
‚Ä¢ CRDL to inform the  local Study team ( Table 15) 
‚Ä¢ The LML/delegate of each country confirm the reception of the holding rule to 
the CRDL and inform all the investigators.  
‚Ä¢ The concerned site staff has to put vaccination and enrolment on hold.  
‚Ä¢ The central study team will ensure SBIR is blocked and all vaccinat ing centres 
are informed.  
‚Ä¢ [COMPANY_004] Safety Review Team (SRT) will further evaluate the case and escalate to 
[COMPANY_004] VSMB for making the decision to stop or to restart the vaccination. All 
site staff will be informed about that final decision by [CONTACT_301952]. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369035]. From an analysis perspective, a ‚Äòwithdrawal‚Äô from the study refers to any 
subject was not available for the concluding contact [CONTACT_91313].  
10.1.2 Sample size calculation  
In order to evaluate the humoral response to 2 dose levels (60 and 120  ÔÅ≠g) of RSVPreF3 
when given alone, and co -administered with dTpa, the difference between co -
administration with dTpa (RSVPreF3 dTpa) and RSVPreF3 alone (RSVPreF3 placebo) in 
terms of RSV -A neutralizing antibody (Nab) ti ters will be evaluated at Day 8  and Day 31. 
Additional sampling at Day 181, and Day 365 will allow evaluation of the 
persistence of RSVPreF3 responses .  
10.2 Populations for analyses  
For purposes of analysis, the following analysis sets are defined:  
Analys is Set  Description  
Enrolled  Subjects who agreed to participate in a clinical study after completion of 
the informed consent process. and subject is not a screen failure . Refer to 
the glossary of terms for the definition of ‚Äòenrolled‚Äô  
All subjects who completed the informed consent process and signed the 
informed consent form  
10.3.3 Immunogenicity analyses  
Endpoint  Statistical Analysis Methods  
Primary  The GMT/GMCs ratio and their 90% CI between RSVPreF3 dTpa and RSVPreF3 alone in terms 
of RSV -A Nab titers and RSV IgG antibody concentrations will may be calculated at Screening, 
and/or  Day 8, and/or  Day 31  pooled for all subjects.  
‚Ä¢ A further exploratory be tween -groups analysis will be performed at Day 8 or Day 31 using 
an ANCOVA model by [CONTACT_301923], study formulation (US and ex -US), age 
category, and level of antibodies at Screening as covariates.  
Secondary  ‚Ä¢ The GMT/GMCs ratio and their 90% CI between RSVPreF3 dTpa and RSVPreF3 alone 
in terms of RSV -A Nab titers and RSV IgG antibody concentrations may be 
calculated at Day 181, and/or Day 365* pooled for all subjects.  
*For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 
as described in the protocol. Participant‚Äôs that do not sign the informed consent addendum,  will complete 
the study at day [ADDRESS_369036].  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  117 10.3.4 Safety analyses  
Primary  (US + ex -US data to be pooled)  
The percentage of subjects with at least one local AE (solicited and unsolicited), with at least 
one general AE (solicited and unsolicited) and with any (‚Äúsolicited or unsolicited‚Äù)  AE during 
the [ADDRESS_369037] 95% 
CI by [CONTACT_2060]. The same computations will be done for Grade [ADDRESS_369038] one local AE (solicited and unsolicited), with at 
least one general AE (solicited and unsolicited) and with any (‚Äúsolicited or unsolicited‚Äù)  
AE during the [ADDRESS_369039] 95% CI by [CONTACT_2060]. The same computations will be done for 
Grade 3 AEs, for any AEs considered related to vaccination, for Grade 3 AEs considered 
related to vaccination and for AEs resulting in medically attended  visits *. 
The percentage of subjects with at least one report of SAE classified by [CONTACT_301953] [ADDRESS_369040] 95% CI for 
each formulation (US and ex -US). The same analysis will be  done covering the entire study 
period (from vaccination up to day 365) In addition, similar analyses covering the 30 -day 
follow up period and the 365 day follow up period will be performed for pooled 
formulations and pooled all groups receiving RSVPreF3 S AEs.  
The percentage of subjects using concomitant medication (any medication, any antipyretic and 
any antipyretic taken prophylactically, respectively) from vaccination up to day 181 * will be 
summarized by [CONTACT_301954] (US and ex -US). 
*For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 
as described in the protocol. Participant‚Äôs that do not sign the informed consent addendum  will complete 
the study at day [ADDRESS_369041] primary and 
secondary endpoints up to study conclusion (D365) are available . 
After Day 181(Visit 4) the study participants will be unblinded and the st udy 
extension phase will continue as an open study until the final study visit (Visit 5).  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  118 Table 19 Protocol-Required Safety Laboratory Assessments  
System  Discipline  Component  Method  Scale  Laboratory  
Whole 
blood  Haematology1 Leukocytes (White Blood Cells)  
As per local 
practice  Quantitative  
At 
investigator‚Äôs 
laboratory  Lymphocytes  
Eosinophils  
Basophils  
Haemoglobin  
Platelets  
Neutrophils  
Serum  Biochemistry  Alanine Aminotransferase (ALT)  
As per local 
practice  Quantitative  Aspartate Aminotransferase 
(AST)  
Creatinine  
Blood Urea Nitrogen 
(BUN)/urea]* 
Urine1  Pregnancy  As per local 
practice; dipstick 
provided by [CONTACT_301934]‚Äôs 
laboratory  
* Sites not able to directly test for BUN, will test for urea and then convert urea values into BUN using the applicable 
established conversion factor(s). Only BUN values will be entered into the eCRF.  
Serum pregnancy test (instead of urine test) may be perf ormed if required by [CONTACT_1606], local or ethics committee 
regulations. 
1 In certain local  labs a complete blood counts will be required per local laboratory 
practice (more than just those listed in table).  
Table [ADDRESS_369042] is not a screen failure.  
[IP_ADDRESS] Time period for detecting and recording adverse events, serious adverse 
events and pregnancies  
The time period for collecting and recording pregnancies will begin at the receipt of study 
vaccine(s) and will end 181 365 days following administration of the dose of study 
vaccine(s). 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW )LQDO
$SULO  2YHUDOO5DWLRQDOHIRU $PHQGPHQW 
7KHVSRQVRUKDVGHFLGHGQRWWRLPSOHPHQW WKHVL[PRQWKH[WHQVLRQIRUSURORQJHG
LPPXQRJHQLFLW\GHVFULEHGXQGHU$ PHQGPHQW7KHUDWLRQDOHIRUW DNLQJWKLVGHFLVLRQLV
WKDWWKHVSRQVRULQWHQGVWRVXEPLWD QDPHQGPHQWWKDWZLOOHQURO OQHZSDUWLFLSDQWV&RKRUW
WRDOORZDPRUHUREXVWDVVHVVPHQWRIQR QLQIHULRULW\RI %RRVWUL[UHVSRQVHLQFR 
DGPLQLVWUDWLRQZLWK5693UH) $QDVVHVVPHQWRIDQWLERG\SHUVLVW HQFHDQGUHVSRQVHWRD
VHFRQGGRVHRI5693UH)ZLOOEHLQFOXGH GLQWKHVHQHZO\HQUROOH GVXEMHFWV+HQFHWKH
HYDOXDWLRQRISURORQJHGLPPXQRJHQLFLW\LQ&R KRUWKDVEHFRPHUHGXQGDQW 
'HWDLOHGGHVFULSWLRQRI3URWRFRO$PHQGPHQW 
&RQWULEXWLQJDXWKRUV&RQW 
x /HDG6WDWLVWLFLDQ 
x  
2EMHFWLYHVDQG(QGSRLQWV 
x To evaluate the safety of 2 dose levels (60 and 
120 Œºg) of RSVPreF3 when given alone and co-
administered with dTpa compared to dTpa- Placebo 
groups from Vaccination up to Day 181365. x Occurrence of SAEs from Vaccination up to Day 181 
365. 
x To evaluate the safety of 2 dose levels (60 and 
120 Œºg) of RSVPreF3 when given alone and co-
administered from Vaccination up to Day 181 365 by 
[CONTACT_14509]. x Occurrence of SAEs from Vaccination up to Day 
181365.  
x To evaluate the safety of RSVPreF3 (pooled for all 
groups receiving RSVPreF3). x Occurrence of SAEs from Vaccination up to Day 
181365. 
Immunogenicity 
x To evaluate the humoral immune response to 2 
dose levels (60 and 120 Œºg) of RSVPreF3 when 
given alone and co-administered with dTpa at 
Screening, Day 8, and Day [ADDRESS_369043] vaccination by [CONTACT_14509].  Immunogenicity 
x RSV A neutralizing antibody titers at Screening, Day 
8, and Day 31 , Day 181, and Day 365 
x RSV IgG antibody concentrations at Screening, Day 
8, and Day 31 , Day 181, and Day 365 
)LJXUH6WXG\'HVLJQRYHUYLHZ 
Note: study groups labeled X = ex -US; study groups labeled U = US.  
x = Vaccination; N = number of subjects; CHS= Chem ical/Hematological Screening Visit; D = Day; AE = 
adverse event; UP = Urine pregnancy test; FU = follow -up; BSH = blood sample (5 mL) for hum oral immune responses 
(RSV -A neutralization and RSV IgG an tibody concentrations at Screening, Visit 2 [Day 8], and Visit 3 [Day 31], Visit 4 
[Day 181], and Visit 5 [Day 365],  and dTpa ELISAs at Scree ning and Visit 3 [Day 31])  
For the participants that sign the informed consent addendum, the conclusion  of the study will be on Day [ADDRESS_369044].  _3URWRFRO$PHQGPHQW$SU_70)_
[COMPANY_003]
[COMPANY_003] [COMPANY_003]
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  120 Table 3 Schedule of Activities  
Epoch  Epoch 
001 Epoch 002  
(Vaccination)  Epoch 003   
(Follow -up)8 Epoch 004   
(Extension Study)[ADDRESS_369045] Vacc  
Physical examination 2  ‚óè ‚óè ‚óè O  O O 
Informed consent for extension 
study       ‚óè  
Phone contact      ‚óè   
Blood sampling for humoral 
immune response (~5 mL) 4 ‚óè  ‚óè ‚óè  ‚óè ‚óè 
Recording of AE leading to 
withdrawal   ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè8 
Recording of serious AE 6 ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè8 
Recording of pregnancies   ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè8 
Recording of concomitant 
medications/vaccinations7  ‚óè ‚óè ‚óè ‚óè 7 ‚óè ‚óè 7, [ADDRESS_369046] any intercurrent medical 
conditions    ‚óè ‚óè ‚óè ‚óè ‚óè8 
Screening conclusion  ‚óè       
Investigator sign -off on eCRF 
before analysis  ‚óè    ‚óè8  ‚óè8 
Study conclusion      ‚óè  ‚óè8 
2 Physical examination including resting vital signs (blood pressure, heart rate and respi[INVESTIGATOR_697], temperature) after 
at least [ADDRESS_369047]. Weight, height and BMI will only be collected at Screening. Physical examination at  
Visit 2 , and Visit 3,  Visit 4 and Visit 5 , will be performed only if deemed necessary by [CONTACT_093]. For Visit 1 and 
Visit 2, (if performed), only vital signs will be collected in the eCRF.  
[ADDRESS_369048].  
Table 4 Intervals between study visits  
Interval  Optimal timing  Allowed interva l 
Screening Visit  ‚ÜíVisit 1  ‚â§7 days  -7- 1 days  
Visit 1‚ÜíVisit 2  8 days  7- 10 days  
Visit 1‚ÜíVisit 3  31 days  30- 45 days  
Visit 1‚ÜíPhone Contact   [ADDRESS_369049] ‚ÜíVisit 4   0-30 days  
Visit 1 ‚ÜíVisit 5  365 days  335-396 days  
5.2 Overall design 
‚Ä¢ Duration of the study: Approximately [ADDRESS_369050] 
approximate ly 6 months.  
‚Ä¢ Epoch 001: Screening  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  121 ‚Ä¢ Epoch 002: Primary (i.e., vaccination phase) starting at Visit 1 (Day 1) and 
ending just before the Visit 3 (Day 31)   
‚Ä¢ Epoch 003: Follow -up Phone Contact (Day 181)  
‚Ä¢ Epoch 004: Follow Visit 4 (Day 181) to Visit 5 (Day 365)  
‚Ä¢ Primary completion Date (PCD): Visit 3 (Day 31) or last visit of Primary Epoch  
Refer to glossary of terms for the definition of PCD.  
‚Ä¢ End of Study (EoS):  Last testing results released of samples collected at Visit  [ADDRESS_369051] visit (LSLV), which occurs with 
Visit [ADDRESS_369052] 1  on Day 365 181. 
Table 6 Study groups, treatment and epochs foreseen in the study  
Study Groups  Number 
of 
subjects  Age 
(Min-
Max)  Treatment 
name  [CONTACT_301959]  
(Blinding)  
Epoch 001  
(Screening)  Epoch 002 
(observer -
blind)  Epoch 003  
(single -
blind)  Epoch 004  
(open 
study)  
XRSV120_dTpa  50 18 - 
45 
years RSV MAT 
120  
Boostrix -ex-
US 
(dTpa_500)  x x x x 
XPlacebo_RSV120  50 18 - 
45 
years RSV MAT 
120 
Placebo  x x x x 
XRSV60_dTpa  50 18 - 
45 
years  RSV MAT 
60 
Boostrix -ex-
US 
(dTpa_500)  x x x x 
XPlacebo_RSV60  50 18 - 
45 
years  RSV MAT 
60 
Placebo  x x x x 
XPlacebo_dTpa  50 18 - 
45 
years  Boostrix -ex-
US 
(dTpa_500)  
Placebo  x x x x 
URSV120_dTpa  50 18 ‚Äì 
45 
years  RSV MAT 
120 
Boostrix -US 
(dTpa_300)  x x x x 
UPlacebo_RSV120  50 18 ‚Äì 
45 
years  RSV MAT 
120 
Placebo  x x x x 
URSV60_dTpa  50 18 - 
45 
years  RSV MAT 
60 
Boostrix -US x x x x 
UPlacebo_RSV60  50 18 - 
45 
years  RSV MAT 
60 
Placebo  x x x x 
UPlacebo_dTpa  50 18 ‚Äì 
45 
years  Boostrix -US 
(dTpa_300)  
Placebo  x x x x 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369053] completed the study if he/she is available for the 
concluding contact [CONTACT_765] (Visit 5, Day 181365) as described in the protocol. For those 
participants that do not sign the ICF amendment the EOS will be the Day [ADDRESS_369054] as described in previous version of protocol (RSV MAT -011 (209141) Protocol 
Amendment 1 ([ADDRESS_369055]-2019). 
7.[ADDRESS_369056]‚Äôs treatment assignment and will communicate this to the subject.  For Visit 4 
(Day 181) and Visit 5 (Day 365), the study will continue during the extended follow -up 
phase as an open study.  
7.5.1 Recording of concomitant medications/products a nd concomitant vaccinations  
‚Ä¢ Any concomitant vaccination administered in the period starting 30 days before the 
dose of study vaccine(s) and ending at the last  study visit/contact  (Day -30 to Day 
181 365). 
8.0 Study assessments and procedures  
For subjects consenting to the extended follow -up phase, 2 additional evaluations will be 
performed at Day 181 (Visit 4) and Day 365 (Visit 5).  The subject will be queried for the 
occurrence of  SAE and associated concomitant medication, pregnancy, and vaccinations 
received. In addition, approximately [ADDRESS_369057]  Unit Time point  Additional Information  
Whole blood for 
immune response*  5 ml Visit 4 (Day  181) Immune response: 5 mL (~ 2 mL 
serum) . 
Whole blood for 
immune response*  5 ml Visit 5 (Day  365) Immune response: 5 mL (~ 2 mL 
serum) . 
 3020.5* ml Minimum Total, not including repeat or unscheduled samples  
*For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 as 
described in the protocol and 30.5 mL of blood will be collected in total during the study. Participant‚Äôs that do not sign 
the informed consent addendum  will complete the study at day [ADDRESS_369058] and 20.5 m of blood will be 
collected in total during the study.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  123 Table 11 Humoral Immunity (Antibody determination)  
Samplin
g time 
points  Syste
m Componen
t Metho
d Kit/ 
Manufactur
er Unit Cut-
off* Group
s Numbe
r of 
subject
s Laborato
ry 
Screeni
ng Serum  Respi[INVESTIGATOR_301883]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  
 
Serum  Respi[INVESTIGATOR_301883]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  
 
Day 31           
Serum  Respi[INVESTIGATOR_301883]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  
 
Day 
181* Serum  
Respi[INVESTIGATOR_301882] A Ab 
neutralizing  NEU  In house  ED60 
and/or IU 
(internation
al unit)  18 
for 
ED6
0 
TBD 
for 
IU All 500 [COMPANY_004]  
Serum  Respi[INVESTIGATOR_301883]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  
Day 
365* Serum  
Respi[INVESTIGATOR_301882] A Ab 
neutralizing  NEU  In house  ED60 
and/or IU 
(internation
al unit)  18 
for 
ED6
0 
TBD 
for 
IU All 500 [COMPANY_004]  
Serum  Respi[INVESTIGATOR_301883]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  124 Ab = antibody; ELI = Enzyme -linked immunosorbent assay (ELISA); IgG = immunoglobulin G; RSV = respi[INVESTIGATOR_14256]; ED60  = serum dilution inducing 60% inhibition in plaque forming units; IU/ml = International 
units/milliliter, IU= International units; TBD = to be determined  
Assay cut -off and unit might be subject to change before starting of testing (e.g. in case of requalification, revalidation 
or standardisation). In this case, this will be documented in the clinical report.  
* For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 as 
described in the protocol. Participant‚Äôs that do not sign the informed consent addendum will complete the study at 
day [ADDRESS_369059].  
***[COMPANY_004] laboratory refers to the Clinical Laboratory Sciences (CLS) in Rixensart, Belgium; Wavre, Belgium; Marburg, 
[LOCATION_013].  
Table 12 Immunological read -outs  
Blood sampling timepoint  Subset name  [CONTACT_301961]. subjects  Component  Components 
priority rank  
Visit 4 (Day 
181)***  Post-Vacc  All 500 RSV-A neutralizing 
antibody  1 
All 500 RSVPreF3 IgG antibody 
concentration  2 
Visit 5 (Day 
365)***  Post-Vacc  All 500 RSV-A neutralizing 
antibody  1 
All 500 RSVPreF3 IgG antibody 
concentration  2 
*** For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 as 
described in the protocol. Participant‚Äôs that do not sign the informed consent addendum will complete the study at 
day [ADDRESS_369060].  
Table 13 Reporting periods for collecting safety information  
Event  Pre- 
V1*  V1  V2  V3 Phone contact 1   V4** V5 (Study 
Conclusion  
D1 D7 D8 D30 D31 D181  D181  D365  
Solicited local and general 
AEs           
          
          
Unsolicited AEs            
          
          
AEs leading to withdrawal from 
the study            
          
          
SAEs            
          
          
SAEs related to study 
participation  
or concurrent [COMPANY_004] 
medication/vaccine            
          
          
Pregnancies            
          
          209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  125 * i.e. consent obtained. Pre -V: pre -vaccination; V: vaccination; Post -V: post -vaccination; D: Day, M: Month  
**For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 as 
described in the protocol. Participant‚Äôs that do not sign the informed consent addendum will complete the study at 
day [ADDRESS_369061].  From an 
analysis perspective, a ‚Äòwithdrawal‚Äô from the study refers to any subject was not available 
for the concluding contact [CONTACT_91313].  
10.1.2 Sample size calculation  
In order to evaluate the humoral response to 2 dose levels (60 and 120  ÔÅ≠g) of RSVPreF3 
when given alone, and co -administered with dTpa, the difference between co -
administration with dTpa (RSVPreF3 dTpa) and RSVPreF3 alone (RSVPreF3 placebo) in 
terms of RSV -A neutralizing antibody (Nab) titers will be evaluated at Day 8 and  Day 31. 
Additional sampling at Day 181, and Day 365 will allow evaluation of the persistence of 
RSVPreF3 responses.   
10.3.3 Immunogenicity analyses  
Endpoint  Statistical Analysis Methods  
Secondary  ‚Ä¢ The GMT/GMCs r atio and their 90% CI between RSVPreF3 dTpa and RSVPreF3 alone in 
terms of RSV -A Nab titers and RSV IgG antibody concentrations may be calculated at Day 
181, and/or Day 365* pooled for all subjects.  
*For the participants that sign the informed consent add endum, the conclusion of the study will be on Day 365 as 
described in the protocol. Participant‚Äôs that do not sign the informed consent addendum, will complete the study at 
day [ADDRESS_369062] one local AE (solicited and unsolicited), with at least 
one general AE (solicited and unsolicited) and with any (‚Äúsolicited or unsolicited‚Äù)  AE during the 
7-day or [ADDRESS_369063] 95% CI by [CONTACT_2060]. The same computations will be done for Grade 3 AEs, for any 
AEs considered related to vaccination, for Grade 3 AEs considered related to vaccination and 
for AEs resulting in medical ly attended visits *. 
*For the participants that sign the informed consent addendum, the conclusion of the study will be on Day 365 as 
described in the protocol. Participant‚Äôs that do not sign the informed consent addendum will complete the study at 
day [ADDRESS_369064] primary and 
secondary endpoints up to study conclusion (D 181365) are available.  
After Day 181(Visit 4) the study participants wil l be unblinded and the study extension 
phase will continue as an open study until the final study visit (Visit 5).  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  126 [IP_ADDRESS] Time period for detecting and recording adverse events, serious adverse 
events and pregnancies  
The time period for collecting and re cording pregnancies will begin at the receipt of study 
vaccine(s) and will end 181 365 days following administration of the dose of study 
vaccine(s). 
Overall Rationale for Amendment [ADDRESS_369065] dosing. 
Long term persistence data will be useful to inform the boosting schedule for women 
entering successive pregnancies. Unblinding after Day 181 will still occur and the 
extended study (epoch 4) will be open label.  
In addition, several discrepan cies with the protocol with the study procedures manual 
were aligned.  
Detailed description of Protocol Amendment 4 
This study has been amended to administer a second dose of the 120 ¬µg RSVPreF3 
Maternal investigational vaccine to all consenting subjects within a 6 -month period from 
the beginning of 12 months to the beginning of 18 months following initial immunization 
(‚â•12 to <18 months). This extension part of the study will use non -pregnant women as a 
proxy for women who may require additional dosing in successive pregnancies. 
Specifically, this extension will provide information on:  
1. Long term immunogenicity of a 1st dose of 60 ¬µg or 120 ¬µg RSVPreF3 vaccine  
2. Safety and immunogenicity of 2nd dose of 120 ¬µg RSVPreF3 vaccine  
In addition, this protocol amendment outlines measures that may be applicable during 
special circumstances (e.g., COVID -19 pandemic). The purpose of the amendment is to 
protect the subject‚Äôs welfare, and as far as possible ensure the potential benefit to the 
subject and promote data integrity.  
Title 
Phase II randomized, observer -blind, placebo -controlled, multi -country study in healthy 
non-pregnant women 18 -45 years of age to evaluate the safety, reactogenicity and 
immunogenicity of a 1stsingle intramuscular dose of [COMPANY_004] Biologicals‚Äô investigational 
RSV maternal vaccine ([COMPANY_004]388550A) when given alone and given in co -administration 
with a single intramuscular dose of Boostrix (US formulation SB776423 or ex -US 
formulation SB263855) and to evaluate the safety, reactogenicity and 
immunogenicity of a 2nd dose of the RSV maternal vaccine .  
A Phase II study of a primary  2 dose levels of an investigational RSV maternal vaccine, 
given alone or with Boostrix, with a 2nd dose investigational RSV maternal vaccine  to 
healthy non -pregnant women . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW )LQDO
$SULO  &RQWULEXWLQJDXWKRUV &RQW
x  

x 7DQYLU.DXU 6WXG\'HOLYHU\/HDG 
x 6DIHW\3K\VLFLDQ 
x 6DIHW\3K\VLFLDQ 6FLHQWLVW
6\QRSVLV
)RUWKRVHZKRSURYLG HFRQVHQWWKHGXUDELOLW\RIWKHUHVSRQVHWR5693UH)ZLOO
EHPHDVXUHGIURPWRPRQ WKVIROORZLQJLQLWLDOYDFFLQDWLRQ ,QDGGLWLRQD
VHFRQGLPPXQL]DWLRQZ LWKWKH5690DWHUQDO ¬óJYDFFLQHZLOOEH
DGPLQLVWHUHGIURPPRQWKVWRPRQWKVDIWHUWKHI LUVWYDFFLQDWLRQWRHYDOXDWH
WKHLPPXQRJHQLFLW\DQGVDIHW\SURI LOHRI5693UH)YDFFLQHVHFRQ GGRVH
2EMHFWLYH 
xTo evaluate the safety of a 2nd dose of RSVPreF3 
given from [ADDRESS_369066] 2nd dose vaccination  x Occurrence of any AEs from 2nd dose to Day [ADDRESS_369067]-2nd dose vaccination, for all subjects:  
x Occurrence of each solicited local AE at the site 
of injection in both deltoids from 2nd dose 
vaccination to Day [ADDRESS_369068]-2nd dose vaccination  
x Occurrence of solicited general AEs from 2nd 
dose vaccination to Day [ADDRESS_369069] 2nd dose 
vaccination 
x Occurrence of any unsolicited AEs from 2nd dose 
to Day [ADDRESS_369070]- 2nd dose vaccination 
x Occurrence of Serious Adverse Events (SAEs) 
from 2nd dose vaccination to Day [ADDRESS_369071] 2nd 
dose vaccination.  
x To evaluate the safety of 2nd dose of RSVPreF3 
given from [ADDRESS_369072] 2nd dose 
vaccination. x Occurrence of SAEs from 2nd dose vaccination 
up to Day [ADDRESS_369073]-2nd dose vaccination. 
Immunogenicity 
x To evaluate the humoral immune response and 
persistence  to 2 dose levels (60 and 120 Œºg) of 
RSVPreF3 when given alone and co- administered 
with dTpa at Screening, Day 8, and Day [ADDRESS_369074] vaccination , and at 12 to 18 months  
by [CONTACT_14509]. Immunogenicity 
x RSV A neutralizing antibody titers at Screening, Day 
8, and Day 31,  a single timepoint between [ADDRESS_369075] vaccination . 
x RSV IgG antibody concentrations at Screening, Day 
[ADDRESS_369076] vaccination . 
x To evaluate the humoral immune response of a 
2nd dose vaccination of RSVPreF3 (120 Œºg), 
following a first dose vaccination of either 60 Œºg 
or 120 Œºg.  x RSV A neutralizing antibody titers 
concentrations [ADDRESS_369077] 2nd dose 
vaccination. 
x RSV IgG antibody concentrations [ADDRESS_369078] 
2nd dose vaccination. _3URWRFRO$PHQGPHQW$SU_70)_
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  128 Overall Design  
 
 
BSH = blood sample (5 mL) for humoral immune responses (RSV -A neutralization and RSV IgG antibody 
concentrations at Screening, Visit 2, [Day 8] and Visit 3, [Day 31], Visit 4, [up to D7 prior to 2nd vaccination], and 
Visit 6 [D31 post 2nd vaccination]  
And dTpa ELISAs at Screening and Visit 3 [Day 31])  
* All subject groups will be given RSV 120mcg and subjects will be followed in an open labeled study  
209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  129 ** Hematological and biochemical laboratory testing at Visit 4 (D -7 up to and including 2nd dose vaccination) at 
the investigator‚Äôs discretion  
***There will be no follow -up between C1 and V4. New medical history and relevant new safety events during 
this period will be recorded at visit 4 for subjects who agree to the study extension and sign the informed 
consent addendum.  
2. Schedule of Activities  
Epoch   Epoch 004  
(Vaccination 2)  Epoch 005  
(Follow -up 
2) 
Type of contact   [CONTACT_4838] [ADDRESS_369079] -Vacc 2  
Informed consent   ‚óè     
Check inclusion/exclusion 
criteria   ‚óè     
Check contraindications to 
subsequent vaccine(s) 
administration   O O    
Phone contact     ‚óè  ‚óè 
Medical history   ‚óè      
Physical examination 2   ‚óè   O  
Urine pregnancy test 3    ‚óè    
Pre-vaccination body 
temperature and heart rate    ‚óè    
Distribution of subject card    O    
Hematological and 
biochemical laboratory 
testing (~5.5 mL)   O8     
Blood sampling for humoral 
immune response (~5 mL) 4  ‚óè   ‚óè  
Treatment number allocation 
(SBIR)    O    
Vaccine administration    ‚óè    
Recording of administered 
treatment number    ‚óè    
[ADDRESS_369080] transcription by 
[CONTACT_301892]      ‚óè  
Recording of solicited 
adverse events    ‚óè ‚óè   
Recording of unsolicited 
adverse events     ‚óè ‚óè ‚óè  
Recording of AE leading to 
withdrawal    ‚óè ‚óè ‚óè ‚óè 
Recording of serious AE 6  ‚óè ‚óè ‚óè ‚óè ‚óè 
Recording of pregnancies   ‚óè ‚óè ‚óè ‚óè ‚óè 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  130 Epoch   Epoch 004  
(Vaccination 2)  Epoch 005  
(Follow -up 
2) 
Type of contact   [CONTACT_4838] [ADDRESS_369081] -Vacc 2  
Recording of concomitant 
medications/vaccinations7  ‚óè ‚óè ‚óè ‚óè ‚óè 
Record any intercurrent 
medical conditions   ‚óè ‚óè ‚óè ‚óè ‚óè 
Investigator sign -off on 
eCRF before analysis      ‚óè ‚óè 
COVID -19 eCRFs log page   ‚óè ‚óè ‚óè ‚óè ‚óè 
Study conclusion 
extension       ‚óè 
2 Physical examination including resting vital signs (blood pressure, heart rate and respi[INVESTIGATOR_697], temperature) after 
at least [ADDRESS_369082]. Weight, height and BMI will only be collected at Screening and V4 . Physical examination 
at Visit 2, and Visit 3, and Visit 4  will be performed only if deemed necessary by [CONTACT_093]. For Visit 1 and Visit 
2 (if performed), only vital signs will be collected in the eCRF.  
Table 4 Intervals between study visits  
Interval  Optimal timing  Allowed interval 
Screening Visit  ‚ÜíVisit 1  ‚â§7 days  -7- 1 days *  
Visit 1‚ÜíVisit 2  8 days  7- 10 days  
Visit 1‚ÜíVisit 3  31 days  30- 45 days  
Visit 1‚ÜíPhone Contact  1 181 days  165- 195 days  
Visit 4‚ÜíVisit 5  ‚â§7 days  -7 to 1 days*  
Visit 1‚ÜíVisit 5  365 days  365 - 548 days**  
Visit 5‚ÜíPhone Contact 2  8 days  7 - 10 days  
Visit 5‚ÜíVisit 6  31 days  30 - 45 days  
Visit 5‚ÜíPhone Contact 3  181 days  165 - 195 days  
*From 7 days prior to vaccination up to and including the day of vaccination.  
** For a 6 -month period ‚â•12 to <[ADDRESS_369083] vaccination  
3.1 Study Rationale  
Finally, a second dose vaccination of RSVPreF3 (120 ¬µg) will be administered to the 
consenting subjects from 12 months to 18 months following initial vaccination to 
evaluate the immunogenicity and safety profile of RSVPreF3. This extension of the 
study wil l recruit the same non -pregnant women as a proxy for women who may 
require additional dosing in successive pregnancies.  
4 Objectives  
(See 1. Synopsis  for Objectives and Outcome Table ) 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369084] dose 
vaccination, and to assess the safety and immunogenicity following a second dose 
vaccination of the RSVPreF3 maternal vaccine. This extension of the study will 
recruit the same non -pregnant women as a proxy for women who m ay require 
additional dosing in successive pregnancies.  
5.2 Study Design  
(See 1. Synopsis  for Design Figure ) 
‚àí Primary Vaccination  
‚àí Epoch 001: Screening  
‚àí Epoch 002: Primary (i.e., vaccination phase) starting at Visit 1 (Day 1) and 
ending just before the Visit  3 (Day 31)   
‚àí Epoch 003: Follow -up after Visit 3 (Day 31)  to Phone Contact [ADDRESS_369085] on 
(Day 181)  
‚àí End of Primary Study: Subjects must sign the ICF addendum to join the 
study extension.  
‚àí Study Extension: 6 -month period starting at the beginning of 12 months u p 
to the beginning of 18th month after Visit 1 (‚â•12 to <18 months)  
‚Ä¢ Epoch 004: 2nd dose vaccination starting from Visit 4 (up -7 days prior 
to vaccination) to Visit 6 (Day [ADDRESS_369086] 2nd dose vaccination)  
‚Ä¢ Epoch 005: 2nd dose vaccination Study Follow -up 2 start ing after Visit 6 
(Day [ADDRESS_369087] 2nd dose vaccination) and ending at Phone Contact  3 (Day 
[ADDRESS_369088] 2nd vaccination).  
‚Ä¢ End of Study (EoS):  Last testing results released of samples collected at Visit 63, to 
occur no later than [ADDRESS_369089] v isit (LSLV), which occurs with 
phone contact [ADDRESS_369090]
s Age 
(Min
-
Max
) Treatmen
t name 1 Treatme
nt name 
2 Epochs  
(Blinding)    
Epoch 
001 
(Screenin
g) Epoch 
002 
(observe
r-blind)  Epoch 
003 
(singl
e-
blind)  Epoc
h 004 
(open 
study
) Epoc
h 00 
5 
 
(open 
study
) 
XRSV120_dTpa  50 18 ‚Äì 
45 RSV MAT 
120  RSV 
MAT 120  x x x x x 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369091]
s Age 
(Min
-
Max
) Treatmen
t name 1 Treatme
nt name 
2 Epochs  
(Blinding)    
Epoch 
001 
(Screenin
g) Epoch 
002 
(observe
r-blind)  Epoch 
003 
(singl
e-
blind)  Epoc
h 004 
(open 
study
) Epoc
h 00 
5 
 
(open 
study
) 
year
s Boostrix -
ex-US 
(dTpa_50
0) 
Xplacebo_RSV1
20 50 18 ‚Äì 
45 
year
s RSV MAT  
120 
Placebo  RSV 
MAT 120  x x x x x 
XRSV60_dTpa  50 18 ‚Äì 
45 
year
s RSV MAT 
60 
Boostrix -
ex-US 
(dTpa_50
0) RSV 
MAT 120  
x x x x x 
Xplacebo_RSV6
0 50 18 ‚Äì 
45 
year
s RSV MAT 
60 
Placebo  RSV 
MAT 120  x x x x x 
Xplacebo_dTpa  50 18 ‚Äì 
45 
year
s Boostrix -
ex-US 
(dTpa_50
0) 
Placebo  RSV 
MAT 120  
x x x x x 
URSV120_dTpa  50 18 ‚Äì 
45 
year
s RSV MAT 
120 
Boostrix -
US 
(dTpa_30
0) RSV 
MAT 120  
x x x x x 
Uplacebo_RSV1
20 50 18 ‚Äì 
45 
year
s  RSV MAT 
120 
Placebo  RSV 
MAT 120  x x x x x 
URSV60_dTpa  50 18 ‚Äì 
45 
year
s  RSV MAT 
60 
Boostrix -
US RSV 
MAT 120  x x x x x 
Uplacebo_RSV6
0  50 18 ‚Äì 
45 
year
s RSV MAT 
60 
Placebo  RSV 
MAT 120  x x x x x 
Uplacebo_dTpa  50 18 ‚Äì 
45 
year
s Boostrix -
US 
(dTpa_30
0) 
Placebo  RSV 
MAT 120  
x x x x x 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369092] 3 (Day [ADDRESS_369093] second vaccination ) as described in the protocol.  
For those subjects that do not agree to participate in the study extension, the 
concluding contact [CONTACT_301894] [ADDRESS_369094] as described in previous 
version of protocol (RSV MAT -011 (209141) Protocol Amendment 3 (03 -APR-2020). 
6.[ADDRESS_369095] 
safety. Therefore, adherence to the criteria as specified in the protocol is essential.  
‚Ä¢ Completed in primary study and received 1st dose vaccinatio n of a study vaccine 
(RSVPreF3 or Boostrix). 
‚Ä¢ Written or witnessed/thumb printed informed consent obtained from the 
subject prior to performance of any study specific procedure to the study 
extension.  
Are eligible if they meet the following criteria below  
All subjects must satisfy ALL the following criteria:  
‚Ä¢ Subjects who, in the opi[INVESTIGATOR_871], can and will comply with the 
requirements of the protocol (e.g. completion of the diary card, return for 
follow-up visits).  
‚Ä¢ Female subjects remain healt hy; as established by [CONTACT_301898], aged [ADDRESS_369096] vaccination;  
‚Ä¢ Female subjects of childbearing potential are eligible for the extension, if the 
subject: 
‚àí has practiced adequate contraception for 30 days prior to 2nd vaccination  
‚àí has a negative pregnancy test with results available on the day of 2nd 
vaccination  
‚àí has agreed to continue adequate contraception for [ADDRESS_369097] not be included in the extension.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  134 6.4.1 Medical conditions for extension  
‚Ä¢ History of any reaction or hypersensitivity likely to be exacerbated by [CONTACT_301896];  
‚Ä¢ Any confirmed or suspected immunosuppressive or immunodeficient condition, 
based on medical history and physical examination (no laboratory testing 
required);  
‚Ä¢ Hypersensitivity to latex;  
‚Ä¢ Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or 
renal functional abnormality, as determined by [CONTACT_9870], physical 
examination or laboratory screening tests;  
‚Ä¢ Significant or uncontrolled psychiatric illness;  
‚Ä¢ Recurrent hi story or un -controlled neurological disorders or seizures;  
‚Ä¢ Documented HIV -positive subject;  
‚Ä¢ History of or current autoimmune disease;  
‚Ä¢ Body mass index (BMI) > 40 kg/m2; 
‚Ä¢ Participants who experienced any SAE judged to be possibly or probably 
related to first dose vaccination of RSVPreF3, including hypersensitivity 
reactions.  
‚Ä¢ Any other clinical condition that, in the opi[INVESTIGATOR_871], might pose 
additional risk to the subject due to participation in the study.  
6.4.2 Prior/Concomitant therapy for exte nsion 
‚Ä¢ Use of any investigational or non -registered product (drug, vaccine or medical 
device) other than the study vaccines during the period starting 30 days before 
the second dose of study vaccine (Day -29 to Day 1), or planned use during the 6 
month stud y extension period;  
‚Ä¢ Administration of long -acting immune -modifying drugs at any time during the 
study period (e.g. infliximab);  
‚Ä¢ Administration of immunoglobulins and/or any blood products or plasma 
derivatives during the period starting [ADDRESS_369098] dose of study 
vaccines or planned administration during the study period;  
‚Ä¢ Chronic administration (defined as more than 14 days in total) of 
immunosuppressants or other immune -modifying drugs during the period 
starting [ADDRESS_369099] vac cine dose(s). For corticosteroids, this will 
mean prednisone  ÔÇ≥5 mg/day, or equivalent. Inhaled and topi[INVESTIGATOR_46279]; 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  135 ‚Ä¢ Planned administration/administration of a vaccine not foreseen by [CONTACT_301897] 30 days before  and ending 30 days after 
study 2nd dose vaccination, with the exception of any licensed influenza vaccine 
which may be administered ‚â• 15 days before or after study vaccination.  
6.4.3 Prior/Concurrent clinical study experience for extension  
‚Ä¢ Concurrently pa rticipating in another clinical study, at any time during the 
study period, in which the subject has been or will be exposed to an 
investigational or a non -investigational vaccine/product (drug or medical 
device); 
6.4.4 .Other exclusions for extension  
‚Ä¢ Pregnant or lactating female at the time of Visit 4 ; 
‚Ä¢ Female planning to become pregnant or planning to discontinue contraceptive 
precautions;  
‚Ä¢ History of alcoholism, drug abuse and/or use disorder within the past two years 
(as defined in DSM -5 Diagnostic Cr iteria) [Camargo , 1984; Christy, 1995; 
Hasin, 2013];  
‚Ä¢ Any study personnel or their immediate dependents, family  or household 
members  
6.7 Screen failures for the extension  
‚ÄúScreening failures‚Äù for the extension are subjects who withdraw or are withdrawn 
from the extension after giving informed consent to the extension, but before 
extension eligibility (presence of all inclusion and absence of all exclusion criteria) is 
confirmed. Limited data for screening failures (including reason for screening 
failure and any SAEs that occurred at the visit) will be collected and reported in the 
eCRF. 
7.1 Treatments administered  
 RSV MAT 120  RSV MAT 60  Boostrix -ex-US 
(dTpa_500)  Boostrix -US 
(dTpa_300)  
 Placebo  
 NaCl  NaCl     
Presentatio
n Powder for 
suspension for 
injection  (vial)  
Freeze -dried 
Antigen  
(174mcg/vial)  Powder for 
suspension for 
injection (vial)  
Freeze -dried 
Antigen  
(87mcg/vial)  Suspension for 
injection 
prefilled  syringe ) Suspension 
for injection 
prefilled  
syringe ) Solution for 
injection; 
vial)Clear 
liquid in 
monodose 
ampule or vial   
Solution for 
solution for 
injection; 
(vial) Clear liquid in 
monodose ampule 
or vial  Solution for 
solution for 
injection; 
(vial) Clear liquid in 
monodose ampule 
or vial  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  136  RSV MAT 120  RSV MAT 60  Boostrix -ex-US 
(dTpa_500)  Boostrix -US 
(dTpa_300)  
 Placebo  
 NaCl  NaCl     
Formulation  RSVPreF3 (120 
¬µg)/Trehalose(12.7
3 mg).  
NaCl solution (4.5 
mg/0.5 mL, ~150 
mM) 
NaCl=150mM  RSVPreF3 (60 
¬µg)/Trehalose(6.4
2 mg).  
NaCl solution (4.5 
mg/0.5 mL, ~150 
mM) 
NaCl=150mM  Diphtheria 
toxoid (‚â• 2 IU) 
adsorbed on 
aluminium 
hydroxide and 
aluminium 
phosphate; 
Tetanus toxoid 
(‚â• 20 IU) 
adsorbed on 
aluminium 
hydroxide and 
aluminium 
phosphate; 
Pertussis toxoid 
(8 ¬µg) adsorbed 
on aluminium 
hydroxide and 
aluminium 
phosphate; 
Filamentous 
haemagglutinin 
(8 ¬µg) adsorbed 
on aluminium 
hydroxide and 
aluminium 
phosphate; 
Pertactin (69 
kDa outer 
membrane 
protei n) (2.5 ¬µg) 
adsorbed on 
aluminium 
hydroxide and 
aluminium 
phosphate; 
Aluminium 
hydroxide (0.3 
mg Al ¬≥+); 
Aluminium 
phosphate (0.2 
mg Al¬≥+); 
Sodium 
chloride; Water 
for injections 
q.s. 0.5 mL  
 DT>=2IU; 
TT>=20IU; 
PT=8¬µg; 
FHA=8¬µg; 
PRN=2.5¬µg; 
Aluminium=500¬µ
g Al3+ Diphtheria 
toxoid (‚â• 2 IU) 
adsorbed on 
aluminium 
hydroxide; 
Tetanus 
toxoid (‚â• 20 
IU) adsorbed 
on aluminium 
hydroxide; 
Pertussis 
toxoid (8 ¬µg) 
adsorbed on 
aluminium 
hydroxide; 
Filamentous 
haemagglutini
n (8 ¬µg) 
adsorbed on 
aluminium 
hydroxide; 
Pertactin (69 
kDa outer 
membrane 
protein) (2.5 
¬µg) adsorbed 
on aluminium 
hydroxide; 
Aluminium 
hydroxide (0.3 
mg Al¬≥+); 
Sodium 
chloride (4.4 
mg); Water for 
injections q.s. 
0.5 
mLDT>=2IU; 
TT>=20IU; 
PT>=8¬µg; 
FHA=8¬µg; 
PRN=2.5¬µg; 
Al(OH) 3=300¬µg 
Al3+ NaCl 
solution (4.5 
mg/0.5 mL, 
~150 mM)  
NaCl=150mM  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  137  RSV MAT 120  RSV MAT 60  Boostrix -ex-US 
(dTpa_500)  Boostrix -US 
(dTpa_300)  
 Placebo  
 NaCl  NaCl     
Route of 
Administratio
n  Intramuscular 
useIM Intramuscular 
useIM Intramuscular 
useIM Intramuscular 
useIM Intramuscula
r use IM 
No of doses  21 1 1 1 1 
Manufacturer  RSVPreF3: [COMPANY_004]  
Biologicals  
NaCl: [COMPANY_004]  
Biologicals  RSVPreF3: [COMPANY_004]  
Biologicals  
NaCl: [COMPANY_004]  
Biologicals  [COMPANY_004]  Biologicals  [COMPANY_004]  
Biologicals  [COMPANY_004]  
Biologicals  
Table 8 Treatments administered (Part 2)  
Primary Vaccination  
2nd Vaccination  
Groups in primary 
vaccination  Formulation 
in primary 
vaccination  N Groups in 2nd 
vaccination  Laterality  
XRSV120_dTpa  
ex-US 50 RSVPreF3=120¬µg  Non-Dominant  
Xplacebo_RSV120  50 RSVPreF3=120¬µg  Non-Dominant  
XRSV60_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
Xplacebo_RSV60  50 RSVPreF3=120¬µg  Non-Dominant  
Xplacebo_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
URSV120_dTpa  
US 50 RSVPreF3=120¬µg  Non-Dominant  
Uplacebo_RSV120  50 RSVPreF3=120¬µg  Non-Dominant  
URSV60_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
Uplacebo_RSV60  50 RSVPreF3=120¬µg  Non-Dominant  
Uplacebo_dTpa  50 RSVPreF3=120¬µg  Non-Dominant  
7.2.[ADDRESS_369100] identification number will be the same in the study extension. No new 
subjects will be recruited.  
[IP_ADDRESS] Treatment allocation by [CONTACT_301955], [ADDRESS_369101].  
[IP_ADDRESS].[ADDRESS_369102] sequentially at each centre.  
7.3 Blinding and unblinding  
Data will be collected in an observer -blind manner during the primary study.   209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369103]‚Äôs assigned study treatment until 
completion  throughout the course  of the primary vaccination day [ADDRESS_369104] (C1) for a given subject, the investigator will be 
informed of the subject‚Äôs treatment assignment and will communicate this to the 
subject. The study extension will then be conducted as an open label study . 
Unblinded monitors and in the event of a Quality Assurance audit, the auditor(s) will be 
allowed access to un -blinded study treatment records at the site(s) to verify that 
randomisation/dispensing has been done accurately. Please refer to the SPM for detai ls 
on blinding of the vaccine.  administration.  
8.1 Study Procedures During Special Circumstances  
During special circumstances (e.g., the COVID -19 pandemic), the specific guidance 
from local public health and other competent authorities regarding the prote ction of 
individuals‚Äô welfare must be applied.  
For the duration of such special circumstances : 
‚Ä¢ Reconsent of subjects for the study extension may be placed on hold.  Decisions 
on re-starting will be made in a manner consistent with guidance from public 
health and other competent authorities.  
‚Ä¢ Informed consent must take place in a face to face contact [CONTACT_301956].  
‚Ä¢ Certain procedures may be performed at an alternate location.  his includes, 
signing of informed consent, physical examination and vaccine dosing.  If 
vaccinating in an alternate location, it must be assured that train ed staff and 
equipment are available to manage an acute vaccine reaction. Biological 
samples may be collected at a different location* other than the study site or at 
participant‚Äôs home. Biological samples should not be collected if they cannot be 
processed in a timely manner or appropriately stored until the intended use.  
‚Ä¢ Safety follow -up may be made by a telephone call, other means of virtual 
contact [CONTACT_228983], if appropriate.  
‚Ä¢  ‚ÄúMedically attended visits‚Äù include instances where, due to the special 
circumstances, the subject cannot seek medical advice for symptoms/an illness 
by [CONTACT_156995] a medical facility or arranging for a home visit, and seeks this advice 
instead via telephone , SMS, email, videotelephony or telemedicine, or other 
means.  
‚Ä¢ The paper Diary card provided to the subject may be transmitted from and to 
the site by [CONTACT_301904] . 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  139 ‚Ä¢ If despi[INVESTIGATOR_301884] (see Table 4), then the interval may be 
extended up to a maximum length described in Table 10, however efforts should 
be made to adhere as closely as possible to the optimal timing .  
‚Ä¢ If despi[INVESTIGATOR_301885] (see Table 4), a maximum dose interval described in 
Table 10 may be used, however efforts should be made to adhere as closely as 
possible to the optimal timi ng. 
Table 10 Intervals between study visits under Special Circumstances  
Interval  Optimal timing  Allowed interval Adapted interval 
under special 
circumstances  
Screening Visit  ‚ÜíVisit 1  ‚â§7 days  -7- 1 days  -30 to 1 days  
Visit 1 ‚ÜíVisit 2  8 days  7- 10 days  7- 10 days  
Visit 1 ‚ÜíVisit 3  31 days  30- 45 days  30 ‚Äì 60 days  
Visit 1‚ÜíPhone Contact  1 181 days  165- 195 days  165 ‚Äì 195 days  
Visit 4‚ÜíVisit 5   -7 to 1 days  -30 ‚Äì 1 days*  
Visit 1‚ÜíVisit 5  365 days  365-548 days**   
Visit [ADDRESS_369105] 2  8 days  7- 10 days  7- 10 days  
Visit 5‚ÜíVisit 6  31 days  30- 45 days  30 ‚Äì 90 days  
Visit 5‚ÜíPhone Contact 3  181 days  165- 195 days  165 ‚Äì 195 days  
*From 30 days prior to vaccination up to and including the day of vaccination.  
** For a 6 -month period ‚â•12 to <[ADDRESS_369106] on the per protocol set for immunogenicity will be determined on a case by 
[CONTACT_413].  
‚Ä¢ Any impact of above -mentioned measures on the study results will be described 
in the clinical study report.  
 * It is the inves tigator‚Äôs responsibility to identify an alternate location. The investigator should ensure that this 
alternate location meets ICH GCP requirements, such as adequate facilities to perform study procedures, 
appropriate training of the staff and documented de legation of responsibilities in this location. This alternate 
location should be covered by [CONTACT_301957] a site other than the designated study site.  
8.3.2 Medical and vaccination histo ry 
Significant medical conditions and vaccinations that occurred during the C1 -V4 will 
be reviewed during the screening for the second vaccination and reported as 
medical history.  
8.3.3 Physical Exam  
‚Ä¢ Perform a history directed physical exam plus vital signs at Visit 4 [D -7 2nd 
vaccination to 2nd vaccination]. Note that laboratory assessments of 
haematology and biochemistry may be made on the investigator‚Äôs discretion.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  140 8.4.2 Biological samples  
Whole blood for 
hematology, 
biochemistry*  
Whole blood for 
immune response  10.5 or 5  ml Visit 4 (up Day -7 prior 
to 2nd vaccination)  Hematology, chemistry: 5.5 mL.  
Immune response: 5 mL (~ 2 mL 
serum).  
Whole blood for 
immune response  5 ml Visit 6 (Day  [ADDRESS_369107] 
2nd vaccination)  Immune response  : 5 mL (~ 2 mL 
serum) . 
 36 or 30 20.5 ml Minimum Total, not including repeat or unscheduled samples  
Urine for Pregnancy  - - screening visit  
Visit 1 (day 1) and Visit 
5 (2nd Vaccination)   
*Hematological and biochemical laboratory testing at Visit 4 (D -7 up to and including 2nd dose vaccination) at 
the investigator‚Äôs discretion  
8.4.3 Laboratory Assays  
Table 12 Humoral Immunity (Antibody determination)  
Sampling 
time 
points  Syste
m Component  Metho
d Kit/ 
Manufactur
er Unit Cut-
off Group
s Numb
er of 
subjec
ts Laboratory
*** 
Day -7 up 
to 2nd 
vaccinati
on 
 Seru
m Respi[INVESTIGATOR_301882] A Ab 
neutralizing  NEU  In house  ED60 
and/or IU 
(internatio
nal unit)  18 
for 
ED6
0 56 
for 
IU All 500 [COMPANY_004]  
Seru
m Respi[INVESTIGATOR_301881]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  [ADDRESS_369108] 
2nd 
vaccinati
on 
 Seru
m Respi[INVESTIGATOR_301882] A Ab 
neutralizing  NEU  In house  ED60 
and/or IU 
(internatio
nal unit)  18 
for 
ED6
0 56 
for 
IU All 500 [COMPANY_004]  
Seru
m Respi[INVESTIGATOR_301881]3 
Ab.IgG 
concentrati
on ELI In house  ELU/mL  25 
All 500 Nexelis  
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment [ADDRESS_369109] 
and timepoint*  Sampling 
timepoint  
Day -[ADDRESS_369110] -Vacc  All 500 RSV-A neutralizing 
antibody  1 
 All 500 RSVPreF3 IgG antibody 
concentration  2 
* The results of this testing might potentially impact the subject medical care  
Boostrix  recipi[INVESTIGATOR_840] = subjects in the following study groups: -XRSV120_dTpa, XRSV60_dTpa, Xplacebo_dTpa, 
URSV120_dTpa, URSV60_dTpa, Uplacebo_dTpa.  
8.5.2 Time period and frequency for collecting AE and serious adverse event (SAE) 
information  
Table 14  Reporting periods for collecting safety information  
Event  Phone 
Contac
t C1  C1 
to 
V4** V4 V5*  C2  V6 C3 
D181   D -[ADDRESS_369111] 2nd 
vaccinat
ion 
Solicited 
local and 
general AEs           
         
         
Unsolicited 
AEs          
         
         
AEs leading 
to withdrawal 
from the 
study          
         
         
SAEs **          
         
         
SAEs related to 
study 
participation  
or concurrent 
[COMPANY_004]          
         
         209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  142 Event  Phone 
Contac
t C1  C1 
to 
V4** V4 V5*  C2  V6 C3 
D181   D -[ADDRESS_369112] 2nd 
vaccinat
ion 
medication/vacc
ine 
Pregnancies *
**          
         
         
** There will be no follow -up between C1 and V4. New medical history and relevant new safety events during 
this period will be recorded at visit 4 for subjects who agree to the study extension and sign the informed 
consent addendum. In addition, SAE related to vaccination are reported during the period C1 -V4 will be 
reported to the Investigator at the time of awareness.  
***Pregnancies that occurred during the C1 -V4 period will be reported as medical history  
A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
reporting period defined in Table 13. Investigators are not obligated to actively seek AEs 
or SAEs in former study subjects. However, if the investigator learns of any SAE, 
including a death, at any time after a subj ect has been discharged from the study, and 
he/she considers the event to be reasonably related to the study vaccine(s), the 
investigator will promptly notify the Study Contact [CONTACT_43075].  
8.5.[ADDRESS_369113]-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
reporting period defined in Table 14. Investigators are not obligated to actively seek 
AEs or SAEs in former study participants. However, if the investigator learns of any 
SAE at any time after a subject has been discharged from the study, and he/she 
considers the event reasonably related to the investigational vaccine/product, the 
investigator will promptly notify the Study Contact [CONTACT_43075].  
9.[ADDRESS_369114] 
those subjects who do not return for scheduled visits or follow -up. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  143 9.2 Discontinuation of study vaccine(s)  
‚ÄòDiscontinuation‚Äô of study intervention refers to any participant who has not 
received all planned doses of study intervention. A participant who discontinued 
study intervention may continue other study procedures (e.g. safety or 
immunogenicity), planned i n the study protocol at the discretion of the investigator.  
The primary reason for premature discontinuation of the study intervention will be 
documented on the eCRF as follows:  
‚Ä¢ Adverse event requiring expedited reporting to [COMPANY_004]  
‚Ä¢ Unsolicited non -serious ad verse event  
‚Ä¢ Solicited adverse event  
‚Ä¢ Not willing to be vaccinated  
‚Ä¢ Other (specify).  
‚Ä¢ Not applicable . 
10.[ADDRESS_369115] -vaccination data (Full Analysis Set)  minus 
subjects with protocol deviations that lead to exclusion  
Unsolicited Safety  All subjects who received at least 1 dose of the study treatment (Exposed Set) 
that report unsolicited AEs/report not having unsolicited AEs  
10.3.3. Immuno genicity analysis  
The primary analysis will be based on the Per Protocol set for analysis of 
immunogenicity. If, in any study group and at any timepoint, the percentage of enrolled 
or vaccinated subjects with serological results excluded from the Per Proto col set for 
analysis of immunogenicity is 5% or more, a second analysis based on the Exposed Full 
Analysis Set will be performed to complement the Per Protocol analysis.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  144 10.3.4 Safety Analysis  
Endpoint  Statistical Analysis Methods  
Primary  (US + ex -US data to be pooled)  
For each group with 1st dose vaccination of RSVPreF3 (two dose levels) when given alone 
or co -ad with dTpa; the following points will be analysed for 1st and 2nd dose vaccination . 
The percentage of subjects with at least one local AE (solicited and unsolicited), with at least 
one general AE (solicited and unsolicited  and with any (‚Äúsolicited or unsolicited‚Äù)  AE during the 
7-day or [ADDRESS_369116] 95% CI by [CONTACT_2060]. The same com putations will be done for Grade 
3 AEs, for any AEs considered related to vaccination, for Grade 3 AEs considered related to 
vaccination and for AEs resulting in medically attended visits.  
The percentage of subjects with any unsolicited AEs during the 30 -day follow -up period (i.e. on 
the day of vaccination and 29 subsequent days) with its exact 95% CI will be tabulated by [CONTACT_301926] (MedDRA) SOC and preferred term. Similar 
tabulation will be done for Grade 3 un solicited AEs, for any causally related unsolicited AEs, for 
Grade 3 causally related unsolicited AEs and for unsolicited AEs resulting in a medically 
attended visit. The verbatim reports of unsolicited AEs will be reviewed by a physician and the 
signs and  symptoms  will be coded according to the MedDRA Dictionary for Adverse Reaction 
Terminology.  Endpoint  Statistical Analysis Methods  
Primary  (US + ex -US data to be pooled for the first vaccination ) 
Secondary  (US and ex -US data to be considered pooled, then separately  for the first vaccination)  
For the data collected for the second vaccination, the humoral immune response of RSV 
PreF3 will be summarized based on 2 dose level (60 and 120 ¬µg) from the first 
vaccination.  
‚Ä¢ GMCs/GMTs and their 95% CI will be tabulated and represented graphically for prior 
and post 2nd dose vaccination  
‚Ä¢ Geometric mean of ratios of antibody titer/concentrations at individual post - 2nd 
dose vaccination time  point (visit 6) over prior 2nd dose vaccination time point (visit 
4) will be tabulated with 95% CI  
‚Ä¢ Antibody titer/concentration will be displayed using reverse cumulative curves on 
prior and post 2nd vaccination  
‚Ä¢ The kinetics of GMT/GMCs will be plotted as  a function of time for subjects with 
results available at all time points including the visits from the first vaccination.  209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  145 Endpoint  Statistical Analysis Methods  
Secondary  (US and ex -US data to be considered pooled, then separately)  
For each group with 1st dose vaccination of RSVPreF3 (two dose level) when given alone 
or co -ad with dTpa; the following points will be analysed for 1st and 2nd dose vaccination.  
The percentage of subjects with at least one local AE (solicited and unsolicited), with at least 
one general AE (solicited and unsolicited) and with any (‚Äúsolicited or unsolicited‚Äù)  AE during the 
7-day or [ADDRESS_369117] 95% CI by [CONTACT_2060]. Th e same computations will be 
done for Grade [ADDRESS_369118] 
95% CI for each formulation (US and ex -US).  
For each formulation (US a nd ex -US), the percentage of subjects with any unsolicited AEs 
during the 30 -day follow -up period (i.e. on the day of vaccination and 29 subsequent days) with 
its exact 95% CI will be tabulated by [CONTACT_301929] 
(MedDRA) SOC and preferred term. Similar tabulation will be done for Grade 3 unsolicited AEs, 
for any causally related unsolicited AEs, for Grade 3 causally related unsolicited AEs and for 
unsolicited AEs resulting in a medically attended visit. The verbati m reports of unsolicited AEs 
will be reviewed by a physician and the signs and symptoms  will be coded according to the 
MedDRA Dictionary for Adverse Reaction Terminology.  
10.4 Sequence of analysis  
‚Ä¢ The second analysis will evaluate safety data and will be performed when all 
subjects have completed visits up to (and including) C1 (Day 181) and the data 
are available. From this point the study is unblinded.  
‚Ä¢ The third analysis will evaluate safety and immunogenicity data and will be 
performed when all subject s have completed visits up to (and including) Visit 6 
(Day [ADDRESS_369119] 2nd dose vaccination) and the data are available. At this time, any 
available safety data will also be provided.  
‚Ä¢ The final end -of-study analysis will be performed when all data for at least primary 
and secondary endpoints up to study conclusion at Day [ADDRESS_369120] 2nd dose 
vaccination (C3) are available.  (D181) are available. Any available tertiary 
endpoints will also be  analyzed in this step. Individual listings will only be provide d 
at this stage.  An integrated clinical study report containing all available data will be 
written and made available to the investigators  
[IP_ADDRESS] Time period for detecting and recording adverse events, serious adverse 
events and pregnancies  
All AEs durin g 7 days following administration of each the dose vaccination  of study 
vaccine(s) (Day  [ADDRESS_369121] 2nd 
vaccination ) must be recorded into the appropriate section of the eCRF, irrespective of 
intensity or wh ether or not they are considered vaccination -related. 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW )LQDO
$SULO  2YHUDOO5DWLRQDOHIRU $PHQGPHQW 7KLVVWXG\KDVEHHQDPHQGHGWRDOLJQWKH
SK\VLFDOH[DPDQGYLWDOVLJQVWKURXJKRXWWKHVWXG\ZLWKWKHH&5 ),QDGGLWLRQVHYHUDO
DGPLQLVWUDWLYHF KDQJHVLQSHUVRQQHODQG PLQRUHGLWVWRWKHSURWRFRODUHLQFOXGHG 
'HWDLOHGGHVFULSWLRQRI3URWRFRO$PHQGPHQW 
&RQWULEXWLQJDXWKRUV 
x 

x &OLQLFDO5HVHDUFK'HYHORSPHQW
/HDG([SHUW
x 6DIHW\3K\VLFLDQ 
x 6DIHW\6FLHQWLVW 
6FKHGXOHRI$FWLYLWLHV6R$ 
Type of contact  [CONTACT_159337] 
[ADDRESS_369122] 3 
Pre-vaccination body 
temperature and heart rate  ‚óè      ‚óè    
Pre-vaccination  vital sign 
readings4        ‚óè    
2 Physical examination including resting vital signs (blood pressu re, heart rate and respi[INVESTIGATOR_697], temperature) 
measured after at least [ADDRESS_369123].  
Screening: Physical exam, vital signs (blood pressure, heart rate and respi[INVESTIGATOR_697], temperat ure), and 
weight, height and BMI will be recorded in the eCRF.  
Visit 1: History directed physical exam will be perf ormed and the vital signs will be recorded in the eCRF  
Visit 2 Physical examination will be performed only if deemed necessary by [CONTACT_093].  If performed, 
only vital signs (blood pressure, heart rate and respir atory rate) will be required recorded in the eCRF  
Visit 3: Physical examination w ill be performed only if deemed necessary by [CONTACT_093].   
Visit 4: Perform history d irected physical exam will be performed and vital signs (blood pressure, heart rate 
and respi[INVESTIGATOR_697], temperature) will be recorded in the eCRF. Weight, height and BMI should also be 
recorded in the eCRF.  
Visit 6: Physical examination will be performed only if deemed necessary by [CONTACT_093] .   
Weight, height and BMI will only be  collected at Screening and V4. Physical examination at Visit 2, Visit 3, and Visit 4 
will be performed only if deemed nece ssary by [CONTACT_093]. For Visit 1 a nd Visit 2 (if performed), only vital signs 
will be collected in the eCRF.  
4Pre-vaccination vital signs: At Visit 5, the pre -vaccination vital signs (blood pressure, heart rate and 
respi[INVESTIGATOR_697], temperature) will be recorded in the eCRF  
3K\VLFDO ([DP
x$Q\YLWDOVLJQVPHDVXUHGDW9LVLW>'D\@ DQG9LVLW>QG9DFFLQDWLRQ@ VKRXOGEH
UHFRUGHGLQWKHH&5) 
3UH9DFFLQDWLRQ 9LWDO6LJQV 
3UHYDFFLQDWLRQYLWDOVLJQV$W9LVLWWKHSUH YDFFLQDWLRQYLWDOVLJQVEORRG
SUHVVXUHKHDUWUDWHDQG UHVSLUDWRU\UDWHWHPSHU DWXUHZLOOEHUHFRUGHGLQWKH
H&5)_3URWRFRO$PHQGPHQW$SU_70)_
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
&21),'(17,$/ 
5690$7 
3URWRFRO $PHQGPHQW )LQDO
$SULO  'LVFRQWLQXDWLRQIURPWKHVWXG\ 

,QFDVHDVXEMHFWLVZLWKGUDZQIURPWKHVWXG\EHFDXVHVKHKDV ZLWKGUDZQFRQVHQWWKH
LQYHVWLJDWRUZLOOGRFXPHQWWKHUHD VRQIRUZLWKGUDZDORIFRQVHQW LIVSHFLI LHGE\WKH
VXEMHFWVXEMHFW¬∂VSDUHQWV/$5V LQWKHH&5) 
,QIRUPHGFRQVHQWSURFHVV 
)RUVXEMHFWVZKREHFRPHOHJDOO\HPDQFLSDWHGGXULQJWKHFRXUVHR IWKHVWXG\HJEHFRPH
RIWKHOHJDODJHRIFRQVHQWUH FRQVHQWLVVRXJKWLQDFFRUGDQFHZLWKORFDOOD ZVDQG
UHJXODWLRQV7KHVXEMHFWFDQSURYLGHFRQVHQWE\VLJQLQJDQ,&) VLPLODUWRWKDWSURYLGHG
WRWKHSDUHQWV/$5VDWWKHVWXG\VWDUWZKLFKVX[COMPANY_003]ULVHVWK HVWXG\DQGLQFOXGHVD
FRQVHQWVWDWHPHQWDQGGRFXPHQWVW KDWWKHVXEMHFWDJUHHVWRFRQW LQXHSDUWLF LSDWLQJLQWKH
VWXG\
$FRS\RIWKH,&)VPXVWEHSURYLGHGWRWKHVXEMHFW RUWKHVXEMHFW¬∂VSDUHQWV/$5V 
7KHVWXG\LQYHVWLJDWRULVHQF RXUDJHGWRREWDLQDVVHQWIURPWKH PLQRULQDGGLWLRQWRWKH
FRQVHQWSURYLGHGE\WKH/$5VZKHQDPLQRULVDEOHWRJL YHDVVHQWWRGHFLVLRQVDERXW
KLVKHUSDUWLFLSDWLRQLQDVWXG\7KHLQYHVWLJDWRULVDOVRDFFR XQWDEOHIRUGHWHUPLQLQJD
PLQRU
VFDSDFLW\WRDVVHQWWRSDUWLFLSDWLRQLQ DUHVHDUFKVWXG\DFFRUGLQJWRWKHORFDOODZV
DQGUHJXODWLRQV 
2YHUDOO5DWLRQDOHI RU$PHQGPH QW7KLVVWXG\KDVEHHQDPHQGHGWRLQFOXGHD
FODULILFDWLRQLQWKH([FOX VLRQFULWHULDVHFWLRQWRDOLJQZLWK3 URWRFROVHFWLRQDQG
UHIOHFWWKHIOH[LELOLW\RIUH GXFLQJWKHLQWHUYDOEHWZHHQDGPLQL VWUDWLRQRIDFRURQDYLUXV
GLVHDVH&29,' YDFFLQH DQGWKH569PDWHUQDOYDFFLQH $OVRVHYHUDO
DGPLQLVWUDWLYHFKDQJ HVLQSHUVRQQHODQGPLQRUHGLWVWRWKHSURW RFRODUHLQFOXGHG 
'HWDLOHGGHVFULSWLRQRI3URWRFRO$PHQGPHQW 
&RQWULEXWLQJDXWKRUV&RQW   6WXG\'HOLYHU\/HDG 
3ULRU&RQFRPLWDQWWKHUDS\IRUH[WHQVLRQ 
1RWH,QFDVHDQHPHUJHQF\PDVVYDFFL QDWLRQIRUDQXQIRUHVHHQS XEOLFKHDOWKWKUHDW
HJDSDQGHPLFLVRUJDQLVHGE\WKH SXEOLFKHDOWKDXWKRULWLH VRXWVLGHWKHURXWLQH
LPPXQLVDWLRQSURJUDPWKHWLPHSHULRGGH VFULEHGDERYHFDQEHUHGXFHGLIQHFHVVDU\
IRUWKDWYDFFLQHSURYLGHGLWLVOLFHQV HGDQGXVHGDFFRUGLQJWR LWV6X[COMPANY_003]U\RI3URGXFW
&KDUDFWHULVWLFV6P3&RU3UHVFULELQ J,QIRUPDWLRQDQGDFFRUGLQJ WRWKHORFDO
JRYHUQPHQWDOUHFRPPHQGDWLRQV 
_3URWRFRO$PHQGPHQW$SU_70)_
[COMPANY_003] [COMPANY_003]
CONFIDENTIAL  
209141 (RSV MAT -011) 
Protocol Amendment 6  Final  
9 April 2021  148 8.5.4 Reporting of serious adverse events, pregnancies, and other events  
Type of Event  Initial Reports  Follow -up of Relevant Information on a 
Previous Report  
Timeframe  Documents  Timeframe  Documents  
Pregnancies  2 weeks*  Paper pregnancy notification 
report/electronic pregnancy 
report  2 weeks  24 
hours * electronic pregnancy report  
 
[IP_ADDRESS] Contact [CONTACT_301910] (SAEs), pregnancies 
and study holding rules  
24/24 hour and 7/7 -day availability:  
[COMPANY_004] Clinical Safety & Pharmacovigilance  
Outside US & Canada sites:  
Fax: [PHONE_6284] 16 or +32 2  656 80 09  
Email address: [EMAIL_5932]  [EMAIL_5931]  
[IP_ADDRESS] Completion and transmission of pregnancy reports to [COMPANY_004]  
Once the investigator becomes aware that a subject is pregnant, the investigator (or 
designate) must complete the required information onto the electronic pregnancy report 
WITHIN 2 WEEKS  24 HOURS . 
8.3.2 Medical and vaccination  history  
Significant medical conditions and vaccinations that occurred during the C1 -V4 will be 
reviewed during the screening for the second vaccination and reported as medical history  
and concomitant medications, respectively.  
 
 209141 | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0
Signature [CONTACT_1219]  209141 TMF-11921449 v1.0
Signature [CONTACT_1220]-11921449 v1.0Reason for signing: Approved Name: [CONTACT_301962]: Approver
Date of signature: 14-Apr-2021 19:05:50 GMT+[PHONE_6281] | Protocol Amendment 6 14 Apr 2021 | TMF-11921449 | 1.0